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Summary:
Hypertension is a common disorder affecting a large heterogeneous patient 
population. Despite improved understanding of its pathophysiology and 
availability of effective treatment strategies, hypertension remains a major, 
potentially modifiable, risk factor for cardiovascular disease.
Aldosterone, the principal human mineralocorticoid, is increasingly recognised 
as playing a significant role in cardiovascular morbidity and its role in 
hypertension has recently been re-evaluated with studies that suggest that 
increased aldosterone concentration (as defined by an elevated aldosterone 
to renin ratio -  ARR) is a key phenotype in up to 15 per cent of hypertensive 
subjects. We have previously reported that polymorphisms of the gene (C to T 
conversion at position -344 and intron conversion (1C) in intron 2) encoding 
aldosterone synthase (CYP11B2) are associated with hypertension, 
particularly in individuals with a high ARR. In normotensives, the T and 1C 
alleles associate with raised basal and ACTH-stimuiated levels of the 11- 
deoxysteroids, deoxycorticosterone and 11-deoxycortisol which are 
substrates for the enzyme 1113-hydroxylase, encoded by the adjacent and 
homologous gene CYP11B1.
This has led to speculation that the T and 1C alleles of CYP11B2 are in 
linkage disequilibrium (LD) with functional variants in CYP11B1 resulting in 
reduced efficiency of this enzyme. In order to maintain cortisol production, 
positive feedback to the pituitary leads to a subtle but more pronounced 
adrenocorticotrophic hormone (ACTH) drive to the adrenal cortex and 
enhanced synthetic capacity of the zona glomerulosa resulting in increased
25
production of aldosterone and suppression of renin. Thus in such individuals, 
there should be recognisable, genotype dependent, changes in the pattern of 
adrenal steroid production as well as alteration in the cortisol/ACTH 
relationship.
In chapter 3, by sequencing the entire CYP11B locus in a cohort of 
normotensive subjects, I demonstrated that there was indeed tight LD across 
this locus and identified a number of novel polymorphisms in both genes 
linked to the T and 1C alleles. Whilst most of these were in non-coding 
regions, making analysis of their functional effects difficult, two were in the 
promoter region of CYP11B1 and reduce transcriptional activity of this 
enzyme in vitro (reported elsewhere).
In chapter 4, the effect of CYP11B2 genotype on intermediate corticosteroid 
phenotype was explored further in a large, severely hypertensive cohort. In 
this population, cortisol production was unaffected by CYP11B2 genotype but 
there was a significant elevation of the ratio of deoxycortisol to cortisol in 
subjects homozygous for the -344T allele suggesting reduced efficiency of 
1113-hydroxylase. In addition, excretion of aldosterone was found to correlate 
strongly with that of ACTH-dependent steroids (total cortisol and adrenal 
androgens) in TT subjects. This suggests that in such subjects, there is an 
important common regulatory influence on aldosterone, cortisol and androgen 
production that is likely to be ACTH.
The association of CYP11B2 polymorphisms as well as the novel SNPs in 5’ 
untranslated region (UTR) of CYP11B1 with alterations in cortisol/ACTH 
relationship as well as on aldosterone was assessed in a cohort of 
hypertensives homozygous for the -344T allele. In chapter 5, I report that TT
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homozygotes demonstrated diminished suppressibility of ACTH with 
dexamethasone leading to a decreased cortisol/ACTH ratio. These findings 
are in keeping with a mild increase in ACTH secretion in order to maintain 
cortisol production. Additionally, aldosterone exhibited diurnal variation and 
correlated closely with cortisol levels only in TT homozygotes. This supports 
further the proposal that, in TT individuals, ACTH contributes to the regulation 
of aldosterone production. In addition, the novel alleles of CYP11B1 (-1888T 
and -1858G) identified in chapter 3 resulted in similar changes in 
cortisol/ACTH relationship and in aldosterone regulation as the -344T+ 1C 
alleles of CYP11B2. These alleles have been reported to result in reduced 
transcription of CYP11B1 and so provide a plausible explanation for the 
altered efficiency of 1113-hydroxylation described in several populations.
The hybrid corticosteroids, 18-oxocortisol and 18-hydroxycortisol are found in 
the urine of individuals with primary aldosteronism (PA) due to glucocorticoid 
remediable Aldosteronism (GRA) and Conn's adenoma where they play a 
diagnostic role. However, they have also been identified in normal individuals. 
In chapter 6, I explored the origins of these steroids in order to provide a 
better understanding of corticosteroid physiology and production. I showed 
that 18-oxocortisol is produced in normal subjects by the action of zona 
glomerulosa aldosterone synthase on recirculating cortisol whilst 18- 
hydroxycortisol is produced by the action of zona fasciculata 11 (3-hydroxylase 
on locally produced cortisol. Subsequently, 18-oxocortisol was used as a 
marker of aldosterone synthase activity and was detectable in subjects who 
had previously undergone bilateral adrenalectomy (chapter 7). 18-
hydroxycortisol was also found in easily detectable amounts and its
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production was independent of ACTH suppression by exogenous 
glucocorticoid supporting the concept of extra-adrenal aldosterone synthase 
activity.
In summary, I have shown that there is strong LD across the CYP11B locus. 
In particular, variants in the 5’ UTR of CYP11B2 (-344T) are in tight LD with a 
number of polymorphisms across this and the adjacent CYP11B1 locus. 
These polymorphisms (of which -1888T and -1858G are likely candidates) 
result in altered expression of the enzyme product of GYP11B1, 1113- 
hydroxylase. in turn, this leads to changes in hypothalamic pituitary adrenal 
(HPA) axis activity consistent with a subtle increase in ACTH-mediated 
adrenal stimulation to maintain cortisol production. Finally, these data are also 
consistent with a contribution of ACTH to the production of aldosterone (in - 
344T & CYP11B1 -1888T/ -1858G) leading to the eventual phenotype of 
hypertension with aldosterone excess.
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Chapter 1: Introduction
1.1 Blood Pressure -  a historical perspective
The study of hypertension stemmed from one of the single most influential 
discoveries in medical science- the circulation of the blood (William Harvey. 
1578-1657)(1). It was not until a century later, however, that the Reverend 
Stephen Hales made the first quantitative measure of blood pressure. Hales 
measured arterial pressure by inserting a brass tube into the crural artery of a 
horse and connecting this to a vertical glass tube(2). Consequently, the first 
arterial blood pressure measurements were recorded in feet of water- in this 
case, 8 feet 3 inches. Whilst this was a key discovery, it was clearly not a 
practical method for blood pressure measurement in man. However, it was 
not until 172 years later that the Russian military surgeon Nicolai Korotkoff 
reported a reliable, simple and reproducible method of measuring systolic and 
diastolic pressure in man using an inflatable cuff to compress an upper limb 
artery and listening to the sounds created by the arterial flow on release of the 
compression(3). One hundred years later, Korotkoff’s auscultatory method 
remains the principal technique of blood pressure measurement in man. 
Despite an initially slow start, progress in hypertension research has 
accelerated in an exponential fashion over the past 100 years. In particular, 
there have been major advances in understanding the underlying 
biochemistry and physiology as well as, more recently, genetic mechanisms. 
Observational studies in large populations have identified hypertension as a 
major health problem in the developed world and highlight the importance of a 
better understanding of its pathophysiology and eventual treatment to 
minimise its consequences.
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1.2 Clinical relevance of hypertension
Hypertension is the commonest indication in the Western world for chronic, 
lifelong pharmacological treatment(4). Despite improved understanding of its 
pathophysiology and availability of effective treatment strategies, hypertension 
remains a major, potentially modifiable, risk factor for cardiovascular disease 
(Table 1.2a). Over the past 15 years, age-adjusted rates of stroke incidence 
have risen slightly and the rate of decline in coronary disease has slowed (5). 
The incidences of end-stage renal disease and cardiac failure have also 
increased (5). Inadequate control of blood pressure within a hypertensive 
population is thought to be a major contributor to these worrying trends. It is 
clear that any insight into underlying mechanisms, which can subsequently 
make a positive impact upon treatment regimes, would be desirable.
1.2.1 Definition of Hypertension
This has always been a controversial area. Historically, it was argued by Platt 
that hypertension was an entity distinct from normotension(G) whilst Pickering 
claimed that blood pressure was on a continuous spectrum and hypertension 
was a quantitative deviation from the norm(7). Clearly, Pickering has been 
proven correct and it is now accepted that blood pressure is indeed a 
quantitative trait that is highly variable. In population studies, blood pressure 
has a normal distribution that is slightly skewed to the right(5). This obviously 
makes the definition of hypertension problematic. Moreover, as there is no 
specific level of blood pressure where cardiovascular and renal complications 
start to occur then an exact definition is somewhat arbitrary but necessary for
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Stroke Myocardial
Infarction
Peripheral 
arterial disease
Age
(years)
Hypertensive
status
Men Women Men Women Men Women
35-64 Normal 0 0 4 1 2 1
Mild 1 1 8 2 4 1
Definite 4 2 10 3 5 3
65-94 Normal 3 1 7 4 6 3
Mild 5 4 17 7 7 3
Definite 12 9 21 9 9 5
Table 1.2a. Incidence of atherosclerotic cardiovascular events (as age- 
adjusted annual rate per 1000) according to hypertensive status.
Data taken from 30-year follow up of Framingham study
patient assessment and treatment. It should also be noted that there remains 
a strongly positive correlation between blood pressure and the risk of 
cardiovascular disease, renal disease and mortality even within the 
normotensive range(8).
The recently published British Hypertension Society (BHS) Guidelines(9) have 
based classification of blood pressure levels upon those previously published 
by the World Health Organisation- International Society of Hypertension(IO). 
Hypertension, according to the BHS, is defined as a systolic blood pressure of 
140 mm/Hg or greater and/or a diastolic blood pressure of 90mm/Hg and 
above in subjects who are not taking anti-hypertensive medication (Table 
1.2b). Within the normal blood pressure category 3 subgroups exist- optimal, 
normal and high/normal as well as in the hypertension category -  gradel, 
grade2 and grade 3.
For a brief period, these classifications were universally accepted resulting in 
reduced confusion and providing consistent advice to clinicians around the 
world. However, in 2003, the Joint National Committee VII (JNC Vll)(11) in the 
United States published another classification system stating that the risk of 
cardiovascular disease began at 115/75mm/Hg and calling systolic pressures 
of 120-139 mm/Hg and diastolic pressures of 80-89 mm/Hg ‘pre­
hypertension.’
1.2.2 Prevalence of Hypertension
Obviously, given the changing definition of true hypertension and the lack of 
clear distinction between ‘normotension’ and hypertension, exact prevalence 
is difficult to estimate. The most recent data, using a cut off of 140/90 mm/Hg
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Category Systolic blood
pressure
(mm/Hg)
Diastolic blood
pressure
(mm/Hg)
Blood pressure
Optimal <120 <80
Normal <130 <85
High/normal 130-139 85-89
Hypertension
Grade 1 (mild) 140-159 90-99
Grade II (moderate) 160-179 100-109
Grade III (severe) >180 >110
Isolated systolic
hypertension
Grade 1 140-159 <90
Grade 2 >160 <90
Table 1.2b. Classification of blood pressure according to the British 
Hypertension Society (9)
estimates the age-adjusted prevalence of hypertension in the UK to be around 
42% in individuals aged 35-64 with only 24% of these individuals on anti­
hypertensive treatment(12) (Figure 1.2a, Table 1.2c). Unsurprisingly, these 
data represent an increase in prevalence from earlier data which were based 
on more generous definitions of hypertension (>160/95 mm/Hg). Nonetheless, 
in both cases, there is a similar association between age and the prevalence 
of hypertension with a 20-fold increase in prevalence in the oldest age group 
compared with their counterparts in the lowest age group.
In the United States, data from the fourth survey conducted by the National 
Health and Nutrition Examination Survey (NHANES) seem to indicate that, 
contrary to earlier reports, hypertension prevalence is increasing with an 
overall age-adjusted prevalence of 28.7% compared with 25% in 1988(13).
1.2.3 Incidence of Hypertension
There is a considerable lack of studies examining the incidence of 
hypertension in the general population. Probably the best data still derives 
from the Framingham Heart Study(14). Briefly, this large-scale, prospective 
study examining factors related to development of vascular disease has 
followed a cohort of over 5000 men and women for over forty years with 
biennial examinations at the study clinic in Framingham, USA. This study 
helped identify hypertension as a major cardiovascular risk factor as well as 
quantify its atherogenic cardiovascular disease potential(15). The incidence of 
hypertension increases with age in men from 3.3 per cent per year at ages 
30-39 to 6.2 per cent at ages 70-79 and in women from 1.5 per cent at ages 
30-39 to 8.6 per cent at ages 70-79(15;16) (Figure 1.2b). This trend is
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Figure 1.2a. Hypertension prevalence in England and North America, 
men and women combined, by age group.
Adapted from ref (12).
Prevalence (%)
Country All Men Women On treatment 
(%)
North America 27.6 30.4 24.8 44.4
USA 27.8 29.8 25.8 52.5
Canada 27.4 31.0 23.8 36.3
Europe 44.2 49.7 38.6 26.8
Italy 37.7 44.8 30.6 32.0
Sweden 38.4 44.8 32.0 26.2
England 41.7 46.9 36.5 24.8
Spain 46.8 49.0 44.6 26.8
Finland 48.7 55.7 41.6 25.0
Germany 55.3 60.2 50.3 26.0
Table 1.2c. Hypertension prevalence and treatment among subjects age 
35-64 in 6 European countries and North America.
Adapted from ref (12).
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Figure 1.2b. Two year incidence of hypertension per 100 by sex and age 
based on a pooling of 15 bienniums
Adapted from ref 16
consistently observed across other populations(17). It has become 
increasingly understood that the incidence of hypertension is affected by other 
factors such as body weight (18), alcohol intake(19), smoking(20) and 
physical activity(21).
1.2.4 Morbidity and Mortalitv from Hypertension
Hypertension affects around one billion people worldwide and is the most 
common treatable risk factor for cardiovascular disease in patients aged over 
50(22). Both systolic and diastolic blood pressure levels have been shown to 
be positively and continuously related to the risk of stroke across a wide range 
of levels worldwide(23). Amongst middle-aged individuals, lowering diastolic 
blood pressure by 5mm/Hg for a prolonged period associates with a 35-40 per 
cent lower risk of stroke with no lower level below which the risks of stroke do 
not continue to decline(23) (Figure 1.2c). Levels of blood pressure are 
positively associated with both intra-cerebral haemorrhage and cerebral 
infarction, but the relationship is stronger with haemorrhagic stroke.
It is also well established that blood pressure levels are positively and 
continuously related to the risks of major coronary heart disease (death or 
non-fatal myocardial infarction) (24) (Figure 1.2d). This association is slightly 
less strong than that of blood pressure and stroke but remains constant 
across a broad range of blood pressure levels. One recent prospective cohort 
study demonstrated that hypertensive men had 50 per cent more myocardial 
infarctions than normotensive men and their mortality for coronary heart 
disease was doubled(25).
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Figure 1.2c. Estimates from 7 studies of eventual difference in stroke 
risk associated with a 7.5mm/Hg reduction in DBF
Solid squares represent estimated difference in risk (adjusted for age, 
cholesterol and smoking) in each study; sizes of squares are proportional to 
number of events in each study and 95% CIs are denoted by horizontal lines. 
The broken vertical line represents a 46% difference in risk, which was the 
weighted mean difference in risk for all studies combined.
MRFIT Screenees (men)
Chicago HA (men) 
Chicago HA (women) 
Whitehall (men)
Puerto Rico (men)
Honolulu (men)
LRC Prevalence (men) 
LRC Prevalence (women) 
Framingham (men) 
Framingham (women) 
Western Electric (men) 
People's Gas (men)
ALL STUDIES*
^Heterogeneity NS
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Figure 1.2d. Estimates from 9 studies of eventual difference in coronary 
heart disease risk associated with a 7.5mm/Hg reduction in DBF.
Broken vertical line represents total difference in risk of 29%.
Hypertension also contributes to the development of heart failure and renal 
disease but the strength of these relationships is less well established than 
those for stroke and coronary heart disease(23). Nonetheless, there is 
evidence to suggest that patients with a history of hypertension have a six-fold 
greater risk of heart failure than normotensive subjects(26). In renal failure, 
each 5 mm/Hg lower level of DBP is associated with at least a one-quarter 
lower risk of development of end-stage renal disease (27). As well as its 
significant vascular effects, elevated blood pressure leads to a variety of so- 
called ‘end-organ’ effects, i.e. the presence of hypertension has deleterious 
effects on a number of important body tissues. Organs susceptible to the 
adverse effects of hypertension include the heart, kidney, retinal vessels, the 
cerebral circulation as well as the general systemic arterial circulation.
1.2.5 Importance of Drug Treatment in Hypertension
In light of the information outlined previously, it is not surprising that large 
benefits, in terms of avoided cardiovascular disease, are expected from the 
treatment of hypertension. This is perhaps best appreciated by considering 
the number of deaths from stroke or coronary heart disease that could be 
prevented by a 9/5 mm/Hg reduction in population blood pressure (Table 
1.2d).
Many large-scale morbidity and mortality trials have compared different 
classes of anti-hypertensive drugs. The Blood Pressure Lowering Trialists’ 
Collaboration has conducted two major meta-analyses of blood pressure 
lowering agents (28;29). In the first, ‘newer’ therapies such as treatments
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Annual mortality Deaths avoided by 9/5 mm/Hg 
reduction in population BP*
Country Stroke Coronary Heart 
Disease
Stroke Coronary Heart Disease
UK 76308 169481 26000 36000
USA 149972 509412 51000 107000
Table 1.2d. Annual mortality from stroke and coronary heart disease, 
and number of deaths likely to be avoided by a reduction in the 
population blood pressure of 9/5 mm/Hg
"(adjusted for age, smoking and blood cholesterol)
Adapted from ref (24)
targeting the renin-angiotensin system or calcium channel blockers were 
compared with ‘conventional’ therapies (d i u retics/beta-b locke rs). The 
conclusion made here has been that newer therapies are as effective but no 
more so than conventional therapies at reducing stroke, coronary heart 
disease or all cause mortality. The second meta-analysis reviewed 29 major 
trials published as of 2003, with over 700,000 years of patient follow-up. As 
with the previous conclusion, this demonstrated that the main benefit from 
anti-hypertensive therapy is blood pressure lowering per se, with little 
evidence to suggest additional benefits specific to a class of drug regarding 
major cardiovascular outcomes.
However, recent data from the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) challenges this(30). The ASCOT trial involved >19000 hypertensive 
patients with at least three other cardiovascular risk factors, randomised to 
receive old conventional treatment (beta-blockers/diuretics) or newer 
treatments (calcium channel blocker/angiotensin converting enzyme (ACE) 
inhibitor). The trial was halted early because of a significant benefit in terms of 
cardiovascular mortality in the amlodipine/perindopril treated arm despite 
similarities in blood pressure reduction between the two groups.
There Is a lack of definitive evidence on optimal targets for blood pressure 
lowering. The hypertension optimal treatment (HOT) study provides the best 
evidence to date on desired targets(31). It reports that the optimal blood 
pressure for reduction of major cardiovascular events is 139/83 mm/Hg but 
that reduction below this value causes no harm. Overall however, benefits 
from treatment of hypertension are not seen because the control of 
hypertension remains poor in European countries. This is particularly true of
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the UK where it is controlled in only 10 per cent of the hypertensive 
population(32).
1.3 Mechanisms of Hvoertension
Despite many years of research, the underlying aetiology of the vast majority 
of cases of hypertension is unknown. Such individuals are said to have 
‘essential’ or ‘primary’ hypertension and account for between 95-99 per cent 
of all cases of hypertension. The remaining cases are classified as 
‘secondary’ hypertension- i.e. where hypertension arises due to a biochemical 
or mechanical pathology which is potentially reversible and the hypertension 
curable.
1.3.1 Secondary Hvoertension
Secondary causes of hypertension are widely accepted to be relatively 
uncommon. Although there is a lack of recent data, several published series 
from the past three decades have reported a prevalence of 1.1-11 per 
cent(33-37). This variation in prevalence is due to a combination of 
differences in the populations screened and differences in the type of 
screening tests used.
The causes of secondary hypertension are numerous and outlined in table 
1.3a. The majority of causes are due to hormone excess, renal disease or 
vascular disease such as renal artery stenosis.
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Organ
Kidney
Arterial
disease
Adrenal
gland
Drugs
Others:
Example_______________________________________________
Autosomal Dominant Polycystic Kidney Disease 
Renal parenchymal disease: chronic glomerulonephritis, chronic 
interstitial nephritis, reflux nephropathy, amyloidosis 
Renal artery stenosis
(atheromatous or 2° to fibromuscular dysplasia)
Medulla: phaeochromocytoma
Cortex: cortisol overproduction
Aldosterone overproduction
Other mineralocorticoid excess syndromes
Oral contraceptive pill
Glucocorticoids
Cyclosporin
Non-steroidal anti-inflammatory agents
Carbenoxolone
Acromegaly
Hyperthyroidism
Acute Intermittent Porphyria
Table 1.3a. Secondary causes of hypertension
1.3.2 Essential Hypertension
Essential hypertension is a multi-factorial disorder thought to be caused by 
the interaction of an individual's genetically determined risk of developing 
hypertension with environmental factors including diet, levels of physical 
activity and other modifiable factors (37) (Figure 1.3a)
1.3.3 Lifestyle factors and essential hypertension
A variety of lifestyle factors have been shown to directly influence blood 
pressure levels at both an individual and population level (38)(Table 1.3b).
Of these, the most important are excess body fat, alcohol consumption, 
physical activity and a variety of dietary constituents including salt, potassium, 
and a complex of fruits, vegetables and saturated fat as well as n3 fatty acids. 
The role of stress in sustained blood pressure elevation remains controversial 
other than through possible influences of coping mechanisms that determine 
dietary, drinking, exercise and smoking habits(39).
Moderate changes in combinations of some of these factors have additive 
effects on blood pressure reduction in all grades of hypertension. Indeed, the 
effects are often as large as those seen with antihypertensive drug therapy, 
but with a greater potential to simultaneously reduce the risk of cardiovascular 
disease by mechanisms other than blood pressure reduction. Cook et al., 
using data from a number of observational studies and randomised controlled 
trials, estimated that reducing the average population diastolic blood pressure 
by as little as 2 mm/Hg by lifestyle measures would decrease the prevalence 
of hypertension by 17 per cent, with a six per cent reduction in risk of coronary 
heart disease and a 15 per cent reduction in the risk of stroke(40).
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Figure 1.3a The multifactorial model of essential hypertension.
Gene-gene and gene-environment interactions may be dependent on a background context 
of factors such as age and sex.
Men Women
Variable SBP DBP SBP DBP
Lifestyle factors
BMI 0.3911 0.3311 0.4111 0.2611
Exercise 0.03 0.11$ 0.17$ 0.14$
Cigarettes (g/wk)* 0.06 -0.04 -0.05 0.05
Smoking status -0.09 -0.09 0.05 0.07
Alcohol intake^ 0.14$ 0.14$ 0.10 0.10
Drinking status 0.07 -0.04 0.01 0.00
Unhealthy eating 0.01 0.07 0.00 0.07
Healthy eating 0.07 0.03 0.03 0.04
Stress Measures
Job stress 0.03 0.06 0.01 0.08
Home/work stress 0.08 0.09 0.01 0.1
Table 1.3b. Pearson correlation co efficients among lifestyle, stress and 
blood pressure
*non-smokers included
^  non-drinkers excluded from average weekly alcohol intake 
$ p<0.05 t  p<0.01 II p<0.001 
Adapted from (39)
1.3.4 Renin-angiotensin system in essential hypertension
The renin-angiotensin system (Figure 1.3b) is central to blood pressure 
regulation in man. Briefly, the precursor peptide, angiotensinogen, is cleaved 
by renin (produced by renal juxtaglomerular cells) to produce angiotensin I. In 
turn, this is converted (predominantly within pulmonary vasculature) by the 
Angiotensin Converting Enzyme (ACE) into angiotensin II (Ang II). This system 
is described in more detail in section 1.6.2. Ang II increases blood pressure by 
various mechanisms including constriction of resistance vessels, stimulating 
aldosterone synthesis by the adrenal gland (discussed in detail 1.6.2), renal 
tubular sodium absorption (directly and indirectly via aldosterone), stimulating 
thirst and release of anti-diuretic hormone and enhancing sympathetic outflow 
from the brain(41). Locally produced Ang II plays both an autocrine and 
paracrine role in maintaining cardiovascular homeostasis, acting via specific 
receptors.
In particular, Ang II induces cardiac and vascular cell hypertrophy and 
hyperplasia directly by activating the angiotensin II type 1 receptor (ATI) and 
indirectly by stimulating the release of several growth factors and 
cytokines(42). The role of angiotensin II type 2 receptors (AT2) has been less 
clear but recent evidence suggests that activation of this receptor leads to 
vasodilation, growth inhibition and cell differentiation(43), hence opposing the 
biological effects of ATI receptor activation.
1.3.5 Genetic factors in essential hvoertension
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Figure 1.3b. The renin-angiotensin system
It is clear from many sources of evidence that there is a considerable genetic 
influence on the development of hypertension. Twin studies have 
demonstrated greater concordance of blood pressure between monozygotic 
than dizygotic twins (44) and population studies show greater similarity in 
blood pressure within families than between families (45). This latter 
observation cannot only be attributed to a common environment as adoption 
studies demonstrate greater concordance of blood pressure among biological 
siblings than adoptive siblings living in the same household (46). A 
comparison between essential hypertension and ‘Mendelian’ hypertension 
(due to a single gene disorder) is outlined in table 1.3c.
Studies of rare single-gene disorders resulting in hypertension (Mendelian 
hypertension) can give some insight into underlying pathophysiological 
mechanisms (Figure 1.3c). This is particularly true of adrenal steroid 
biosynthesis and two particular syndromes of aberrant production of adrenal 
steroids resulting in hypertension (Glucocorticoid Remediable Aldosteronism 
and 11 {3-hydroxylase deficiency) will be considered later.
However, it is clear that, in the overwhelming majority of cases, essential 
hypertension results from a complex interaction of genetic, environmental and 
demographic factors. It is estimated that between 30-40 per cent of BP 
variation in a population has an underlying genetic basis(47) and so it is clear 
that a better understanding of the genetic basis of essential hypertension 
could result in significant benefits such as tailoring treatment regimes and 
developing preventive strategies. The use of genome-wide linkage analysis 
has found statistically significant linkage of blood pressure with several 
chromosomal regions(41). These findings suggest there are multiple genetic
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MENDELIAN ESSENTIAL
Rare
Minimal contribution to global 
disease burden.
M onogenic
Mutations in one gene are 
necessary and sufficient.
Sim ple genetic syndrom e
Effect of causative gene is large. 
Interactions with other genes are 
of secondary importance.
Unifactorial
Gene defect is highly penetrant.
Relative risk is high
Risk of syndrome in 1st degree 
relative of affected person is 
much higher than the general 
population.
Com m on
Affects about 20% of subjects in 
industrialised societies.
O ligogenic or polygenic
Subtle polymorphisms in multiple - 
possibly many - genes increase 
susceptibility.
C om plex genetic trait
Gene-gene interactions are important 
and result in clinically relevant effects 
on blood pressure.
M ultifactorial
Effects of genes are important in the 
context of environmental and dietary 
factors.
Relative risk is low er
Risk of hypertension in 1®‘ degree 
relative of affected person is about 2- 
5 fold higher than the general 
population.
Table 1.3c. Comparison between Mendelian and essential hypertension
Cortical collecting duct
Glucocorticoid remediable aldosteronism (GRA)
Increased aldosterone production from abnormally regulated chimaeric 
aldosterone synthase gene increases sodium reabsorption via ENaC.
Normal aldosterone synthase regulation 
Renin angiotensinogen system
Angiotensin II
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Figure 1.3c. Molecular mechanisms of Mendelian hypertension
loci, each with small effects on blood pressure in the general population. 
Linkage analysis in hypertension has a number of shortcomings most 
especially due to locus heterogeneity (more than one causal gene) and 
clinical heterogeneity. Indeed, genome-wide scans have yielded loci linked to 
hypertension in almost every chromosome(48)l Nonetheless, as long as these 
are interpreted with caution, genome wide scans are useful tools in identifying 
candidate genes for further analysis.
The candidate gene approach typically compares the prevalence of 
hypertension or the level of blood pressure among individuals of contrasting 
genotypes at candidate loci in pathways known to be involved in blood 
pressure regulation. Numerous genes have been linked to essential 
hypertension but, to date, no single gene is consistently linked to or 
associated with this complex disorder. The major genes still hypothesised to 
contribute to essential hypertension are listed in Table 1.3d (49). A few will be 
discussed further.
(a) Renin-angiotensin system genes
The idea of a candidate gene has been most readily studied in the renin- 
angiotensin system. Animal model studies have clearly demonstrated that 
variations in the renin gene affect blood pressure and that the renin gene is 
directly involved in the development of hypertension (50). However, as yet 
there is no convincing evidence linking the renin locus to human essential 
hypertension.
The most promising results have been obtained with the angiotensinogen 
gene located on chromosome 1q 42-43. The link between angiotensinogen 
and the development of hypertension has been demonstrated in human
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Statistical approach
Gene or protein Linkage Association
Renin-angiotensin-aldosterone system or 
Na  ^volume
+/- +/-
Angiotensin-converting enzyme (ACE) 0/1 12/14
Angiotensinogen (ACT) 3/4 13/9
Aldosterone synthase (GYP11B2) 1/1 6/7
AT 1 receptor 6/6
Adducin (ADD1) 0/1 5/3
Adducin (ADD2) 0/1
Atrial natriuretic peptide 2/5
Human natriuretic peptide receptor (A) 1/1
Human natriuretic peptide receptor (B) 1/2
Renin (REN) 3/2 2/2
Protein kinase lysine deficient 4 (WNK 4) 1/1
11B Hydroxysteroid dehydrogenase type 
2(11BHSD2)
Adrenergic
2/2
B2-Adrenoceptor 3/4
Bs-Adrenoceptor 3/1
Dopamine D2 receptor gene 2/0
a-Adrenoceptor
Vascular
1/1
Endothelln-1 gene 3/1
Nitric oxide synthase, endothelial (NOS3) 0/2 5/10
Nitric oxide synthase, inducible (N0S2A) 
Metabolic
1/1
Glycogen synthase 1/1
Insulin receptor 0/1 3/0
Lipoprotein lipase 1/2
Apolipoprotein C-lll 1/1
Table 1.3d Genes hypothesised to be involved in essential hypertension.
Number of pertinent positive (+) and negative (-) published studies in humans 
since 1997. Two statistical approaches have been reported: linkage and 
association (see text)
studies where plasma angiotensinogen levels co-segregate with blood 
pressure in families (51) as well as transgenic mouse models which develop 
hypertension when over-expressing angiotensinogen (52). Specific mutations 
in this gene have been associated with essential hypertension. The most 
commonly occurring is the M235T polymorphism which encodes a change in 
amino acid from methionine to threonine (53). This polymorphism is 
associated with raised circulating levels of angiotensinogen, hypertension (54) 
and pre-eclampsia (55). The results from some studies suggest that the 
association with essential hypertension is limited to men(56) or to non­
overweight hypertensives (57). Moreover, recent haplotype analysis suggests 
that the mutation acts as a marker linked to the actual aetiological 
mutation(58).
The gene for angiotensin-1-converting enzyme (ACE) has been cloned, 
mapped to chromosome 17 and a polymorphism in intron 16 of the gene 
characterised(59). This polymorphism consists of the presence or absence of 
an Alu repeat which can be detected by PCR amplification of intron 16 
(insertion (l)Zdeletion (D) polymorphism). The I/D polymorphism accounts for 
approximately 50 per cent of the variance in plasma ACE levels in normal 
populations, with DD homozygotes having the highest plasma ACE levels, II 
homozygotes the lowest and heterozygotes intermediate levels (60). Again, 
evidence that the ACE I/D polymorphism is associated with hypertension is 
inconclusive. A number of studies have shown no association between this 
polymorphism and hypertension (61 ;62), whilst more recent investigation has 
suggested a link with blood pressure variation in men only(63;64). In an 
attempt to clarify this controversial area, a meta-analysis of studies involving
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ACE polymorphism with cardiovascular parameters has been published (65). 
Significant odds ratios for disease susceptibility with the DD genotype of 1.3 
were reported for coronary heart disease, 1.4 for myocardial infarction and 1.5 
for both diabetic and non-diabetic renal disease. Significantly, no association 
was found for left ventricular hypertrophy or hypertension in non-diabetic 
subjects.
(b) Adducin genes
Adducin is a cytoskeletal protein that interacts with Na-K ATPase.Adducin 
exists within the cell as a heterodimer comprising various combinations of its 
a,p and 7  subunits (termed ADD1, 2 and 3 respectively). Adducin variants 
associated with both rat and human hypertension show greater affinity for 
proximal renal tubular Na-K ATPase resulting in an increase in its membrane 
expression and activity(66). Initial positive association studies in humans(67) 
have been followed by significant linkage in hypertensive siblings(68) and 
have identified a Gly460Trp variant (with an allele frequency of 0.13-0.16 in 
controls)in ADD1 in association with hypertension. One study identified an 
approximate 50-70 per cent increase in hypertension risk in older, heavier 
Caucasians carrying the 460Trp variant (odds ratio 4.2)(69). Phenotypic 
studies identify a significant increase in salt retention associated with the 
460Trp variant(70) providing a plausible pathophysiological mechanism. 
Additionally, 460T rp homozygotes more frequently have low-renin 
hypertension and have a greater capacity for sodium reabsorption. 
Polymorphisms have also been described in the ADD2 and ADD3 genes but 
these, by themselves, have no effect on blood pressure or renal sodium 
handling. However, there is a suggestion that a polymorphism in ADD3
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accentuates the effect of ADD 1 460Trp suggesting epistatic effects between 
these loci(71).
(c) Role of WNK kinase polymorphisnns
The WNK kinases are a small group of serine/threonine kinases with unique 
catalytic domains that lack the lysine residue used in other kinases to co­
ordinate ATP (hence, With No K [WNK]). Their closest homologues are found 
within the mitogen-activated protein kinase (MAPK) pathway suggesting a role 
in signalling. To date, four WNK kinases have been identified in different 
chromosomal locations and share 84-92 per cent homology across their 
catalytic domains(72). Two WNK isoforms, WNK1 and WNK4, have been 
identified as the disease genes for a rare monogenic hypertension syndrome 
(Gordon's syndrome or pseudohypoaldosteronism type 2 [PHA2]) implicating 
them in salt homeostasis by the kidney(73).
WNK4 is located on chromosome 17 and several lines of evidence have 
implicated a region of human chromosome 17 that harbours a gene 
influencing blood pressure(74;75). However, as yet, no plausible candidate 
SNP within the WNK4 gene has been identified and studies are ongoing 
within this field(76;77).
In summary, these variants seem to only modestly affect blood pressure (if at 
all) and other candidate genes have not shown consistent associations with 
blood pressure or hypertension in larger populations(78); thus, demonstration 
of common genetic causes of hypertension in the general population remain 
elusive.
1.3.6 Sub-groups in essential hypertension
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Over the years, there has been a substantial effort to categorize large 
heterogeneous groups of essential hypertensives into smaller homogeneous 
sub-groups based on hormonal responses to biological stimuli. In the mid 
1980s Williams and Hollenberg(79) described a subgroup of hypertensives in 
whom changes In sodium intake failed to produce the anticipated reciprocal 
changes in adrenal (aldosterone) and renal vascular responses to angiotensin 
II infusions. Such individuals, who have normal/high renin levels, have been 
termed ‘non-modulators’. Non-modulators tend to be older than modulators 
and there is evidence to suggest that non-modulation has a genetic basis. In 
one study of hypertensive individuals, 81 per cent with a positive family history 
of hypertension were non-modulators (80). A previous study of hypertensive 
sibling pairs showed that non-modulation tended to aggregate within families 
and is independent of sodium intake (81). In common with low-renin essential 
hypertension, non-modulators also demonstrate salt sensitivity. In contrast to 
low-renin hypertension, however, non-modulators clinically respond best to 
ACE inhibitors as opposed to diuretics (Table 1.3e) (82).
One of the earliest classifications was that of low-renin hypertension(83). In 
this form of hypertension, subjects exhibit low plasma renin activity (PRA) 
which does not respond normally to sodium restriction, and maintain basal 
aldosterone levels which, whilst not elevated, are inappropriate for the 
principal trophin, angiotensin II. Such a hormonal profile may be due to 
increased responsiveness of aldosterone to angiotensin ll(84;85), although 
not all patients share this abnormality (42). Classically, low-renin subjects 
have sodium sensitive hypertension, which tends to respond better to 
diuretics than agents that block the RAA system. Low-renin hypertension is
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LOW RENIN NON-MODULATORS
Plasma renin level Low Normal-high
Salt sensitive Yes Yes
Anti-hypertensive Diuretics ACE inhibitors
Phenotype Elderly Males>Females
Response to Ang II Normal Reduced
Table 1.3e. Sub-groups in essential hypertension
found more frequently among black and elderly populations (86).Thus it is 
clear that production of aldosterone and regulation of sodium states are 
important features amongst large sub-groups of subjects with hypertension.
1.4 The Adrenal Gland
The first anatomical description of the adrenal gland was made in 1563 By 
Eustachius{87). The first differentiation of the adrenal gland into cortex and 
medulla was made by Huchke and in the 19^  ^ century Arnold first described 
the concentric zones we now use to describe the adrenal cortex (88). 
However, ideas about the function of the adrenal gland were slower to 
develop but were pioneered by observations by Thomas Addison(89). It was 
six years later that Addison published his authoritative account of the effects 
of adrenal disease in man(90). Experimental confirmation of these clinical 
findings came the following year when Brown-Séquard demonstrated the 
detrimental effect of adrenalectomy in various animal species(91). It was not 
until 1930 however, that the efficiency of adrenal cortex extracts in 
maintaining the health and growth of adrenalectomised cats was noted (92) 
and these extracts used to successfully treat patients with Addison’s disease 
(93).
1.4.1 The Anatomy of the Adrenal Gland
Each adrenal gland represents a functionally distinct endocrine gland within a 
single fibrous capsule. The adrenal glands are situated on the superior poles 
of the kidneys and normally weigh four grams in healthy adults (Figure 1.4a). 
The outer capsule consists of loose fibrous tissue and surrounds the outer
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cortex of the adrenal. The cortex accounts for 90 per-cent of the weight of the 
adult adrenal and is derived from the mesenchymal cells adjacent to the 
urogenital ridge. The inner adrenal medulla is derived from cells of the neural 
crest which migrate into the adrenal during the third month of fetal life. Its cells 
secrete the catecholamines, adrenaline, noradrenaline and dopamine; its 
function will not be discussed further.
The adrenal cortex is divided into three roughly concentric zones based on 
the light microscopic appearance of the cells (88) (Figure 1.4b). The outer 
zone, the zona glomerulosa, constitutes 15 per cent of the cortex and consists 
of poorly demarcated islands of cells lying subjacent to the capsule of the 
gland. In the majority of instances these islands do not form a continuous 
layer. The glomerulosa cells are small and have a low cytoplasm: nuclear 
ratio and an intermediate number of lipid inclusions. The adjacent zone is the 
zona fasciculata which constitutes 75 per cent of the cortex. It is not well 
demarcated from the glomerulosa and cells from the fasciculata may 
penetrate the glomerulosa to contact the capsule. Cells in this zone have a 
high cytoplasm: nuclear ratio, are large and have a foamy, vacuolated 
cytoplasm because of the numerous lipid deposits. The innermost zone of the 
cortex is the zona reticularis, and is sharply demarcated from the fasciculata 
and the medulla. Cells in this zone have a compact, lipid-poor cytoplasm and 
lie in anastomosing cords separated by sinusoidal spaces (94).
1.4.2 Corticosteroid Svnthesis in the Adrenal Cortex
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Figure 1.4c Cyclopentanophenanthrene ring structure
The adrenal cortex is the site of synthesis of a number of important steroid 
hormones in man. Steroid hormones are derived from the 
cyclopentanopentane ring (Figure 1.4c).
The starting point for the synthesis of all adrenal corticosteroid hormones in 
man is cholesterol. Cholesterol can be synthesized de novo from acetate, 
mobilized from intracellular pools or imported from plasma lipoproteins by 
steroidogenic tissues. About 80 per-cent of cholesterol is provided by 
circulating lipoproteins, principally iow-density lipoprotein (LDL) which acts via 
a cell surface receptor (95). The LDL particle undergoes receptor-mediated 
endocytosis to be internalised by the cell and cholesteryl esters are released 
for use as steroidogenic substrates (96). Under normal conditions, a further 
20 per-cent of cholesterol is synthesised de novo from acetyl coenzyme A 
(95).
Three major groups of steroid hormones are synthesised in the adrenal cortex 
in man. The outer zona glomerulosa is the exclusive site of synthesis of 
aldosterone whilst the zonae fasciculata and reticularis synthesise cortisol and 
the adrenal androgens dehydroepiandrosterone (DHEA) and 
androstenedione. The most abundant product of the adrenal cortex, 
dehydroepiandrosterone sulphate (DHEAS), is formed exclusively in the zona 
reticularis(94).
Synthesis of the various adrenal corticosteroids is compartmentalised within 
the cells of the adrenal cortex as a result of the subceliular location of the 
enzymes involved (Figure 1.4d). The biosynthetic pathways for the conversion 
of cholesterol to aldosterone, cortisol and adrenal androgens are outlined in
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Figure 1.4e. Corticosteroid biosynthesis in the adrenal cortex
Many of the biosynthetic reactions are catalysed by cytochrome P450 
enzymes;
see- side chain cleavage 
c17~ 17a-hydroxylase 
c21- 21a-hydroxylase 
aldo- aldosterone synthase 
11 f j - 11 ^-hydroxylase 
3B/17fJ-HSD: 3B /171^ hydroxysteroid dehydrogenase
figure 1.4e. The aldosterone synthetic pathway is discussed in detail in 
section 1.6.
The synthetic action of the steroidogenic enzymes is made possible by the 
existence of a coupled enzyme system that transfers electrons to the P-450 
enzymes as reducing equivalents and allow the final hydroxylation step to 
occur. In the human adrenal, two such systems exist, both coupled to the 
action of the steroidogenic P-450 enzymes. The first is based on adrenodoxin, 
a non-haem iron binding protein that exists in soluble form in the 
mitochondrial matrix and in man is linked to the activity of P-450scc, P-450nR 
(1 Ifi-hydroxylase) and P-450aido (aldosterone synthase)(97). Linked to 
adrenodoxin is the enzyme adrenodoxin reductase which accepts electrons 
from NADPH in the first step of the reduction cascade. This so called ‘electron 
shuttle' system is illustrated in Figure 1.4f. NADPH donates electrons to an 
adrenodoxin reductase and converts it to its reduced state. This then acts to 
convert adrenodoxin to a reduced state that in turn transfers reducing 
equivalents to the P-450 enzyme.
A second system exists coupled to the activity of P-450ci7 and P-450c2i (98). 
This system utilises a flavoproten distinct from adrenodoxin reductase. This 
enzyme, P-450 reductase, transfers two electrons from NADPH to P-450ci7 
and P-450c2i - In addition, cytochrome b5 may also donate electrons to P- 
450c17 and P-450c2i (99) (Figure 1.4g).
Cholesterol is converted to pregnenolone by the enzyme P-450scc located on 
the inner mitochondrial membrane. This step is the rate-limiting step in 
steroidogenesis and involves two oxidations at the 020 and 022 positions 
followed by the removal of isocaproic acid from the 020 position (100). This
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Figure 1.4g. Electron shuttle system for P-450ci7 and P-450c2i.
enzyme, the so-called ‘Side-chain Cleavage’ enzyme is encoded by a single 
gene found on chromosome 15 and is found in all steroidogenic tissues (101). 
This cholesterol transport process is hormonally regulated via cAMP and 
synthesis of the Steroidogenic Acute Regulatory (StAR) protein in response to 
trophic stimuli(102). The StAR protein is thought to be located within the 
mitochondria of adrenocortical cells and is key in the binding and transport of 
cholesterol to the inner mitochondrial membrane (the sub-cellular location of 
P-450scc)(103;104).
The newly synthesised pregnenolone is returned to the cytosolic compartment 
where a series of microsomal enzymes convert it to 11-deoxycortisol (S). 
Pregnenolone is converted to progesterone by the enzyme 3li-hydroxysteroid 
dehydrogenase/A^-A"^ isomerase, a non P-450 enzyme encoded by a gene on 
chromosome 1 (105). A number of isoforms of this enzyme have been 
described with tissue specific expression (106).
The enzyme P-450ci7 is encoded by the gene CYP17A on chromosome 10 
(107) which transcribes a single mRNA message and protein product. The 
degree of P-450ci7 activity helps determine which pathway the reaction 
products take. In the zona glomerulosa P-450d7 activity is absent and 
therefore pregnenolone is converted to progesterone as a precursor in the 
formation of aldosterone. In the zona fasciculata pregnenolone undergoes 
hydroxylation of the C-17 position and the product, 17a-hydroxyprogesterone 
undergoes subsequent 21-hydroxylation to 11-deoxycortisol and then 11- 
hydroxylation to produce cortisol. However, some pregnenolone may be 
converted to progesterone before being converted to 17a- 
hydroxyprogesterone and subsequently cortisol. If the action of the enzyme is
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to cleave the two-carbon chain at C-21 in addition to the hydroxylation of 
pregnenolone (i.e. 17a-hydroxylase 17,20 lyase) the product is DHEA -  a 
major adrenal androgen and the precursor of other adrenal androgens (94). 
Whether 17-hydroxycorticosteroids are formed by this enzyme system is 
determined by the relative electron supply from the P-450 reductase system. 
This system donates electrons to P-450d7 in competition with P-450c2i and 
the relative excess or defecit of donated electrons can determine the degree 
of P-450c17 activity (108). In the zona glomerulosa there is no P-450ci7 
activity.
The next step in the sequence is the conversion of 17a-hydroxyprogesterone 
to 11-deoxycortisol (S) by the enzyme P-450c21. This enzyme resides in the 
smooth endoplasmic reticulum of the cell and is encoded by the gene 
CYP21A which lies on chromosome 6 in the midst of the Major 
Histocompatibility Complex region. It lies in tandem with a highly homologous 
pseudogene, CYP21P, which has no known function and can participate in 
gene conversion events to cause the clinical syndromes of steroid 21- 
hydroxylase deficiency (109).
Once formed, 11-deoxycortisol is transported to the inner mitochondrial 
membrane where the final hydroxylation step to form cortisol, the principal 
human glucocorticoid, is formed. This step is catalysed by the enzyme P- 
450ii(j (lip-hydroxylase) whose gene, CYP11B1, is found on the long arm of 
chromosome 8 (8q22)(110). In addition to the formation of cortisol, P-450im is 
also thought to catalyse the formation of corticosterone, 18-hydroxy-11- 
deoxycorticosterone and 19-hydroxy-11-deoxycorticosterone from 11- 
deoxycorticosterone in the zona fasciculata, emphasising the close
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relationship between this enzyme and P-450aido (aldosterone synthase) in 
their catalytic properties (111).
The gene for 11 (3-hydroxylase (CYP11B1) and its closely related homologue, 
CYP11B2 (encoding aldosterone synthase) are of central importance in the 
biosynthesis of aldosterone and in the pathogenesis of hypertensive disorders 
of adrenal metabolism and are discussed further in section 1.6.5.
1.4.3 Regulation of Adrenal Steroid Secretion
Control of the rate of synthesis of cortisol and the adrenal androgens is 
determined by factors outwith the adrenal gland. Principally, these include 
interactions between the hypothalamus, anterior pituitary and adrenal glands 
as well as neural stimuli and other factors such as stress. The normal 
regulation of human cortisol secretion is summarised in figure 1.4h.
1.4.4 Adrenocorticotrophin (ACTH)
The principal secretory stimulus to the cortisol-producing cells of the adrenal 
cortex is ACTH. ACTH is synthesised as part of a large precursor molecule 
(241 amino acids), pro-opiomelanocorticotrophin (POMC), which also 
contains other peptides, including melanocyte-stimulating hormone. The gene 
for POMC is located on chromosome 2 (112;113). The gene product of the 
POMC gene undergoes significant post-translational processing to produce 
multiple peptides. In the anterior pituitary, the products of this enzymatic 
cleavage are ACTH, p-lipotrophin and the joining (J) peptide. ACTH is a 39 
amino acid peptide, of which the first 24 are conserved in all species studied.
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Figure 1.4i. Amino acid sequence of human ACTH.
Bold residues indicate those common to ACTH, alpha and beta MSH.
The biological activity of ACTH is conferred by the first 18 NH2-terminal amino 
acids (114) (Figure 1.4i).
The ACTH peptide also contains the precursor molecule for one of the 
melanocyte-stimulating hormones (a-MSH) the effect of which can be seen 
when ACTH is present in gross excess in Nelson’s syndrome (skin 
pigmentation as a result of chronically elevated plasma ACTH levels from an 
ACTH-secreting pituitary adenoma).
ACTH release from the pituitary gland is pulsatile with brief episodic bursts of 
ACTH release throughout a 24 hour period. Release of ACTH is greater in the 
early hours of the morning due to pulses of greater amplitude (115). The 
increase in amplitude of the pulses occurs after 3-4 hours of sleep and 
reaches a maximum prior to waking and for 1 hour after waking before 
declining over the course of the day (115). Plasma cortisol levels mirror these 
changes in ACTH secretion but the longer clearance time for cortisol results in 
a slower decline in plasma cortisol relative to ACTH (116). This so-called 
‘nyctothemeral’ or ‘diurnal’ rhythm is maintained in the physiological state but 
lost in disease states where ACTH or cortisol secretion becomes 
autonomous, e.g. Cushing’s disease (ACTH-secreting pituitary adenoma) or a 
cortisol-secreting adrenal adenoma/carcinoma.
Under normal circumstances, ACTH and cortisol regulate their own secretion 
by means of a negative feedback loop whereby high levels of cortisol inhibit 
the secretion of ACTH and corticotrophin releasing hormone (CRH; which 
regulates ACTH secretion). However, ACTH secretion and consequently 
plasma cortisol levels can be influenced by inputs from ‘higher’ centres. For 
example, hypoglycaemia, fever and mental stress all raise ACTH and cortisol
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levels and are important sources of variation in day-to-day measurement of 
plasma levels.
The primary action of ACTH on the cells of the zona fasciculata is to increase 
cortisol secretion by increasing its synthesis; intra-adrenal storage of cortisol 
is minimal (117; 118). ACTH depletes adrenal cholesterol content to an extent 
which corresponds with increased synthesis (119). ACTH acts by binding to a 
high-affinity cell-surface receptor, and each adrenocortical cell is said to 
possess approximately 3600 ACTH-binding sites (94). In turn, ACTH binding 
promotes the generation of cyclic AMP (cAMP) via adenylate cyclase, which 
subsequently activates protein kinase A and leads to the phosphorylation of a 
number of proteins and increase in nuclear mRNA production.
The effects of ACTH can be divided into acute (within minutes) and chronic 
(after several hours). The acute effect of ACTH is to increase conversion of 
cholesterol to pregnenolone, the rate-limiting step of cortisol synthesis, by 
activation of P-450scc (120). Using polyclonal antibodies directed against the 
various steroidogenic enzymes it has been demonstrated that ACTH 
treatment of bovine adrenal cortex cells results in a 4-5-fold increase in the 
rate of synthesis of P-450scc, P-450np, P-450c2i, P-450i7a, StAR and 
adrenodoxin 24-36 hours after ACTH treatment. ACTH and cAMP treatment 
lead to similar increases in the levels of translatable mRNA of all of these 
enzymes (120) and this is thought to be due to an increase in transcription of 
the corresponding genes. These increases in mRNA synthesis can be 
detected as soon as 4 hours after ACTH treatment. Similar results have been 
found using human fetal adrenal cells (121).
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The chronic effects of ACTH involve increased synthesis of most of the 
enzymes In the steroidogenic pathway as well as actions on cell growth 
(118;120). When there is a prolonged deficiency of ACTH, such as following 
hypophysectomy, the level of steroidogenic enzymes and RNA synthesis fails 
in association with atrophy of the adrenal cortex. These changes are reversed 
by ACTH administration but may require several days to return to normal (94). 
Using nuclear run-on assays, it has been demonstrated that ACTH 
administration results in increased transcription of the various steroidogenic 
enzyme genes, and that the increased mRNA synthesis leads to chronically 
enhanced enzyme production (121). Moreover, the addition of cycloheximide, 
an inhibitor of RNA translation, to ACTH-stimulated bovine adrenocortical 
cells inhibits production of steroidogenic enzyme species, but the total 
enzyme levels remain normal. Therefore, it would appear that ACTH, acting 
via cAMP generation, generates short-lived protein factor(s), which may 
interact directly with steroidogenic genes to influence their expression.
1.5 Adrenal Glucocorticoids
Glucocorticoids exert effects on every system in the body, although their 
name derives from their effects on carbohydrate metabolism. In common with 
all steroid hormones, glucocorticoids produce their effects via binding to 
soluble intracellular receptor proteins. The steroid is thought to enter the cell 
by passive diffusion and once inside binds to the specific glucocorticoid 
receptor (GR), to form a complex capable of activating transcription of target 
genes.
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1.5.1 Glucocorticoid Receptors
Glucocorticoid receptors belong to the steroid/thyroid/retinoid/orphan receptor 
superfamily. Binding of cortisol to the GR leads to activation of c/s-acting 
elements located in or near hormone responsive genes (122). On binding 
steroids the receptor and its associated molecules (‘chaperonins’(123)) 
dissociate and the steroid-receptor complex can travel to the cell nucleus. 
Dissociated from the satellite proteins, the steroid-receptor complex can then 
bind as a dimer to a specific region of DNA termed the hormone response 
element (HRE). HRE are present in many genes and fall into five groups- 
including the glucocorticoid/progesterone responsive element (GRE/PRE), 
which also acts as the mineralocorticoid-responsive element, the estrogen- 
responsive element (ERE) and the thyroid-responsive element (TRE)(Table 
1.5a).
Binding to these sites is through the highly conserved ‘zinc-finger’ region of 
the receptor which, if altered, leads to depression of DNA binding (124). Thus 
bound, the steroid-receptor complex leads to transcriptional activation of the 
bound gene by switching on enhancer regions of the gene(125). It is through 
this series of actions that steroid hormones exert their effects in man.
1.5.2 Phvsiological Actions of Glucocorticoids
The pleiotropic effects of corticosteroids are outlined in Figure 1.5a. Arguably, 
the effects of cortisol on carbohydrate/lipid metabolism as well as the immune 
system are the most biologically significant.
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Hormone-responsive element Consensus sequence
GRE-PRE-MRE-ARE 5’-AGGACANNNTGTACC-3’
ERE 5’-NGGTCANNNTGACCN-3’
VDRE 5’-TTGGTGAGTGACCGGGTGAAC-3’
TRE 5’-GGGTGATGAGAG-3’
RARE 5-AGGAGATGAGGT-3’
Table 1.5a. Consensus sequences of gene hormone-response elements
GRE-glucocorticoid responsive element, MRE-mineralocorticoid responsive 
element, ARE-androgen responsive element, ERE-estrogen responsive 
element, VDRE-vitamin D responsive element, TRE-thyroid responsive 
element, RARE-retinoic acid responsive element.
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Figure 1.5a. The pleiotropic effects of corticosteroids
Glucocorticoids have weak mineralocorticoid activity under normal 
physiological conditions. Cortisol has similar affinity for the mineralocorticoid 
receptor (MR) as aldosterone but in ordinary circumstances is prevented from 
binding the receptor by the 11f2.-hydroxysteroid dehydrogenase system(126). 
This system is discussed in more detail in section 1.6.6.
1.5.3 Glucocorticoids and Hvpertension
Evidence of glucocorticoid modulation of blood pressure comes largely from 
patients with glucocorticoid excess or deficiency. Around 75 per-cent of 
patients with Cushing’s syndrome (glucocorticoid excess) have hypertension 
(127)and subjects with glucocorticoid deficiency are almost always 
hypotensive.
However, the mechanisms underlying glucocorticoid-mediated hypertension 
are unclear since cortisol has only very weak mineralocorticoid activity under 
normal physiological conditions. Moreover, whilst the sodium and water- 
retaining properties of cortisol are ameliorated by use of the mineralocorticoid 
antagonist, spironolactone, this has no effect on the rise in blood 
pressure(128). In addition. Clore et al (129) found that the glucocorticoid 
antagonist RU-486 did not modify cortisol-induced elevations in blood 
pressure despite blockade of cortisol-induced hyperinsulinemia. Thus, the 
hypertension produced by cortisol is not simply explained through classic 
steroid actions.
The mechanism(s) by which cortisol raises blood pressure in humans is 
unclear; cardiac output is increased, but this is not essential for the rise in 
blood pressure, (130) and sympathetic activity is decreased(131-133).
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Cortisol has a variety of effects on kidneys, heart, brain, blood vessels, and 
body fluid volumes, but it is not clear which of these are causal rather than 
coincidental or simply modulators of the rise in blood pressure.
Functional abnormalities of the adrenal cortex were suggested as a cause for 
essential hypertension many years ago (134); indeed, early studies reported 
that adrenal cortex hyperplasia was a feature of many hypertensive 
individuals at post mortem examination (135;136). Additionally, a number of 
abnormalities of urinary excretion, plasma levels and clearance of several 
adrenal steroids in hypertensive patients have been identified over the 
years(137-140). No single defect in adrenal corticosteroid biosynthesis has 
been identified but it is relevant to consider briefly two rare monogenic 
syndromes involving 1 ip-hydroxylase (CYP11B1) and aldosterone synthase 
(CYP11B2) that cause hypertension and help identify candidate mechanisms 
(Table 1.10c).
(a) Glucocorticoid remediable aldosteronism (GRA) is a rare autosomal 
dominant condition characterised by hypertension and aldosterone excess 
that is regulated by ACTFI rather than Ang II. The molecular basis of this 
condition was first described in 1992(141). In GRA, a chimeric gene is created 
containing the 5’ promoter sequence of CYP11B1 and functional elements of 
CYP11B2 resulting in aldosterone production under control of ACTH (Figure 
1.5b).
(b) 11p-hydroxylase deficiency is a rare cause of congenital adrenal 
hyperplasia accounting for 5 to 8% of cases(142). In this autosomal recessive 
disorder, mutations in CYP11B1 result in impaired activity of 11p-hydroxylase 
leading to accumulation of the steroid precursors 11-deoxycortisol and
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Figure 1.5b. Molecular basis of Glucocorticoid Remediable 
Aldosteronism (GRA)
deoxycorticosterone (Figure 1.5c). This leads to mineralocorticoid 
hypertension in approximately two thirds of cases.
In light of these rare syndromes, it is of interest that impaired activity of the 
enzyme 1 ip-hydroxylase has also long been reported to be a feature of 
subjects with essential hypertension. In 1985, de Simone et al demonstrated 
that ACT FI-stimulated plasma levels of deoxycorticosterone (DOC) were 
increased in hypertensives compared to controls(143); a finding similar to that 
of Flonda and colleagues 10 years earlier(144). More recently, we have 
observed a similar phenomenon in hypertensive patients from Italy, in whom 
the ratio of 11-deoxycortisol to cortisol (a marker of 1 ip-hydroxylase activity) 
was elevated (145). Finally, animal models of hypertension confirm an 
aetiological role for the CYP11B locus. The Dahl hypertensive rat is 
characterised, phenotypically, by salt sensitive hypertension in which there is 
altered production of (3-adrenal 18-hydroxylated steroids; this is accounted for 
by mutations at the CYP11B1 and CYP11B2 locus(146).
Thus, these studies provide evidence of alteration of adrenal cortex 1113- 
hydroxylase activity in essential hypertension. The exact nature of this 
abnormality is unclear, but a hypothesis linking this finding to individuals with 
hypertension with aldosterone excess and the underlying genetic explanation 
for this forms much of the work of this thesis.
1.6 Aldosterone
Aldosterone, the principal human mineralocorticoid, is produced in the zona 
glomerulosa of the adrenal gland. After its isolation from bovine adrenal 
glands by Simpson and Tait in 1953 (147), progress into aldosterone research
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Figure 1.5c. Deficiency of steroid 11R-hydroxyIase in man.
Impaired cortisol synthesis results in an increase in ACTH drive to the adrenal 
gland resulting in cortical hyperplasia as well as an increase in steroid 
precursors and adrenal androgens (shown in bold).
Aldosterone synthesis is also defective but excess DOC production proximal 
to the synthetic defect leads to sodium retention with suppression of the renin- 
angiotensin axis.
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was initially fairly rapid. Within months, its structure was reported(148) and 
more sensitive and specific bioassays developed (149). Only 2 years later, 
Jerome Conn described hyperaldosteronism arising from a benign adrenal 
tumour, leading to the identification of a syndrome characterised by 
hypertension and hypokalaemia that bears his name (150).
It was subsequently suggested by Conn in 1964 that Primary Aldosteronism 
(PA) could account for up to 20% of cases of hypertension and hypokalaemia 
was a late manifestation (151).This was never widely accepted and, until 
recently, PA was regarded as a relatively rare cause of secondary 
hypertension accounting for around 1% of cases (152). However, more recent 
evidence discussed in section 1.10 may at least partly vindicate Conn’s views.
1.6.1 Biosynthesis of Aldosterone
Aldosterone is synthesised exclusively in the cells of the zona glomerulosa. 
As has already been described in section 1.4.2, aldosterone is the end 
product of a series of reactions starting with the conversion of cholesterol to 
pregnenolone by P~450scc in the inner mitochondrial membrane with the 
assistance of the StAR protein. Pregnenolone is then converted to 
progesterone by the enzyme 313,-hydroxysteroid dehydrogenase/A^-A"^ 
isomerase and progesterone converted to 11-deoxycorticosterone (DOC) by 
P-4 5 0 c21 in the smooth endoplasmic reticulum of the cell. In the zona 
glomerulosa, there is no significant expression of P-4 5 0 ci7 (153) and the result 
is the production of 17-deoxycorticosteroids (11-deoxycorticosterone). In the 
zona fasciculata, not all progesterone undergoes 17a-hydroxyiation by P- 
450c17 (154) and as a result both DOC and 11-deoxycortisol are formed. In the
59
human adrenal, both the zona fasciculata and zona glomerulosa can convert 
DOC to corticosterone. Indeed, in man, the major source of corticosterone is 
the zona fasciculata. However, it is the formation of aldosterone from DOC 
through corticosterone which is unique to the cells of the zona glomerulosa.
1.6.2 116-hvdroxvlation in the Adrenal Cortex
The steps involved in the conversion of DOC to aldosterone and 11- 
deoxycortisoi to cortisol are often referred to as the ‘late reactions’ or ‘late 
pathways’ in adrenal steroid synthesis. The conversions of 11-deoxycortisol to 
cortisol and DOC to corticosterone requires the addition of an 1 ip -0H  group 
at the C l 1 position of both DOC and 11-deoxycortisol (Figure 1.6a). The 1 ip - 
hydroxylase step is carried out by the enzyme 11p-hydroxylase (P-450np). 
This enzyme is able to 11-hydroxylate both substrates in man and is encoded 
by a single gene on chromosome 8, CYP11B1 (110). Analysis of a panel of 
somatic cell hybrids coupled with in situ hybridisation to metaphase 
chromosomes has localised this gene to chromosome 8q22 (155). In vitro 
expression of human 11p-hydroxylase cDNA in COS-7 cells has shown that 
the conversion of DOC to aldosterone by 1 ip-hydroxylase is negligible 
although it can form corticosterone and a little 18-hydroxycorticosterone 
(Table 1.6a) (156). Thus, this provides good evidence that human 11p- 
hydroxylase is responsible for the formation of cortisol and corticosterone in 
the zona fasciculata but is unable to perform the necessary reactions for the 
conversion of DOC to aldosterone.
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Figure 1.6a. The terminal steps in the biosynthesis of aldosterone and 
cortisol within the adrenal cortex.
Substrate Product Hydroxylase activity
P-450iir P-450aido
DOC Corticosterone 482 438
18-OH-corticosterone 2.7 14
Aldosterone <0.02 2
11-deoxycortisol Cortisol 411 393
18-OH-cortisol 1.1 7
18-oxocortisol <0.02 1.8
Corticosterone 18-OH-corticosterone 1.5 10.6
Aldosterone <0.02 0.9
Cortisol 18-OH-cortisol 0.7 4
18-oxocortisol <0.02 0.4
Table 1.6a. Hydroxylase activity of P-450s expressed in COS-7 cells
Results are expressed in pmoi/mg of protein.
Adapted from ref 156.
1.6.3 Regulation of aldosterone production
Three major stimulants of aldosterone secretion have been identified in man; 
angiotensin II (Angll), plasma potassium (K+) and ACTH. The classical renin 
angiotensin system (RAS) is outlined in Figure 1.3b. This consists of a 
precursor protein, angiotensinogen, produced by the liver, and two enzymes, 
renin (first described in the juxtaglomerular cells of the kidney) and 
angiotensin I converting enzyme (ACE) which is widely distributed but found 
predominantly in pulmonary vascular endothelium.
Renin is an aspartyl protease which has only one substrate in vivo, 
angiotensinogen, and cleaves this protein to release angiotensin I (AngI). 
Angiotensin I is converted into the octapeptide Ang II in the pulmonary 
circulation by ACE. Once formed, Ang II acts directly on the adrenal cortex to 
stimulate aldosterone secretion as well as producing a direct pressor 
response through increased resistance vessel tone(37). Secretion of renin 
(and hence activation of the RAS) is increased under conditions of reduced 
sodium intake, sodium loss or reduced extracellular fluid volume. Hence, the 
RAS is important in acute cardiovascular homeostasis, i.e. the response to 
head-up tilt or blood loss and in the regulation of aldosterone secretion in 
response to salt depletion.
Renin is thought to have no direct biological (non-enzymatlc) function, 
although a pro renin or renin receptor has recently been identified (157). Ang I 
has no other known function other than as a substrate for ACE. Ang II 
produces most of its effects on aldosterone secretion via the type I 
angiotensin II receptor (ATi) (Figure 1.6b). Binding to this G -protein coupled 
receptor results in activation of phospholipase C. In turn this leads to
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Figure 1.6b. Schematic depiction of the regulation of blood pressure 
and renal function by the ATi and AT2 receptor.
PLA2"phospholipase A2; COX-2-cyclooxygenase-2; BK-bradykinin; NO-nitric 
oxide; cGMP-guanosine 3% 5’ monophosphate; PGE2-prostagiandin E2 ; PG I2- 
prostacyclin and PGp2a -prostaglandin p2a.
hydrolysis of phosphatidyl inositol biphosphate producing inositol triphosphate 
(IP3) and diacylglycerol (DAG) causing a rapid rise in intracellular calcium and 
activation of aldosterone synthesis by activating transcription factors such as 
activating transcription factor (ATF)-1, ATF-2 and cAMP-response element 
(CRE)-binding protein (CREB)(158;159). Recent studies have identified the 
transcription factor NURR-1 as a key regulator of CYP11B2 transcription that 
responds to Ang II; its expression is up regulated in aldosterone-secreting 
tumours (160). Concurrently, there is a decrease in membrane potassium 
permeability and resultant rapid depolarisation of the cell(161). Voltage- 
dependent calcium channels open and there is entry of extra-cellular calcium 
which results in opening of calcium-dependent potassium channel and 
repolarisation of the membrane. This rise in intracellular calcium correlates 
well with aldosterone production(162). In addition, DAG activates protein 
kinase C which then acts on cellular proteins to alter gene expression, most 
notably at the side-chain cleavage step(163) and the aldosterone synthase 
step(153).
In man, studies have defined the sensitivity threshold to intravenous Ang II 
infusion (164). The threshold varies from 0.3 to I.Ong Ang I I/kg body weight 
min"  ^ in individuals consuming 100-200 mEq of sodium. A low sodium diet 
increases this sensitivity and the magnitude of response to Ang II rises by up 
to threefold. The threshold sensitivity is often reduced to 0.3 Ang I I/kg body 
weight min an infusion rate that produces no measurable change in 
circulating Ang II levels (165). Potassium loading also increases the maximum 
aldosterone response to Ang II infusion, but has only one third of the effect of 
changes in sodium intake (166). With prolonged Ang II infusion, aldosterone
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secretion decreases, possibly secondary to whole body potassium 
depletion(167).
Recently, the functions of another major Ang II receptor, AT2 , have been 
partially characterised(168;169) (Figure 1.6b). Ang II stimulation of the AT2 
receptor generally opposes Ang II actions mediated via the ATI receptor, 
most notably by promoting vasodilation and growth inhibition. Vasodilation 
mediated by the AT2 receptor is though to occur via the production of 
bradykinin and nitric oxide mainly in peripheral microvessels (e.g. coronary 
and mesenteric vessels)(170).
Besides the conversion of Ang I to Ang II by means of ACE, accumulating 
evidence indicates the existence of an alternative (ACE-independent) 
pathway for generation of Ang II. It has been suggested that chymotrypsin-like 
protease (chymase), which is a potent and specific Ang ll-forming serine 
protease that is not affected by ACE inhibitors, plays a functional role in Ang II 
formation in the human vascular tissue (171) and in the carotid artery of the 
dog (172). Furthermore, chymase may be involved in Ang II synthesis in the 
human heart (173;174) and kidney (171). The possible contribution of non- 
ACE pathways to in vivo Ang II formation remains to be established, because 
most approaches used so far have not made it possible to extrapolate from 
the in vitro to the in vivo situation. Clarification of the mechanisms of the 
tissue Ang II formation in humans, especially in pathological conditions, may 
open new possibilities for therapeutic interventions.
Potassium is a powerful direct stimulus to aldosterone secretion; very small 
increments, which do not alter plasma levels perceptibly, raise aldosterone 
secretion rate(166). The effects of extracellular potassium and Angll are
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synergistic, so that the prevailing potassium determines the
concentration/effect relationship for Angll-mediated aldosterone
production(175). Brief changes in dietary potassium intake can substantially 
modify the adrenal response to acute potassium administration: high dietary 
potassium intake enhances responsiveness, while low potassium reduces it 
(176).
Potassium acts at the plasma membrane of the zona glomerulosa by
modifying the membrane potential. Increasing potassium concentration leads 
to depolarisation of the cell membrane and activation of voltage dependent 
calcium channels (177). The resultant calcium influx leads to a sustained rise 
in cytosolic calcium present for the duration of the stimulus which correlates 
with aldosterone production(162). Ang II and potassium therefore regulate 
CYP11B2 transcription through common calcium-dependent signalling
pathways and also through common transcription factors(178).
ACTH may also increase aldosterone secretion in a dose-dependent manner 
(179). However, this response is abolished as a result of pre-treatment with 
ACE inhibitors implying that Ang II may be necessary for the actions of ACTH 
on aldosterone secretion(180). Moreover, like cortisol, the response of
aldosterone to ACTH is impaired with age with the result of increased 
circulating ACTH levels still within the physiological range (181). However, it 
has been generally accepted that this ACTH-mediated increase in
aldosterone levels is temporary and after 24 hours of continuous ACTH 
infusion, aldosterone levels fall back to normal or even sub-normal levels in 
healthy individuals(182). This effect is thought to be due, in part, to sodium 
retention, and thus suppression of Ang II formation, caused by the ACTH-
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mediated elevation in plasma concentrations of intermediates such as DOC, 
corticosterone and cortisol itself(182). However, this is not the entire reason 
as sodium restricted individuals given ACTH exhibit the same rise and fall in 
plasma aldosterone despite minimal sodium retention(183). The mechanisms 
whereby ACTH increases aldosterone secretion are speculative but are 
thought to be similar to those in the zona fasciculata (163). Of interest, 
individuals with Cushing’s disease (pituitary driven ACTH excess) 
demonstrate no such decline in aldosterone levels despite continuous ACTH 
stimulation (184). Furthermore, recent evidence shows that POMC-knockout 
mice have abnormal adrenal morphology with reduced (although detectable) 
levels of aldosterone, further suggesting that ACTH is required for normal 
aldosterone secretion(185).
In normal subjects, a variety of other amines and peptides exert a minor 
influence on aldosterone secretion (Table 1.6b). Atrial Natriuretic Peptide 
(ANP) is probably the most important of these and levels of ANP negatively 
correlate with plasma renin, indicating that ANP acts as an antagonist of 
aldosterone secretion(186). In patients with primary aldosteronism volume 
expansion results in increased secretion of ANP from the heart. The 
catecholamines (adrenaline, noradrenaline) as well as acetylcholine, 
dopamine and vasoactive intestinal peptide (VIP) act as stimulatory factors.
1.6.4 Aldosterone Synthase Activity in the Adrenal Cortex
In order to produce aldosterone from the zona glomerulosa, the precursor
steroid DOC must undergo sequential 11-hydroxylation, 18-hydroxylation and
65
Control factors Effect Receptor/mechanism
Atrial natriuretic peptide Inhibitory ANP receptori  aldosterone ^ pregnenolone
Adrenaline, noradrenaline Stimulatory 
T aldosterone
R-adrenergic receptors
Acetylcholine Stimulatory 
T aldosterone
Muscarinic receptors
Vasoactive intestinal Stimulatory Synergises with ACTH
peptide t  aldosterone
Dopamine Inhibitory Tonic inhibition via dopamine
i  aldosterone receptor
Table 1.6b. Factors other than angiotensin II, potassium and ACTH 
involved in the regulation of aldosterone secretion.
18-methyl oxidation. A single enzyme, aldosterone synthase, catalyses all 
three reactions.
In addition to describing the presence of a gene for 1 ip-hydroxylase in man, 
Mornet has also described the presence of a second gene, CYP11B2, with a 
high degree of homology to CYP11B1 in human genomic clones (110). The 
nucleotide sequence of CYP11B1 and CYP11B2 are 95 per cent identical in 
coding regions and 90 per cent identical in the intronic regions. The predicted 
amino acid sequence of the gene products of CYP11B1 and CYP11B2 are 93 
per cent identical. Initially, analysis of mRNA from human adrenal glands 
showed that there was strong hybridisation of a CYP11B1-specific probe to 
the adrenal mRNA but no detectable hybridisation of a CYP11B2-specific 
probe, suggesting that CYP11B2 was a pseudogene with no function or was 
expressed at very low levels in man. Later, a cDNA clone was isolated from 
tissue from a patient with idiopathic hyperaldosteronism which was shown to 
be the transcript of CYP11B2 and to possess the ability to convert DOC to 
aldosterone (187). This was the first evidence that CYP11B2 may encode a 
functionally important gene product with aldosterone synthase activity, i.e. P- 
450aido- A similar report of P-450aido expression in aldosterone-producing 
adenoma tissue showed that P-450aido did indeed catalyse aldosterone 
synthesis from DOG and the protein product had a molecular mass of 48.5 
kDa compared with 50kDa for P-450n; (188).
Curnow et al (153) provided the final confirmation that P-450aido was entirely 
responsible for aldosterone synthesis in the human zona glomerulosa. This 
was through the use of reverse transcriptase-PGR (RT-PGR), which revealed 
GYP11B2 transcripts in normal adrenals. However, the level of transcription
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was shown to be low when compared to CYP11B1 transcripts in normal 
adrenals and the levels of transcription of CYP11B2 seen in aldosterone- 
secreting tumours.
Subsequently, the coding sequences for CYP11B1 and CYP11B2 were 
amplified from an aldosterone-secreting tumour tissue and expressed in COS- 
1 cells along with pCD-Adx (a plasmid containing the cDNA for adrenodoxin 
which is poorly expressed in COS-1 celis)(189). These cells were then 
incubated with their respective radiolabelled substrates ([^ "^ C] DOC or [^H] 11- 
deoxycortisol). Cells transfected with CYP11B1 converted 11-deoxycortisol 
almost entirely to cortisol although a small amount of cortisone was also 
formed due to intrinsic 11 B-hydroxysteroid dehydrogenase activity. DOC was 
converted to corticosterone and 11-dehydrocorticosterone but no aldosterone 
was detected. In contrast, cells transfected with CYP11B2 produced 
substantial amounts of corticosterone and 18-hydroxycorticosterone from 
DOC and aldosterone was easily detectable. With 11-deoxycortisol as the 
substrate CYP11B2 produced cortisol, cortisone and a third steroid, 18- 
hydroxycortisol. We have subsequently shown similar results, using a hamster 
cell line (V79) stably transfected with CYP11B1 and CYP11B2 transcripts 
(see chapter 6).
1.6.5 Molecular genetics of CYP11B1 and CYP11B2
The genes encoding CYP11B1 and CYP11B2 are very similar and lie on 
chromosome 8q21-22 (110; 155; 190). The organisation of introns and exons 
within each gene is also very similar with each consisting of nine exons and a 
coding region which spans approximately 7 kilobases of DNA (Figure 1.6c).
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Figure 1.6c. Organisation of human CYP11B genes and the structure of 
CYP11B2 on chromosome 8.
The nucleotide sequence of the exons is 95 per cent identical and that of the 
introns approximately 90%. The putative proteins encoded by CYP11B1 and 
CYP11B2 each contain 503 amino acids including a 24-residue signal 
peptide. These sequences are 93 per-cent similar to each other and 75 per­
cent similar to the predicted sequence of bovine P-450nfi and 36 per cent 
identical to that of CYP11A. The positions of the introns of CYP11B1 and B2 
are identical to those of CYP11A (gene for P-450scc)(191). As a result, these 
genes are grouped into a single family within the cytochrome P-450 gene 
superfamily (192).
Both CYP11B1 and B2 possess a TATA box variant at position -35 to -29 
(GATAAAA) relative to the transcription initiation site. Both possess a 
palindromic sequence identical to sequences seen in cAMP- responsive 
genes (TGCGTA), i.e. a cAMP response element (CRE) which binds to a 
cAMP-responsive element binding protein (CREB), downstream from the 
TATA box. Factors that bind to TATA boxes (193) and cAMP response 
elements (194) have been identified. Clinical and biochemical observations of 
in vitro responses to ACTH suggest that cAMP is responsible for the 
regulation of steroidogenic enzyme synthesis (120) through increased 
transcription of steroidogenic enzyme cDNA (121) and expression of cDNA 
constructs in vitro has shown that cAMP regulates the transcription of 
CYP11B1 (195). It is thought that the generation of cAMP by adenylate 
cyclase leads to activation of cAMP-dependent kinase and subsequent 
phosphorylation of CREB which binds to the CRE with resultant increased 
gene expression.
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Cell-Specific expression of steroidogenic enzymes may arise due to sharing of 
a specific promoter element in these genes. This theory has been supported 
by the discovery of a AGGTCA motif in the promoter regions of murine 
P450scc, P450c2i, P450aido and bovine p450nfi which binds a protein termed 
steroidogenic factor 1 (SF-1) or, alternatively, adrenal-4-binding protein(196). 
SF-1 is a member of the orphan nuclear receptor superfamily. It was first 
isolated from an adrenal cDNA library, and subsequently shown to be 
expressed predominantly within major steroidogenic organs such as the 
adrenals and gonads(197). SF-1 is the mammalian homologue of the Fushi 
taruzu (ftz-fl) gene in Drosophila me/anogasfer which, in humans, is located 
on chromosome 9q33(198). This gene encodes a nuclear protein of 
approximately 54kDa which binds to target gene promoters and recognises 
variations of the DNA sequence PyCAAGGTCA as a monomer (199;200). 
The creation of ftz-fl knockout mice has revealed the critical role of SF-1 in 
adrenal and gonadal development. These animals die of glucocorticoid 
insufficiency within 7 days post partum due to inadequate adrenal 
development(201;202). As well as regulating the major enzymes in adrenal 
steroidogenic pathways, SF-1 additionally regulates the transcription of both 
the ACTH receptor promoter(203) and the steroidogenic acute regulatory 
protein (StAR)(204;205), both essential early determinants of steroid 
production within the adrenal.
Aldosterone synthase activity is confined to the zona glomerulosa cells and 
therefore expression of CYP11B2 must be regulated in a manner different 
from that of CYP11B1. In primary cultures of human zona glomerulosa cells, 
Ang II markedly increases the level of both CYP11B1 and B2 transcripts
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(153). ACTH increases CYP11B1 mRNA levels(153) and causes an acute 
rise in CYP11B2 activity which is apparently reversed by chronic 
administration(206). Recent evidence suggests that CYP11B1 and B2 do not 
respond similarly to SF-1 (207). When human H295R cells are co-transfected 
with human CYP11B2 or CYP11B1 reporter constructs and an expression 
plasmid encoding SF-1, CYP11B1 reporter constructs are activated by SF-1 
whereas CYP11B2 reporter constructs are actually inhibited. Thus, human 
CYP11B2 expression is regulated quite differently from genes for other 
proteins involved in steroid biosynthesis including StAR and CYP11B1 which 
are all positively regulated by SF-1.
Differences in gene transcription may result from important divergences in 
structure of the promoter regions of CYP11B1 and B2. In the 5' untranslated 
region (UTR) of both genes, outwith the immediate vicinity of the transcription 
initiation site, the nucleotide sequence of the two genes diverges quite 
considerably. These regions are only 48% identical, the difference arising 
principally due to the presence of a long palindromic sequence in CYP11B2 
from -1734 to-1001(156). Deletion analysis of 5' flanking DNA of CYP11B1 
suggests that regions between -1093 and -505 significantly decrease 
reporter activity. In contrast, reporter constructs containing from -2105 and -  
65 of the human CYP11B2 5' flanking region are thought to inhibit promoter 
activity, although a previous analysis of human CYP11B2 reporter constructs 
in murine Y-1 cells disagrees with these findings(208). These differences in 
the promoter regions between genes clearly result in important alterations in 
promoter-dependent regulation of gene expression, particularly the differential
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response to cAMP effects, and may also have a role in determining the site- 
specific expression of the genes.
In the mouse, CYP11B1 and CYP11B2 lie in tandem with CYP11B2 on the 
left if the genes are being transcribed right to left (Figure 1.6c)(209). Evidence 
from studies of patients with congenital hypoaldosteronism due to aldosterone 
synthase deficiency (corticosterone methyloxidase II deficiency; 
CMO)(210)and GRA suggest that the same arrangement exists in man. 
Studies of large restriction fragments generated by rare cutting restriction 
enzymes and separated by pulsed field electrophoresis suggest that the two 
genes are located in close proximity, approximately 40 kilobases 
apart(211;212).
In summary, in man two highly homologous genes encoding steroidogenic 
enzymes lie together on chromosome 8q21-22 approximately 40 kilobases 
apart. One gene, CYP11B1, encodes the enzyme HEhydroxylase (P-450im) 
which is expressed throughout the adrenal cortex but principally catalyses the 
formation of cortisol and corticosterone in the zona fasciculate. The 
transcription of CYP11B1 is regulated by ACTH via cAMP and it is unable to 
catalyse the formation of aldosterone. The other, CYP11B2, is expressed only 
in the zona glomerulosa in normal human adrenal tissue and catalyses the 
synthesis of aldosterone from DOC. CYP11B2 is regulated in vitro by Ang II 
and its promoter region differs considerably from that of CYP11B1, a 
difference which may reduce responsiveness to cAMP. These genes are 
clearly of central importance in the synthesis of cortisol and aldosterone and 
mutations altering the activity of their gene products and the intermediate
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hypertensive phenotype that may be the result of this forms much of the focus 
of this thesis and is discussed in detail in section 1.10.
1.7 Aldosterone and its effects in man
Traditionally, the principal target organ for aldosterone was said to be the 
kidney: mineralcorticoid receptors (MRs) are found in high concentration in 
the renal distal nephron as well as other epithelial sites such as the colon and 
ducts of sweat and salivary glands(94). However, MRs have also been 
identified in non epithelial sites such as heart, brain, vascular smooth muscle, 
liver and peripheral blood leucocytes (94).
1.7.1 Mechanism of action of aldosterone-the genomic effects 
Aldosterone binds to the MR, an intracellular receptor similar to the GR 
receptor and also belonging to the steroid/thyroid/retinoid/orphan receptor 
superfamily(213). The DNA binding regions of the two receptors are 94 per 
cent identical with 57 per cent homology at the C-terminal ligand binding 
domain and <15 per cent homology at the N-terminal region (Figure 
1.7a)(213). Once bound, the ligand/receptor complex translocates to the 
nucleus and acts as a transcription factor by direct interaction with DNA 
regulatory elements (the classical genomic effect of aldosterone)(125). The 
mechanism by which the ligand/receptor complex exerts its effects is 
discussed in detail in 1.5.1.
The gene product(s) resulting from the interaction of aldosterone/MR 
complexes binding to DNA regulatory elements are termed Aldosterone- 
induced Protein(s) (AlP). AlP may have effects on the apical membrane.
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Figure 1.7a. Schematic representation of human mineralocorticoid (MR) 
and glucocorticoid (GR) receptors
cellular energy production and/or the basolateral Na/K-ATPase pump 
resulting in increased sodium reabsorption and potassium and hydrogen ion 
excretion (214). (Figure 1.7b)
Recently, a serine/threonine kinase, serum glucocorticoid-regulated kinase 
(sgk) has been identified as an AlP resulting in an increase in activity of the 
epithelial sodium channel (ENaC) located apically in the collecting tubules and 
distal convoluted tubule of the nephron (215). Aldosterone causes 
phosphorylation and activation of sgk which in turn increases ENaC activity by 
an increase in the number of channels at the cell surface (216). The principal 
ENaC inhibitory accessory protein is Nedd 4 (Neuronal precursor cells 
Expressed Developmentally Down regulated). This ubiquitin protein ligase 
binds to the C tails of p and y sub-units of ENaC leading to channel 
internalisation and degradation. Recent work suggests that the stimulatory 
action of sgk on ENaC is mediated through phosphorylation of serine residues 
on Nedd4. Such phosphorylation reduces the interaction between Nedd4 and 
ENaC, leading to elevated ENaC cell surface expression (217).
Another mediator of aldosterone action is Kirsten Ras GTP-binding protein 2A 
(Ki-RasA). Expression of this protein is induced during the early phase of 
aldosterone action and appears to be necessary for the effects of aldosterone 
on sodium transport in renal epithelial cells. The exact mechanism by which it 
mediates this is unclear but Ki-RasA appears to have dual contrasting effects 
on the ENaC channel decreasing the number of channels but keeping 
channels open (218).
Other mediators of aldosterone action include the lipid kinase, PI3K and 
corticosteroid hormone-induced factor (CHIF). Whilst PI3K is not an actual
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Figure 1.7b. intracellular effects of aldosterone on distal collecting 
tubule of nephron
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AlP its activity is increased by aldosterone and insulin in the kidney and 
inhibition of PI3K reduces both the early and late actions of aldosterone(219). 
CHIF is expressed in the basolateral membranes of epithelial cells of the 
distal colon and nephron and belongs to a family of proteins known to regulate 
ion channels and transport proteins (219). Their mechanism of signal 
transduction is unknown.
1.7.2 Non-genomic effects of aldosterone
It is now accepted that, as well as classical genomic effects through 
ligand/receptor binding of DNA regulatory elements, aldosterone also exerts 
rapid, non-genomic, effects. Non-genomic effects are associated with rapid 
activation (occurring within minutes) in the absence of a need for transcription 
or protein synthesis(220). Because of the brief response time, it is presumed 
that non-genomic actions are initiated at the membrane level, and membrane 
signaling transduction pathways have been intensively studied. These studies 
suggest the existence of novel steroid hormone receptors or possibly classical 
receptors embedded in the membrane that initiate the non-genomic signal 
cascade although to date none have been found. However, two recent studies 
have demonstrated a role for intra-cellular calcium as well as protein kinase C 
activity as a potential mechanism of action despite the elusive nature of the 
membrane receptor(221 ;222).
This has led to investigation of aldosterone action in tissues other than the 
kidney. Reports of rapid, non-genomic, effects of aldosterone have been 
described in smooth muscle, cardiac muscle, skeletal muscle, colonic 
epithelial cells and myocardial celis(82). These effects have been linked to the
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development of increased systemic vascular resistance and so could, 
theoretically, contribute to hypertension and cardiovascular disease
1.7.3 11 R-hvdroxvsteroid dehvdroqenase svstem
Studies of the in vitro receptor affinity of GR and MR have revealed that the 
affinity of GR for steroids mirrors their in vivo therapeutic potency whilst the 
MR has equal affinity for aldosterone, cortisol and corticosterone in both 
adrenal tissue and recombinant MR studies (213;223). In normal subjects, 
circulating cortisol concentrations are 100-1000 times that of aldosterone and 
would thus be expected to exert important mineralocorticoid effects well in 
excess of aldosterone at normal plasma concentrations. This is clearly not the 
case in vivo as the 11-p-hydroxysteroid dehydrogenase system (11(3-HSD) 
acts as a gatekeeper to prevent activation of the MR by much higher available 
levels of cortisol(126) (Figure 1.7c). The type 2 isoform of this enzyme is 
found in the renal distal nephron as well as other aldosterone sensitive target 
tissues (colon, salivary glands and placenta) and converts cortisol to its 
inactive metabolite, cortisone, which has no affinity for the MR. The type 1 
isoform of this enzyme was cloned in 1989(224) but only later was recognised 
to act in vivo predominantly as a NADPH dependent reductase performing the 
opposite role to 11p-HSD2(225) (i.e. generating cortisol from inactive 
cortisone). Iip -H S D I is found in many tissues including liver, adipose, 
gonads, brain and vasculature(226). These tissues are abundant in 
glucocorticoid rather than mineralocorticoid receptors.
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Figure 1.7c. 11fi-hydroxysteroid dehydrogenase (11RHSD) activity.
1.7.4 Aldosterone and the renal tubule
The best-characterised physiological effect of aldosterone is to increase the 
reabsorption of sodium in the kidney and at other secretory epithelial sites at 
the expense of potassium and hydrogen ions (227). The major sites of 
aldosterone-induced sodium and potassium transport are luminal cells of the 
cortical collecting tubules and the distal convoluted tubule. The apically 
located epithelial sodium channel (ENaC) is the major determinant of renal 
sodium reabsorption (228). Its availability in open conformation at the apical 
membrane of the cell is increased by aldosterone and also by vasopressin, 
glucocorticoids and insulin; elevated intracellular levels of calcium and sodium 
down-regulate it (229).
Aldosterone also regulates hydrogen ion excretion by the kidney in the distal 
nephron. Hydrogen ion secretion is through a sodium-insensitive route since it 
occurs principally in the intercalated cells of the collecting tubule. This 
segment of the nephron exhibits little or no aldosterone-induced sodium 
transport, and so aldosterone-induced natriuresis and hydrogen ion secretion 
appear to be independent events. This effect is mediated via an effect of 
aldosterone on the activity of the ATP-dependent apical hydrogen ion pump 
and parallel regulation of the basolateral membrane CIVHCOs" 
exchanger(230).
The net effect of aldosterone on the renal tubule is therefore to promote 
sodium retention at the expense of potassium and also to promote hydrogen 
ion excretion by the kidney. This explains the clinical features observed in 
cases of primary aldosterone excess, i.e. plasma hypokalaemia, alkalosis, a 
raised exchangeable sodium content and low total body potassium (231).
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1.7.5 Non-epithelial actions of aldosterone
MRs have been localised in a number of non-epithelial tissues, particularly in 
the cardiovascular system and central nervous system (CNS). While the 
properties of the MRs in these tissues are largely similar, the effects they 
mediate are extremely diverse. In contrast to its established effects on 
electrolyte balance in epithelial tissue, aldosterone in the cardiovascular 
system promotes cardiac hypertrophy, fibrosis and abnormal vascular 
endothelial function. These effects are described more fully in section 1.8.
In the CNS, aldosterone appears to regulate blood pressure, salt appetite and 
sympathetic tone. There are relatively few MRs in the CNS and these are 
concentrated predominantly in the hippocampus, the septum and the 
cerebellum (232). In contrast to epithelial cells, MRs in the CNS do not appear 
to co-localise with 11li-OHSD2(233). However, high levels of 11R-0HSD2 are 
found in the subcommisural organ (SCO) and amygdala(234-236). The SCO 
is involved with the central regulation of aldosterone secretion while the 
amygdala MR has been implicated in the control of salt appetite. The lack of 
11B-OHSD2 in MR-rich areas suggests that the majority of brain MRs are 
likely to be occupied by glucocorticoid.
1.8 Aldosterone as a cardiovascular hormone
As result of a series of in-vitro, animal and large-scale clinical studies, the role 
of aldosterone in the pathophysiology of cardiovascular disease is now 
recognised more fully. Aldosterone is now recognised as an important 
cardiovascular hormone contributing to a number of pathophysiological
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mechanisms in the heart and other organs (Figure 1.8a). As a consequence 
of this, aldosterone antagonists are increasingly used in cardiovascular 
disease.
1.8.1 Traditional effects of aldosterone on the heart
Congestive cardiac failure (CCF) causes activation of the renin-angiotensin- 
aldosterone system (RAAS). The consequent aldosterone excess leads to 
sodium retention and expansion of extra-cellular volume, further impairment of 
haemodynamic response and a fall in cardiac output. Thus, a vicious cycle is 
created whereby reduced renal perfusion causes further activation of the 
RAAS(237). This ‘secondary aldosteronism’ is an important cause of 
potassium depletion in this circumstance.
Moreover, loop diuretics, one of the primary treatments to relieve congestive 
symptoms, are potent stimulators of the RAA system(238). Indeed, some 
researchers have proposed that activation of the RAAS in patients with CCF 
is a result more of diuretic treatment than the disease process itself (239).
In addition to these well-recognized adverse effects of aldosterone excess on 
electrolyte and fluid balance, studies over the past decade have demonstrated 
more direct effects of aldosterone on myocardial and vascular function.
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Figure 1.8a. Widespread effects of aldosterone within the 
cardiovascular system.
Traditional effects are on the left whilst more recently described adverse 
effects are outlined on the right.
1.8.2 Pathological effects of aldosterone on the heart
In 1988 Karl Weber and colleagues pioneered experimental work examining 
the effects of aldosterone on the myocardium(240). In a rat model of 
renovascular hypertension they observed fibrosis not only of the 
hypertrophied left ventricle but also of the non-hypertrophied right ventricle. 
This implied that fibrosis might be a result of humoral rather than 
haemodynamic factors.
Cardiac fibrosis can also be demonstrated in rat models of PA 
(uninephrectomized salt-fed rats infused with aldosterone) (241) (Figure 1.8b). 
Moreover, despite severe persistent hypertension, cardiac hypertrophy and 
fibrosis are blocked by doses of spironolactone insufficient to ameliorate the 
hypertension (154).
Several other investigators have confirmed and developed the findings of 
Weber’s group (242). Thus, if considered together, these observations 
suggest that aldosterone can cause cardiac fibrosis independent of its effect 
on blood pressure or on the development of ventricular hypertrophy.
Crucially, these pro-fibrotic actions of aldosterone only develop in animals fed 
a high salt diet(243). The effect is not observed if dietary salt is restricted 
underscoring the importance of salt with mineralocorticoids in this 
pathophysiological effect. The mechanism that subserves this interaction 
between sodium status and mineralocorticoid related damage is unknown.
A novel hypothesis to partly explain this phenomenon has been proposed by 
Funder and colleagues(244). They propose that cardiovascular damage 
described above can be accounted for not by aldosterone per se but by 
inappropriate activation of the MR by normal levels of glucocorticoids. It is
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iAldosterone+ sait Aldosterone+ salt+ eplerenone
Figure 1.8b. Effects of aldosterone + salt on rat myocardium
Photomicrograph of myocardium in rats treated with aldosterone and salt with 
and without eplerenone. Note the presence of vasculopathy including 
perivascular inflammatory cell infiltrate in rats treated with aldosterone and the 
absence of these findings in rats treated with aldosterone and eplerenone
argued that 11-f2>OHSD2, whilst markedly reducing amounts of locally 
available cortisol, cannot reduce levels to those well below locally available 
aldosterone. Thus cortisol levels remain 10-fold higher than aldosterone 
occupying the majority of the MR. Moreover, a by-product of 11-R0HSD2 
activity is the generation of NADH. Crucially, they maintain that high levels of 
NADH (which reflect high 11-B0HSD2 activity) inhibit the activity of 
glucocorticoid-bound MR(245). When intracellular NADH falls, in response to 
enzyme blockade or generation of reactive oxygen species (as a result of 
tissue damage), the MR is activated by glucocorticoids, mimicking the 
cardiovascular effects of inappropriate aldosterone for salt status. Hence, a 
second function of the enzyme 11-R0HSD2 is to modulate MR activation by 
altering local redox state.
1.8.3 Mechanism of aldosterone-induced myocardial damage 
The exact mechanism by which aldosterone causes tissue damage remains 
controversial; several mechanisms have been proposed and all may 
contribute to a variable extent. Firstly, evidence from animal and human 
subjects suggest that aldosterone is a pro-inflammatory hormone which 
causes cardiac peri-vascular inflammation(82). After several weeks of treating 
rats with aldosterone and salt, macrophages, lymphocytes and proliferating 
endothelial and vascular smooth muscle cells and fibroblasts are found in the 
perivascular space of intra-mural coronary arteries as well as areas of 
cardiomyocyte necrosis in both ventricles(246). This is accompanied by 
fibrosis, as demonstrated by a significant increase in ventricular collagen 
volume fraction. Moreover, there are concurrent increases in mRNA for pro-
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inflammatory mediators and cytokines such as Intercellular Adhesion 
Moleculel (ICAM-1), Monocyte Chemoattractant Protein (MCP-1) and 
Tumour Necrosis Factor alpha (TNFa) (247). Crucially, development of all 
these changes can be prevented by co-administration of selective aldosterone 
receptor antagonists such as eplerenone(248).
Aldosterone also exerts a direct pro-fibrotic action by stimulating collagen 
production by cardiac fibroblasts. Application of aldosterone to rat cardiac 
fibroblasts in vitro has been shown to increase collagen synthesis 
significantly(249). Whether this direct pro-fibrotic effect is solely responsible, 
or occurs via reparative fibrosis secondary to cell necrosis and death 
accounting for the original observations by Weber et al (aldosterone induced, 
blood pressure independent cardiac fibrosis) is yet to be determined.
Chronic aldosterone and salt treatment increases the expression of NADPH 
oxidase which, in turn, catalyses the formation of the superoxide anion(246). 
These changes are mainly seen in inflammatory and endothelial cells in the 
perivascular space of the myocardium. Spironolactone and the two 
antioxidants, pyrrolidine dithiocarbamate and N-acetylcysteine attenuate all of 
these responses, suggesting that aldosterone and salt induce a pro- 
inflammatory phenotype, at least in part by increasing oxidative stress (247). 
However, for aldosterone to act directly on the heart to induce fibrosis, 11 [3- 
HSD2 would also have to be present in order to allow aldosterone access to 
the mineralocorticoid receptor. 11(3-HSD2 has never been detected in rat 
cardiac fibroblasts (250). Therefore, it could be argued that aldosterone 
contributes to the development of myocardial fibrosis indirectly, through its 
actions on systemic sodium retention, expansion of extravascular space and
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hypervolaemia. On the other hand, 11p-HSD2 is present in the vasculature 
suggesting that these pro-fibrotic effects are in fact peri-vascular (251).
1.8.4 Effects of aldosterone on the vasculature
Several human studies have demonstrated that aldosterone is pro- 
atherogenic and promotes endothelial dysfunction (252). One possible 
mechanism by which this occurs is by decreasing nitric oxide (NO) availability 
through superoxide generation. Superoxide anions inactivate NO and produce 
the highly toxic peroxynitrite radical (ONOO“).
Aldosterone has been shown to reduce NO bioactivity in an in-vitro study of 
rat smooth muscle(253). In a study of healthy volunteers, intravenous 
aldosterone significantly attenuated endothelium-dependent vasodilatation (as 
measured by venous occlusion plethysmography) in response to acetylcholine 
(an endothelium-dependent vasodilator). Moreover, in a placebo-controlled 
clinical study of heart failure patients, administration of spironolactone 
significantly increased forearm blood flow response to acetylcholine. This 
improvement was shown to be associated with improved NO bioavailability 
(254).
Aldosterone-associated effects on the vasculature lead to a reduction in 
arterial compliance and, therefore, impaired baroreflex activity(255). As a 
consequence, patients with hypertension and cardiac failure demonstrate 
impaired autonomic control of cardiac and vascular responses. In one study of 
treated heart failure patients, there was a negative correlation between 
plasma aldosterone concentrations and arterial compliance of the aorta and 
its major branches(256).
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1.8.5 Extra-adrenal production of aldosterone
As has already been discussed, the main source of circulating aldosterone is 
the adrenal zona glomerulosa. However, recent studies have demonstrated 
that tissues other than the adrenal cortex express enzymes required for 
corticosteroid biosynthesis, such as aldosterone synthase (CYP11B2) and 
11p-hydroxylase (CYP11B1) and so it is possible that aldosterone can be 
synthesised in a range of other tissues (257). In particular, whilst there is 
strong evidence to support aldosterone production in the brain (258), research 
into the heart has proved to be less conclusive. A number of published studies 
fail to agree as to whether cardiac production of corticosteroids actually 
occurs(259;260). Mineralocorticoid receptors are known to be expressed in 
cardiac tissue as well as brain and blood vessels(94). Thus, locally produced 
aldosterone could potentially act in a paracrine fashion to produce some of 
the effects described above. Given the implications of this for treatment of 
cardiovascular disease and the suggestion by some that cardiac aldosterone 
synthase expression may be increased in heart failure (261), this is an 
important issue that requires further consideration.
Most recently, Gomez-Sanchez et al. addressed this issue by measuring 
cardiac and plasma levels of aldosterone and its precursor, corticosterone in 
rats under varying conditions (260). They have concluded that aldosterone 
concentrations in the heart reflect those in the circulation and are far lower 
than others have previously reported.
Investigators from my group have used our previously validated, highly 
sensitive quantitative RT-PCR method to measure CYP11B1 and CYP11B2
83
mRNA levels in cardiac tissue of several rat models of cardiovascular 
pathology (congestive heart failure, genetic hypertension and cardiac 
hypertrophy). Cardiac CYP11B1 and GYP11B2 mRNA transcript levels from 
all groups were never greater than 10  ^ copies per microgram of total RNA 
(Figure 1.8c) and therefore too low to be detected reproducibly(262). These 
data suggests that cardiac corticosteroid production is of little or no 
pathological or physiolological significance.
Thus, in concordance with the conclusions of Gomez-Sanchez et al., it is 
more likely that cardiac aldosterone derives from the adrenal cortex via the 
circulation. It has been suggested that the high concentrations of aldosterone 
that have been reported in heart tissue could be due to extraction of 
aldosterone from the circulation rather than local synthesis. This has been 
confirmed in rats where endogenous aldosterone production was ameliorated 
by a combination of adrenalectomy and dexamethasone treatment. 
Circulating and cardiac levels of aldosterone were barely detectable in these 
rats in comparison with control animals(263).
1.8.6 Aldosterone escape
This describes the failure to suppress the synthesis of aldosterone during 
treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARBs). This is a common phenomenon with reports of 
aldosterone levels returning to baseline as soon as 3 days after initiation of 
ACE inhibitor therapy in patients with acute myocardial infarction (264). In the 
RESOLVD Pilot study (265), heart failure patients given both enalapril and 
candesartan demonstrated a significant fall in aldosterone levels at 17 weeks
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Figure 1.8c . Real-time polymerase chain reaction amplification of p- 
actin mRNA in rat cardiomyocytes.
(a) CYP11B2 transcripts (b) CYP11B1 transcripts.
In both cases, gene expression undetectable at <100 copies/mg total RNA.
compared to those given either agent alone, but mean aldosterone levels had 
returned to baseline by 43 weeks, even with maximum doses of both agents 
(Figure 1.8d). This is not surprising given the importance of plasma potassium 
as well as Ang II in the regulation of aldosterone production. This is further 
illustrated by the finding of continued aldosterone production in 
angiotensinogen knockout mice (266).
The relationship between aldosterone levels and clinical outcomes has been 
assessed in large-scale clinical studies. In a sub-population of 534 post- 
myocardial infarction (Ml) patients participating in the SAVE trial who were 
randomised to captopril or placebo, mean aldosterone levels were lower 
among patients who remained free of cardiovascular events over 2 years 
compared to those who died, developed heart failure or had a further Ml(267). 
In the CONSENSUS trial, amongst patients who received enalapril those who 
had a large decrease in aldosterone levels at 6 weeks had approximately half 
the 6-month mortality rate of those with smaller reductions in aldosterone 
(268). It has also been reported that aldosterone escape is associated with 
reduced exercise capacity in patients with congestive heart failure(269) and 
decreased vascular compliance (270)despite ACE inhibitor therapy.
The role of aldosterone escape in patients with type 2 diabetes mellitus and 
diabetic nephropathy has also been evaluated. One study demonstrated the 
presence of aldosterone escape in 40 per cent (18/45) of patients with 
nephropathy being treated with an ACE inhibitor. Addition of spironolactone o 
this cohort significantly reduced urinary albumin excretion without alteration in 
blood pressure(271). Taken together, these data suggest that insufficient 
suppression of plasma aldosterone with ACE inhibitor treatment (i.e.
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Figure 1.8d. Changes in plasma aldosterone concentrations at 17 and 43 
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aldosterone escape) correlates with poor outcome and that more specific 
blockade of aldosterone effects could be beneficial.
1.8.7 Aldosterone blockade in cardiovascular disease
The first evidence of the additional benefit of aldosterone blockade in heart 
failure came from the Randomized Aldactone Evaluation Study (RALES) 
published in 1999(272). In this population of patients with chronic moderate- 
to-severe heart failure treatment with the aldosterone antagonist 
spironolactone, given in addition to ACE inhibitor therapy significantly lowered 
mortality (RR 0.70, 95% 01 0.60-0.82, p<0.001) through a reduced risk of 
death from progressive heart failure and sudden cardiac death. A sub study of 
sodium retention demonstrated that the dose of spironolactone used in the 
study (25-50mg) had no apparent diuretic effect. The authors concluded 
therefore that the cardioprotective effect of aldosterone blockade contributed 
to the reduction in mortality rate.
To provide a mechanistic explanation for these benefits a further sub-study of 
the RALES population looking at serological markers of collagen turnover 
(procollagen type 1 carboxy-terminal peptide (PICP), procollagen type 1 
amino-terminal peptide (PINP), procollagen type II amino peptide (PIIINP)) 
was performed(273). The procollagen markers decreased in the 
spironolactone group over 6 months but remained unchanged in the placebo 
cohort, indicating that benefits of aldosterone blockade paralleled the 
reduction in cardiac fibrosis.
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More recently, the Epierenone Post-Acute Myocardial Infarction Heart Failure 
Efficacy and Survival (EPHESUS) study has evaluated treatment with the 
highly selective aldosterone antagonist epierenone (274). This was initiated in 
6632 patients with acute Ml complicated by heart failure. A major difference in 
the patient cohort of this study compared to RALES was pharmacotherapy- 
75% of patients received beta-biockers vs. 10% in RALES. At a mean follow- 
up of 16 months, treatment with epierenone was associated with a 15% 
reduction in overall mortality and a 17% reduction in cardiovascular mortality. 
Hence, the myocardial protective effect of aldosterone blockade is maintained 
even in the presence of optimal therapy and in patients close to the acute 
phase of myocardial infarction.
In summary, the above evidence provides a compelling argument for an 
important role for aldosterone in the clinical deterioration of patients with heart 
failure and myocardial infarction complicated by heart failure. Although the 
exact mechanism by which aldosterone exerts its adverse cardiovascular 
effects remains unresolved, it is now generally accepted that aldosterone 
receptor antagonists have a significant role in the treatment of severe heart 
failure and post acute Ml complicated by heart failure.
1.9 Disorders of mineralocorticoid production
In the majority of clinical syndromes charcterised by disordered 
mineralocorticoid production, mineralocorticoid hormones are produced in 
excess leading to hypertension. Mineralocorticoid hypertension is probably 
the commonest cause of secondary hypertension in man, accounting for 
around 10 per cent of cases (section 1.10). There are a number of clinical
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Cause Subtype Mineralocorticoid 
in excess
Primary
Aldosteronism
Adrenal adenoma 
Bilateral adrenal 
hyperplasia 
GRA
Adrenal carcinoma
Aldosterone
Congenital Adrenal 
Hyperplasia
17a hydroxylase deficiency 
1113) hydroxylase deficiency
Deoxycorticosterone
Corticosterone
Liddle's syndrome
li f t  Hydroxysteroid
Dehydrogenase
deficiency
Apparent mineralocorticoid 
excess
Liquorice /Carbenoxolone
Cortisol
Miscellaneous (rare) Ectopic ACTH syndrome 
Glucocorticoid resistance 
DOC secretion
Deoxycorticosterone
Corticosterone
Aldosterone
Table 1.9a. Classification of Mineralocorticoid excess syndromes
syndromes resulting in mineralocorticoid hypertension and these are 
summarised in Table 1.9a.
1.9.1 Primary aldosterone excess
Excessive production of aldosterone can occur due to an aldosterone 
producing adenoma (APA), idiopathic hyperaldosteronism due to bilateral 
adrenal hyperplasia (BAH) and glucocorticoid remediable aldosteronism 
(GRA; discussed in 1.5.3). This will be discussed in more detail in section 
1. 10 .
1.9.2 Congenital adrenal hyperplasia (CAH)
(a) Deficiency of 11 (3>-hydroxylase
Clinical deficiency of 1113,-hydroxylase was first noted in 1951(275) and it is 
characterised by hypertension in the face of impaired cortisol synthesis. 
Although there is impaired llfi-hydroxylase activity, aldosterone synthesis is 
not impaired although plasma aldosterone may be low due to suppression of 
renin synthesis (276). In these patients hypertension is relieved by 
administration of glucocorticoids. Other features of clinical 1113,-hydroxylase 
deficiency are due to adrenal androgen excess, i.e. masculinisation of the 
female genitalia, premature growth spurt and early closure of the bony 
epiphyses with subsequent short stature. Figure 1.5c summarises the 
underlying mechanism which is due to a combination of increased cortisol and 
aldosterone precursors such as DOC and 11-deoxycortisol (mineralocorticoid 
hypertension) and ACTH drive to the adrenal to maintain cortisol production 
resulting in excess androgens.
Classical 11S-hydroxylase activity is rare with an incidence of 1/100000 births 
in the general Caucasian population (277). It is inherited as an autonomic
recessive condition and so is more common in populations which are 
relatively inbred, e.g. Jews of Moroccan descent living in Israel (incidence of 
1/5000-1/7000 births)(278).
Multiple polymorphisms within CYP11B1 accounting for clinical 11(3,- 
hydroxylase deficiency have been reported and continue to be detected. The 
clinical syndrome is mainly caused by mutations of the coding region, 
clustering at exons 2,6,7 and 8(279).
In Moroccan Jews, almost all affected subjects have the same disease allele, 
R448H (280). R448 is adjacent to C450 which is presumed to be ligand of the 
haem iron atom in the P-450 complex and is highly conserved in all eukaryotic 
p-450 enzymes. This would suggest that C450 is of great importance in the 
function of llf^-hydroxylase and a mutation of this amino acid abolishes 
enzyme activity (281).
(b) Deficiency of 17a-hydroxylase
First described in 1966, 17a-hydroxylase deficiency is an uncommon cause of 
mineralocorticoid dependent hypertension(282). 17a-hydroxylase (P450ci7) is 
active in the zona fasciculata where it is a key enzyme involved in the 
synthesis of cortisol and the adrenal androgens. In the gonads, P450ci7 
catalyses the formation of testosterone and oestrogens because of its 
combined 17a-hydroxylase/17,20 lyase activity. In man, P450ci7 is not 
expressed in the zona glomerulosa. Absence of 17a-hydroxylase leads to 
impaired synthesis of 11-deoxycortisol and cortisol in the adrenal, with 
resultant increased ACT FI secretion from the pituitary (Figure 1.9a). Synthesis 
of oestradiol and testosterone are similarly impaired with a resulting rise in LFI 
and FSFI secretion. The combined effects of excess ACTH and gonadotrophin
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17a-hydroxylase
Pregnenolone
Progesterone
Deficient hormones
Corticosterone
18-OH Corticosterone
17-OH Pregnenolone
Cortisol
Cholesterol
Aldosterone
Deoxycortisol
Androstenedione17-OH Progesterone
Deoxycorticosterone
Dehydroepiandrosterone
Figure 1.9a. Deficiency of steroid 17a-hydroxylase in man.
Termination of steroid biosynthesis at this site leads to impaired synthesis of 
cortisol and adrenal androgens which results in an increase in ACTH-driven 
synthesis of DOC in the zona fasciculata (steroids in bold).
Gonadal steroidogensis is also impaired and secondary sex characteristics fail 
to develop.
Aldosterone synthesis is normal because 17a-hydroxylase is not expressed in 
the zona glomerulosa. Excess DOC in the fasciculata leads to sodium 
retention with suppression of the renin-angiotensin axis and hypertension.
__
secretion are two-fold. Firstly, there is a build up of immediate precursors of 
P450ci7such as progesterone and pregnenolone. Secondly, increased ACTH 
secretion results in activation of conversion of DOC to corticosterone and 18- 
hydroxy DOC in the zona glomerulosa. DOC, and to a lesser extent, 18- 
hydroxy DOC have sodium retaining properties which suppress renin secretion 
and as a result plasma aldosterone levels are suppressed. Signs of 
glucocorticoid deficiency are usually absent and the very high levels of 
corticosterone probably compensate for the lack of cortisol (283).
The clinical features of 17a-hydroxylase deficiency include hypertension and, 
in females, lack of secondary sexual characteristics. In XY genetically male 
fetuses there is a variable degree of pseudohermaphroditism and secondary 
sex characteristics do not develop at puberty. Indeed, affected males are 
often raised as females (283).
Most mutations causing this disorder are found in the structural gene of 
CYP17 as shown in table (284) and some are located in the introns or 
regulatory elements of the CYP17 gene(285).Many of these CYP17 mutations 
are defective in both 17a-hydroxylation and 17,20-lyase activities, suggesting 
that the same residues are required for both enzymatic activities(286).
1.9.3 Liddle’s Syndrome
This was first described by Liddle in 1963 (287)when he reported a family in 
which the siblings appeared to have features of aldosterone excess (early 
onset hypertension and hypokalaemia) but with suppressed plasma renin and 
aldosterone levels. It is now known that this syndrome is inherited as an 
autosomal dominant trait and occurs due to mutations of the gene encoding
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the p or Y subunit of the EnaC of the distal nephron(288) (Figure 1.3c). This 
results in constitutive activation of this receptor (sodium retention and 
potassium excretion) irrespective of circulating mineralocorticoid levels 
(usually suppressed). The clinical and laboratory signs include chronic 
hypokalemia, increase of urinary potassium excretion with sodium retention 
and reduction of plasma renin activity and of circulating levels of Ang II and 
aldosterone. In addition, ten mutations causing Liddle's syndrome have been 
identified and described on the SCNN1B gene at locus 16p12(289) and one 
mutation on the SCNN1G gene at locus 16p12(196). All the mutations 
identified to date either alter or delete (290) a highly conserved PY motif at the 
C-terminal end of the channel which is involved in its normal regulation. 
Interestingly, in the proband of one of Liddle's original cases, renal 
transplantation resulted in normalisation of blood pressure and electrolyte 
abnormalities(291). In practice, however, using antagonists at the sodium 
channel such as amiloride or triamterene usually effectively treats this 
condition(291).
1.9.4 Deficiencv of 11 f^-hvdroxvsteroid dehydrogenase (118>-HSD)
Apparent mineralocorticoid excess (AME) is a rare syndrome of hypertension 
and hypokalaemia associated with suppression of plasma renin activity and 
low plasma concentrations of aldosterone and other known mineralocorticoids 
(292) (Figure 1.3c). IIE-FISD activity is reduced or absent such that cortisol 
overwhelms the MR causing cortisol-mediated mineralocorticoid hypertension. 
The gene encoding llli-H S D  is 6.2kb long, comprises 5 exons and is located 
on chromosome 16q22 (293). Less than 100 cases of AME have been
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reported with >30 different mutations identified clustered in exons 2-5 (294). 
Biochemical diagnosis of AME can be made by measuring the ratio of cortisol 
to cortisone as indicated by the ratios of their urinary metabolites (THE: THE 
ratio abnormally low)(295). Administration of dexamethasone causes reversal 
of the clinical features (by suppression of ACTH-dependent cortisol secretion), 
which are reproduced by administration of physiological doses of cortisol 
(295).
Deficiency of 11I3>-HSD can also occur as a result of ingestion of liquorice or 
carbenoxolone (used for the treatment of peptic ulcer disease). The active 
component of liquorice is glycyrrhetinic acid which has been shown to inhibit 
the activity of 11fï-HSD 2 in the renal tubule(296). Carbenoxolone is a semi­
synthetic hemisuccinate deriviative of glycyrrhetinic acid and has its effect 
through a mechanism analogous to that of liquorice(297).
1.9.5 Hvpoaldosteronism
Primary hypoaldosteronism is a rare autosomal recessive condition due to 
mutations in the aldosterone synthase gene (CYP11B2). Prior to 
characterisation of this gene, this disease was termed corticosterone methyl 
oxidase (CMO) deficiency. In both cases, the disease is sub-categorised into 
type 1 and type 2 depending on the associated biochemical phenotype (298). 
In type 1 deficiency, patients have low to normal levels of 18- 
hydroxycorticosterone and undetectable aldosterone whereas in the type 2 
variant, 18-hydroxycorticosterone levels are high with only mildly reduced or 
even normal levels of aldosterone. The reason for the variation in phenotype
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is unknown, especially since the same mutation in CYP11B2 has been 
identified in both variants (299).
The clinical phenotype associated with aldosterone synthase deficiency is 
also variable but its severity tends to be inversely associated with age at 
diagnosis (300). Whilst it may be asymptomatic in older children and adults, in 
infancy it may present with failure to thrive, vomiting and dehydration with 
hyponatraemia, hyperkalaemia and metabolic acidosis. Such children can be 
treated successfully with mineralocorticoid replacement therapy such as 
fludrocortisone.
1.10 Primarv Aldosteronism (PA)
Primary aldosteronism can be defined as over-production of aldosterone 
independent of its major regulator, Ang II. The first case of PA was reported 
by Dr Jerome Conn in a patient with intractable hypertension and 
hypokalaemia with biochemical evidence of aldosterone excess and an 
adrenal tumour on abdominal imaging(150). Subsequent adrenalectomy 
proved curative and led to the identification of a syndrome initially thought to 
account for<1% of cases of hypertension.
1.10.1 Prevalence of PA
A number of studies around the world over the past decade have reported a 
marked but highly variable increase in the detection of PA with prevalence
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AUTHOR COUNTRY NUMBER
SCREENED
SETTING PREVALENCE
(%)
Hiramatsu Japan 348 Hypertension 2.5
et al. (298) Unit
Gordon et al Australia 199 Hypertension 8.5
(299) Unit
Lim et al UK 115 Primary care 14
(297)
Fardella et Chile 305 Hypertension 9.5
al (300) Unit
Rayner et al South 216 Hypertension 32
(302) Africa Unit
Schwartz et USA 505 Primary care 40
al (303)
Olivieri et al Italy 287 Primary care 32
(304)
Table 1.10a. Increasing prevalence of Primary Aldosteronism worldwide.
rates ranging from 3 to 40% (Table 1.10a)(301-307). Gordon and colleagues 
in Brisbane, Australia provided initial evidence that use of the aldosterone to 
renin ratio (ARR) identifies a higher percentage of hypertensive individuals 
with aldosterone excess than previously thought. After the introduction of the 
ARR as a screening tool in 1983 and, particularly after extending its 
application to include all subjects with hypertension regardless of serum 
potassium, there was a five-fold increase in the diagnosis of PA(308). This 
experience has been repeated worldwide and has been summarised by 
Mulatero and colleagues(309) who examined rates of PA before and after 
introduction of the ARR in centres spanning 5 continents. This retrospective 
study highlights that application of the ARR to an increased cohort of patients 
has led to a 5- to 15-fold increase in the identification of patients affected by 
PA.
Hypokalaemia is no longer a prerequisite for the diagnosis of 
mineralocorticoid hypertension although its presence does make it more 
likely. Indeed, in the first clinical demonstration of the ARR, Hiramatsu et al 
identified adenomatous PA in 9 patients only 3 of whom were hypokalaemic 
(301). The experiences of investigators in the 5 Continent Study indicate that 
the majority of cases of proven PA had normal serum potassium levels at 
presentation.
Some of the high prevalence rates may reflect selection bias as many of 
these studies are with patients referred to secondary or even tertiary care 
facilities with resistant hypertension or hypokalaemia. However, some studies 
have been performed in unselected populations(303;306;308). Most recently, 
investigators in Italy randomly selected a sample of adults from the population
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A. 1957-1985
■  APA
□  Probable APA
□  BAH
B.1999
■  APA
□  Probable APA
□  BAH
Figure 1.10a. Change in prevalence and relative proportions of PA 
subtypes.
A: From 1957-1985, 248 patients were diagnosed with primary aldosteronism 
at Mayo Clinic; 57% had surgically confirmed APA, and 11% had probable 
APA; the remainder (33%) had probable or confirmed bilateral adrenal 
hyperplasia (BAH; idiopathic aldosteronism).
B: In 1999, 120 patients were diagnosed with primary aldosteronism at Mayo 
Clinic; 20% had surgically confirmed APA, and 8% had probable APA; the 
remainder (72%) had probable or confirmed BAH.
register of a local health district(307). Of the 1348 individuals involved, 412 
were found to be hypertensive. 287 of these subjects agreed to estimation of 
their ARR which was elevated in 93 patients, meaning that around one in 
three hypertensive individuals (32.4%) selected at random had evidence of 
aldosterone dysregulation. This rate is in excess of that reported by 
investigators in Dundee, Scotland who found 14% (18/125 patients) of 
unselected hypertensive patients selected at random from a primary care 
population to have an elevated ARR(303). Interestingly, this prevalence is 
very similar to that found in specialist referral clinics from the same 
population(310).
1.10.2 Causes of PA
In association with an increase in detection of PA, there has been a change in 
the relative proportions of PA subtypes. It had been previously accepted that 
adrenal adenoma was the commonest cause of PA accounting for around 
60% of cases, with most of the remainder due to bilateral adrenal hyperplasia 
(idiopathic aldosteronism). This proportion has now effectively been reversed 
with two thirds of cases of PA said to be due to bilateral adrenal 
hyperplasia(304;311) (Figure 1.10a).
Some investigators have reported surprisingly low rates (3-10%) of adrenal 
adenomas in patients with PA(307). This may well reflect more widespread 
screening to include individuals with normal serum potassium, as bilateral 
adrenal hyperplasia is associated with less florid manifestations of PA than 
adenomatous PA.
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DRUG ALDOSTERONE
LEVELS
RENIN
LEVELS
EFFECT ON ARR
p-blockers t
ACE inhibitors t t t
ARBs ; t t t
Diuretics T t t t
Calcium channel 
blockers
T/- t/-
Table 1.10b. Effects of anti-hypertensive medication on aldosterone- 
renin ratio.
1.10.3 Aldosterone-to-renin-ratio (ARR)
More recently, it has become accepted that aldosterone excess is more 
common in hypertension than previously thought. This has coincided with 
widespread use of the ARR as a screening and diagnostic test. It is well 
known that plasma renin activity (PRA) and aldosterone levels vary according 
to posture and salt status. In theory, the ratio between the two, calculated by 
dividing plasma aldosterone by PRA, varies to a lesser extent. This ratio 
capitalizes on divergence between the two neurohormones such that minor 
abnormalities of both parameters will be accentuated by combining the two as 
a ratio. In PA, the ratio should be obviously elevated as a result of 
suppressed PRA and elevated aldosterone levels.
However, the ARR is subject to significant problems. Concomitant drug 
administration affects aldosterone levels and PRA (312) (Table 1.10b). 
Although ideally the ARR should be measured on no anti-hypertensives, it is 
recognised that this can rarely be achieved. The ratio is still interpretable 
under these circumstances as long as drug effects are taken into 
consideration. The PHarst study demonstrated that beta-blockers (by 
suppressing renin) elevate the ratio and ACE inhibitors (by stimulating renin) 
suppress it (313). Thus, a high ARR in a patient on a beta-blocker should be 
viewed with caution but a marginally high ARR in a patient taking an ACE 
inhibitor is more likely to be suspicious. Calcium channel blockers and alpha- 
blockers do not appear to interfere with the ratio(314).
The major criticism of the ARR has been that it is overly renin-dependent. 
Indeed in the majority of patients identified by a raised ARR, the real 
explanation is that low levels of renin dominate the ratio. Subsequent analysis
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> EXCLUDED> NORMAL
HIGH
NORMALISE SERUM POTASSIUM 
ADEQUATE DIETARY Na INTAKE
> EXCLUDEDNORMAL
GH
High \  
clinical 
suspicion 
o f APA
No
latéralisation. la téra lisa tion
Observe, repeat CT
Figure 1.10b . Proposed algorithm for the screening, diagnostic confirmation and 
management of primary aldosteronism.
AVS-adrenal venous sampling: FST-fludrocortisone suppression testing; APA-adenomatous 
primary aldosteronism; ARR-aldosterone-to-renin ratio
ARR
AVS
Mass >2.5cmMass <2.5 cm
CT adrenals
Repeat ARR off 
treatment if possible
Unilateral
adrenalectomy
Confirm by postural 
testing or FST
Medical treatment
Normal/
Micronodularity
Resistant hypertension 
Unprovoked hypokalaemia
of the mathematical derivation of the ARR, has confirmed that the renin 
measurement is the determinant of the ratio, so that its positive predictive 
power for PA is relatively low(315). This criticism is compounded by difficulties 
in accurately measuring PRA when it is below a minimum value of 0.3ng/ml/h. 
To compensate, some groups have proposed interpreting the ARR in 
conjunction with a plasma aldosterone threshold of > 15ng/dL(316). However, 
even when this more stringent of definition of PA is applied, the incidence is 
hardly altered(317).
1.10.4 Diagnosis of PA
The diagnosis of PA can be problematic and hampered by the lack of a single 
coherent diagnostic strategy. The diagnostic strategy applied in my centre is 
outlined in Figure 1.10b. Before performing specific diagnostic tests, serum 
potassium should be normalised if necessary by oral supplementation and 
patients should be encouraged to maintain a liberal dietary salt intake prior to 
ARR testing and throughout subsequent investigations for PA.
a. Detection of aldosterone excess
Although initial ARR can be performed on anti-hypertensive treatment, we 
advocate repeated measurement off treatment in those with an elevated ratio 
and those with a high clinical suspicion of PA. In particular, diuretics (including 
amiloride and spironolactone) should be stopped for up to 4 weeks and other 
medications which cause false negative (ARB or ACE inhibitors) or positive 
(beta-blockers) ratios ceased for at least 2 weeks prior to repeat testing(318). 
During this period, other agents (such as alpha-blockers or verapamil), which
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have a lesser effect on the ratio, are used if necessary to maintain control of 
hypertension.
b. Confirmation of Aldosterone excess
Although its validity as a screening tool is becoming more widely accepted, 
clearly an elevated ARR indicates a need for further investigation of the RAA 
axis and is not sufficient to make a diagnosis of PA. Postural testing of PRA 
and aldosterone can help confirm aldosterone excess as well as clarify the 
underlying cause (319). The rationale behind this is that in normal subjects, 
plasma aldosterone rises with standing due to activation of the renin- 
angiotensin system. In the majority of aldosterone producing adenomas, renin 
does not rise with standing and, as a result, aldosterone is uninfluenced by 
posture but still responds to ACTH resulting in diurnal variation. Furthermore, 
aldosterone may be relatively unresponsive to Ang II in such patients. In 
idiopathic aldosteronism due to adrenal hyperplasia and angiotensin II- 
responsive adrenal adenoma, aldosterone levels may continue to rise on 
standing.
Further confirmation of abnormal regulation of the RAA axis can be made by 
attempts to suppress plasma aldosterone by the administration of 
fludrocortisone or saline.
c. Adrenal Imaging
Adrenal imaging should only be performed when aldosterone excess has 
been confirmed biochemically. Although there have been no recent 
comparison studies, it appears that computerised tomography (CT; using fine 
cuts) is the preferred imaging modality. Most authors report that CT affords 
better spatial resolution and so is more sensitive in detecting smaller
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adenomas than magnetic resonance imaging (MRI). Nonetheless, it is 
estimated that CT detects only around 50 -75% of aldosterone producing 
adenomas(320).
d. Role of Adrenal Vein Sampling (AVS)
Although technically difficult, adrenal vein sampling (AVS) remains the gold 
standard for confirmation and localisation of aldosterone-producing adrenal 
adenomas. Given its complexity, it is generally reserved for those in v\/hom 
adrenal surgery is being considered. Diagnosis of adrenal adenoma can be 
made if aldosterone levels are elevated in one adrenal vein compared to the 
other but simultaneous cortisol measurements must be made to ensure the 
cannula is in the adrenal vein. The Australian group advocate AVS for all 
patients with proven primary aldosteronism irrespective of CT findings (321); 
they argue that adrenal CT lacks sensitivity for adrenal adenomas. This is 
supported by investigators in Japan who used AVS to Identify adenomatous 
primary aldosteronism in 43 (6 6 %) of the 65 patients identified as having PA; 
only 47% of those who lateralized on AVS demonstrated adrenal tumours on 
CT scanning(322).
This is clearly an important issue, as lateralizing excess aldosterone 
production to one adrenal gland affords the possibility of surgical cure. It may 
well be that the apparently low prevalence of adenomatous PA compared with 
bilateral adrenal hyperplasia may be due, in part, to the reliance on CT 
imaging. Moreover, CT can be misleading by demonstrating unilateral masses 
in patients found to have bilateral production(323) or lateralizing to the 
opposite adrenal on AVS. The fact that some patients with bilateral adrenal 
hyperplasia may also exhibit single (focal) adrenal lesions mean that a
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positive adrenal CT alone should not be an indication for surgery even in 
patients with unequivocal PA.
There are clear problems associated with AVS, however, which make it 
impossible to advocate as a diagnostic tool in all patients with PA. Technical 
difficulties mean only skilled, experienced operators cannulate both adrenal 
veins with any degree of success or frequency. This tends to limit availability 
of this procedure to larger centres. Controversy exists over the use of 
concurrent ACTH stimulation during AVS. Moreover, the procedure itself and 
methods used to analyse results vary across referral centres. Three recent 
reports highlight this lack of consensus. One Italian study of 104 patients 
undergoing AVS (without ACTH stimulation)(320) showed that a lateralized 
ratio of at least 2  was most discriminatory for the diagnosis of a unilateral 
adenoma. In contrast, two recent studies from large US referral centres used 
ACTH stimulation and a lateralized ratio of at least 4 and a contralateral ratio 
of <1 to define an adenoma(324;325). It would appear that ACTH stimulation 
does increase the sensitivity of AVS in differentiating bilateral adrenal 
hyperplasia from adrenal adenoma and is performed by most major 
investigating centres.
1.10.5 Treatment of PA
Spironolactone is an effective antihypertensive in patients with aldosterone 
excess due to bilateral adrenal hyperplasia. In a small observational study of 
hypertensive subjects with a raised ARR, Lim and colleagues demonstrated 
that addition of spironolactone to their existing regimen reduced the need for 
antihypertensive drugs by a mean of 0.5 as well as reducing mean BP by
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15/8(326). Moreover, investigators in Cambridge have suggested that ARR 
can predict response to spironolactone treatment(313). In their study of 
unselected hypertensive individuals, 70% of those with a raised ARR 
responded favourably to 50mg of spironolactone treatment with a mean BP 
reduction of 32/17. In contrast, only 40% of those with a lower ARR 
responded adequately to spironolactone. This provides good evidence that 
the ARR can be used as a guide for drug therapy in hypertension. However, 
there has been no properly randomised clinical study demonstrating the 
efficacy of spironolactone in patients with a raised ARR. The use of 
spironolactone is limited by its side effects many of which are related to its 
ability to interact with sex hormone receptors as well as the mineralocorticoid 
receptor(327). This has led to the development of epierenone, a selective 
aldosterone receptor blocker with greater specificity for the mineralocorticoid 
receptor, less than 1 % affinity for the progesterone receptor and less than 
0.1% affinity for the androgen receptor(328). A number of placebo-controlled 
trials have demonstrated that epierenone is an effective antihypertensive 
which is better tolerated than spironolactone(329). The epierenone-induced 
reduction in blood pressure is dose-dependent; response to lOOmg of 
epierenone is about 75% of that observed with lOQmg of spironolactone. 
Epierenone is as effective as ARBs in lowering blood pressure and may be 
more efficacious than losartan in black patients(330;331). The addition of 
epierenone to treatment with ACE inhibitors or ARBs is also effective and well 
tolerated (332).
In patients intolerant of aldosterone receptor antagonists, amiloride may be 
used. This drug blocks the aldosterone-regulated epithelial sodium channel.
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However, in patients with PA it may need to be given in fairly high doses to be 
effective.
Unilateral laparoscopic adrenalectomy is the treatment of choice for 
individuals with an aldosterone-producing adenoma. Although blood pressure 
control improves in almost all patients post-operatively, average long-term 
cure rates of hypertension after unilateral adrenalectomy for adenomatous PA 
range from 30-60%(333). Persistent hypertension after adrenalectomy 
correlates with having > 1  first-degree relative with hypertension, use of > 2  
antihypertensive agents preoperatively, older age, increased serum creatinine 
and duration of hypertension, and is probably due to coexistent primary 
hypertension(334;335).
A laparascopic approach is preferable and associated with shorter in-patient 
stays and less long-term morbidity(327;335). Pre-operatively, patients should 
be treated with spironolactone to lower blood pressure and normalise plasma 
potassium(327). Spironolactone also reduces the risk of post-operative 
hypoaldosteronism because it allows recovery of the renin angiotensin 
aldosterone axis resulting in stimulation of the previously atrophic 
contralateral zona glomerulosa.
In patients who are unfit for or decline surgery medical treatment is preferred 
as outlined above.
1.10.6 PA or not PA?
So far, there have been in excess of 3500 patients tested for PA using the 
ARR as an initial step. As a result, the overall prevalence of PA has been
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reported to be at least 1 0 %, well in excess of the 1 % prevalence widely 
quoted in most hypertension textbooks. However, whether or not these 
subjects have true 'classical' PA, with clear evidence of genuinely 
autonomous aldosterone excess, remains controversial. No gold standard 
definition of PA currently exists. Most centres use a rather arbitrary cut-off for 
a high ARR that depends upon the units used for aldosterone measurement 
(generally >750 if aldosterone expressed in pmol/L and >25 if expressed as 
ng/dL). With this approach, low renin rather than high aldosterone is the 
cause of an elevated ratio in the majority of subjects and aldosterone levels 
are often within the ‘normal’ range. It is uncertain whether they would meet 
earlier criteria for the diagnosis of PA. However, in most individuals who have 
been studied more intensively, dynamic tests of the RAS are abnormal, 
confirming an altered relationship between renin and aldosterone. How this 
group differs from individuals with low-renin hypertension is unclear and there 
is likely to be substantial overlap between the groups(83). This reprises 
previous arguments by Padfield et ai. (336), who claimed that PA due to 
bilateral adrenal hyperplasia was a variant, not of classical Conn’s adrenal 
adenoma, but of low-renin essential hypertension and that in this 
circumstance Ang II probably remains the major trophin for aldosterone.
The concept of ‘tertiary aldosteronism’ where there is sustained and 
prolonged stimulation of the adrenal by angiotensin II Is already recognised in 
renovascular hypertension(337). It has been suggested that the phenotype of 
hypertension with a raised ARR could be redefined as a form of tertiary 
aldosteronism, perhaps preceded by low-renin hypertension over a much 
longer time. Whilst this theory focuses on a single genetic polymorphism, it is
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widely accepted that hypertension is a polygenic disorder. It is likely, 
therefore, that other genes may interact in a synergistic manner to lead to the 
phenotype of hypertension with an elevated ARR.
Thus, within the heterogeneous population of essential hypertension, there 
may be 3 distinct subgroups which are currently classified on a hormonal or 
biochemical basis: low renin hypertensives, non-modulators (normal to high 
renin) and hypertensives with an elevated ARR. These 3 groups may form a 
neurohormonal spectrum which reflects differing stages of hypertension, the 
rate of progression of which depends on other genetic and environmental 
factors. Hence, the natural history of hypertension may proceed from 
essential (high-to-normal renin) hypertension through to low renin 
hypertension and finally to tertiary aldosteronism. Clearly, longitudinal studies 
that compare groups of patients of different ages followed up over time are 
needed to investigate this theory.
In summary, an elevated ARR can be demonstrated in around 10 per cent of 
unselected hypertensive subjects, making it the commonest recognizable 
phenotype in secondary hypertension. Although it is unclear how many of 
these individuals have ‘classical’ PA with truly autonomous secretion of 
aldosterone all clearly have demonstrable abnormalities in renin-angiotensin- 
aldosterone dynamics. Patients with an elevated ARR (and previously 
described subjects with low-renin hypertension) have an inappropriate level of 
aldosterone for its principal trophin Ang II and thus might be better re­
designated as having ‘aldosterone-associated hypertension’ (338).
1.10.7 Possible genetic basis for ‘Aldosterone associated hypertension’
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Debate over the exact physiological differences and similarities between sub­
groups is largely academic. Subjects identified by an increased ARR have an 
inappropriately high aldosterone concentration for its principal trophin, Ang II; 
whatever gives rise to this disproportionate renin for aldosterone level could 
clearly have pathogenic and therapeutic implications and deserves further 
investigation.
The corticosteroid biosynthetic pathway and the crucial role of aldosterone 
synthase (encoded by CYP11B2) and 11p-hydroxylase (CYP11B1) in 
catalysing the terminal steps of aldosterone and cortisol biosynthesis 
respectively have already been discussed (see section 1.6). These genes are 
obvious candidates that might be involved in hypertensive disorders as 
confirmed by monogenic forms of hypertension described earlier (Table 
1.10c). Animal models, and in particular the Dahl salt sensitive rat (146) also 
suggest a role for this locus. Over the last few years, studies have focused on 
2 common polymorphisms within the CYP11B2 gene (Figure 1.10c). One is a 
single nucleotide polymorphism (SNP) in the 5' promoter region at -344 (C-T) 
that alters a putative recognition site for the transcription factor,steroidogenic 
factor 1 (SF-1) (339). It is unclear whether this has any physiological 
significance: binding of SF1 is reduced 4-fold with the T allele and there is no 
detectable effect on gene transcription when studied in vitro(207). The other 
polymorphism involves intron 2 of CYP11B2, which is partly replaced by the 
corresponding intron of CYP11B1(339). These 2 polymorphisms are in close 
linkage disequilibrium such that the common haplotypes generated are 
T/conversion (38%), T/wild type (16%) and C/wild type (45%)(340).
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Model Genotype Phenotype
Glucocorticoid CYP11B1/CYP11B2 hybrid Hypertension with
Remediable (Figure 1.5b) aldosterone excess
Aldosteronism under ACTH control
IIB-hydroxylase Loss of function mutations in Hypertension with t
deficiency CYP11B1 (Figure 1.5c) DOC and deoxycortisol
Dahl salt sensitive Mutations in rat I IB - Salt sensitive
rat hydroxylase gene 
(chromosome 7)
hypertension
Table 1.10c. Summary of evidence illustrating the role of the CYP11B 
locus in monogenic hypertensive syndromes.
-344
T Convers ion
5 ’UTR À  1 2 A  1  1   ^ 1  1 * I 3 ’UTRA 1 2 A 3 4 5  6 7 8  9  $ ■-■ I--------■---------Hi----&
Wild Type Intron 2
Figure 1.10c. Common polymorphisms Identified in CYP11B2
In a previous local study of 138 hypertensive subjects, there was a highly 
significant excess of TT honnozygosity compared to CC homozygosity when 
compared with individually matched normotensive controls(340). Other groups 
report similar findings(341). Moreover, subsequent assessment of aldosterone 
excretion (as its urinary metabolite, tetrahydroaldosterone (THAIdo)) in an 
unrelated population demonstrated a strong association between the T allele 
and higher excretion rates(340). Further investigations have reported that 
plasma levels of aldosterone are raised in subjects with the T allele of - 
344(342). Additionally, an association between T allele frequency and 
elevated ARR has been reported within a population of hypertensive patients 
(Table 1.1 Od) (343). However, the physiological significance of these 
polymorphisms remains controversial with some studies suggesting either no 
effect of the -344C/T polymorphism on blood pressure/aldosterone(344;345) 
or a positive association between the C-allele and aldosterone or 
cardiovascular parameters(346;347). In particular, one case-control study of a 
Japanese population (348) there was a suggestion that the CC genotype was 
more common than TT in hypertensives compared to controls and that the CC 
genotype associated with higher ARR than TT. However, this study may have 
been subject to selection bias; the -344 TT homozygote rate was more than 
twice that observed in European populations (57% vs. 26%), and the T allele 
frequency was about 40% (0.74 vs. 0.53) higher than that found in other study 
populations (0.54-0.56(340;343). This might reflect a true genetic difference 
between the populations, and/or a sampling difference because a subsequent 
Japanese study reported lower but still relatively high T allele frequencies of
0.66 and 0.63 in hypertensive and normotensive subjects, respectively(349).
106
SF-1 CC CT TT p-value
ARR > 750 14 (0.15) 42 (0.46) 35 (0.39)
8 . 6  0.014 
6.5 0.039
ARR < 750 52 (0.22) 129 (0.55) 53 (0.23)
ARR > 1000 8(0.14) 26 (0.46) 23 (0.40)
ARR < 1000 58 (0.22) 145 (0.54) 65 (0.24)
INTRON
CONVERSION
11 (wild type) 12 22(conversion) p-value
ARR > 750 26 (0.29) 40 (0.45) 23 (0.26)
3.2 0.205 
7.1 0.029
ARR < 750 81 (0.35) 111 (0.48) 40 (0.17)
ARR > 1000 14 (0.25) 24 (0.43) 18 (0.32)
ARR <1000 93 (0.35) 127 (0.48) 45 (0.17)
Table 1.1 Od. Genotype distribution stratified by aldosterone to renin 
ratio.
375 hypertensive patients underwent genotyping and assessment of ARR. 
Patients with a raised ARR had a statistically significant excess of the T allele 
at the SF-1 site. A similar pattern was seen with the intron conversion allele 
although this only reached statistical significance at a higher threshold of ARR
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Figure 1.1 Od. 11-Deoxycorticosteroid responses (Increase over basal 
concentration at 30 minutes) to ACTH (250pg i.v.).
(a) SF-1 polymorphism (CC/TT); (b) Intron conversion vs normal intron 2
Additionally, the small sample size necessitated that statistical analyses were 
performed by combining patients with TC and CC genotypes at position -344.
In addition to the data on aldosterone and blood pressure, several
investigators have consistently shown that the -344 T allele and intron 2
conversion are also associated with raised basal and ACTH-stimulated levels 
of the 11-deoxysteroids, DOC and deoxycortisol (Figure 1.10d)(350). These 
steroids are converted to corticosterone and cortisol respectively by 11(3- 
hydroxylase within the zona fasciculata (Figure 1.6a). This evidence, which 
initially appears paradoxical, suggests that the -344T allele of CYP11B2 is 
associated with impaired activity of 11 (3-hydroxylase, which is encoded by the 
adjacent CYP11B1. Although the exact molecular mechanism that accounts 
for this is not understood, we have hypothesized that the -344 T
polymorphism in the promoter region of CYP11B2 is in close linkage 
disequilibrium with a key quantitative trait locus (QTL) in CYP11B1 adversely 
affecting its expression or function resulting in increased levels of 1 1 -
deoxysteroids(351).
1.11 Possible link between variation at CYP11B with hypertension and raised 
ARR
The theory that 11(3-hydroxylation may be impaired in hypertensives is not 
novel (352;353). Fiowever, until now there has been no suggestion that this 
biochemical abnormality is related to variation at the CYP11B locus. These 
data also lead us to speculate on the link between a minor change in 1 1 - 
hydroxylase efficiency and hypertension with aldosterone excess. It is unlikely 
that the minor increases in DOC and 11-deoxycortisol will have significant
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biological effects. However, impaired conversion of deoxycortisol to cortisol as 
a consequence of reduced 11 (3-hydroxylase activity should result in a slight 
reduction in cortisol levels in response to ACTH. In turn, normal feedbacl< 
regulation should result in a resetting of the hypothalamic-pituitary-adrenal 
axis such that cortisol levels are maintained. Consequently, there will a subtle 
increase in ACTH drive to the adrenal cortex (Figure 1.11a).
Thus, if this were a genetically determined phenomenon we would predict that 
subjects with less efficient cortisol synthesis will maintain a slightly enhanced 
ACTH drive to the adrenal (effectively, a minor variant of classical 11(3- 
hydroxylase deficiency). In the long term, this is likely to cause hyperplasia of 
both zona fasciculata and zona glomerulosa of the adrenal cortex resulting in 
increased synthetic capacity for both cortisol and aldosterone. Importantly, 
expression of a number of genes necessary for aldosterone production, 
including steroidogenic acute regulatory protein, p450 side-chain cleavage 
(CYP11A) and p450-21-hydroxylase (CYP21), is responsive to ACTH 
emphasizing the potential for increased synthetic capacity of aldosterone 
(108).
Importantly, we do not propose that ACTH is a principal stimulator of excess 
aldosterone production by the adrenal. Indeed, previous studies have 
demonstrated the ability of pharmacological doses of ACTH to stimulate 
aldosterone production only in the short term with aldosterone production 
decreasing after a few days(354). However, these experiments concentrated 
on very unphysiological exposure of the adrenal to grossly excessive amounts 
of ACTH. In ACTH-dependent Cushing’s disease, where there is chronic 
sustained exposure of the adrenal cortex, aldosterone concentrations are not
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Figure 1.11a. Possible sequence linking impaired l i p  hydroxylase 
activity and hypertension with raised ARR
diminished (184). Other POMC breakdown products such as joining peptide 
(JP) and (3-endorphin have also been shown to stimulate aldosterone 
production by human adrenal cells in-vitro. Thus, we suggest that increased 
levels of a POMC-related product (either ACTH or a related peptide) favours 
zona glomerulosa hyperplasia and may enhance aldosterone secretion in 
response to other, more conventional, trophins such as Ang II or potassium. 
Thus, over a very long period, the genetic change in 11(3-hydroxylation 
efficiency (along with an additional environmental or genetic influence) might 
result in ACTH-driven adrenal zonal hyperplasia, and an alteration 
(steepening of the dose-response relationship) of the response of aldosterone 
to Ang II and potassium. It is pertinent that very early studies reported that a 
proportion of patients with essential hypertension showed a good blood 
pressure lowering response to low dose dexamethasone treatment, 
apparently supporting the suggestion that ACTH was sustaining production of 
a hypertensinogenic adrenal steroid(355). Furthermore, there are reports of 
increased levels of DHEAS (an adrenal androgen driven by ACTH) 
hypertensive patients(356). Finally, it is significant that adrenal gland 
hyperplasia is a common histological finding in hypertensive patients at post 
mortem and even in patients with apparently ‘solitary’ adrenal adenomas 
(357:358).
1.11.1 Hypothesis under investigation
Thus, the principal hypothesis to be explored in this thesis is that, in 
susceptible subjects with hypertension, previously identified polymorphisms 
within CYP11B2 (-344T and intron conversion) act as markers for key variants
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in CYP11B1 resulting in reduced 11 R-hydroxylase efficiency. In turn, this 
leads to a subtle but more pronounced ACTH drive to the adrenal cortex and 
enhanced synthetic capacity of the zona glomerulosa resulting in increased 
production of aldosterone and suppression of renin. Thus in such individuals, 
there should be recognisable, genotype dependent, changes in the pattern of 
adrenal steroid production as well as alteration in the cortisol/ACTH 
relationship. This will be explored in a number of different populations.
1.11.2 Aims of investigation
1. To explore the pattern of variation across the entire CYP11B1 locus, 
identify variants in linkage with known polymorphisms of CYP11B2 and 
construct common haplotypes across this locus.
2. To relate variation across the CYP11B locus with alteration in intermediate 
corticosteroid phenotype within hypertensive and other large populations.
3. To examine, in detail, the effect of variation across the CYP11B locus on 
hypothalamic-pituitary-adrenal axis activity in subjects with hypertension and 
normotensive controls.
4. To further explore the role of aldosterone synthase and 11 fJ-hydroxylase in 
the production of ‘hybrid’ corticosteroids found in certain sub-types of PA and 
compare patterns of production within different sub-groups (normal adrenals/ 
impaired adrenal function/absent adrenal function).
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Chapter 2: Materials and Methods 
CLINICAL
2.1 General points
All studies carried out and reported within this thesis had full approval from 
the local hospital ethics committee as well as the Western infirmary Research 
and Development department.
All patients and volunteers within each study gave their informed, written 
consent. Each clinical visit was arranged and co-ordinated entirely by me 
according to relevant protocols.
2.2 Effect of CYP11B genotype on ACTH/cortisol relationship
Subjects with hypertension were recruited from blood pressure clinics at the 
Western Infirmary, local general practitioners or by advertisement in the local 
press. Normotensive control subjects were recruited simultaneously from 
advertising within the Western Infirmary.
2.2.1 Inclusion/exclusion criteria
Formal inclusion and exclusion criteria are listed in Table 2.2a. Briefly, 
hypertensive subjects had to satisfy British Hypertension Society Guidelines 
for the diagnosis of hypertension and so demonstrated at least 3 blood 
pressure readings of >140/90 mm/Hg at rest and each reading separated by 
at least a week. Resting, supine blood pressure was measured by an Omron 
MX3 digital device. All subjects were either on no hypertensive treatment or 
on medications with minimal/no effect on the RAAS (alpha-blockers or 
calcium channel blockers).
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Inclusion criteria Exclusion criteria
• Age 16-65
• BP> 140/90
• Untreated or on treatment 
not affecting the RAA axis
• Pregnancy
• Use of systemic steroids 
currently or within the preceding 
6  months
• Use of inhaled or topical steroids 
currently or in preceding 6  
months
• Inability to comply with study 
instructions
• History of severe atopy or asthma
Table 2.2a. Inclusion and exclusion criteria for study examining effect of 
CYP11B genotype on cortisol/ACTH relationship in hypertensives
All control subjects were on no medication and had blood pressures within the 
normal range (<140/90 mm/Hg).
2 .2 . 2  initial genotyping
All volunteers who satisfied the inclusion criteria underwent genotyping for the 
-344 polymorphism in CYP11B2 (SF-1 polymorphism). Blood samples were 
obtained via direct venepuncture of a forearm vein using the vacutainer 
system (greiner-bio-one). Blood for DNA extraction was taken into 4.5ml 
bottles containing potassium EDTA (0.054ml of 0.34M EDTA K3) as an 
anticoagulant. Blood was stored at ~4°C until DNA was extracted. DNA 
extraction and details of genotyping technique are explained in sections 2 . 6  
and 2 . 8  respectively.
2.2.3 Clinical protocol
On each occasion, on arrival to the day ward of ward E3/4, Western Infirmary, 
a 14 gauge intravenous catheter (Venflon, Helsinberg, Sweden) was inserted 
into the antecubital fossa and subjects lay recumbent for 30 minutes before 
blood was drawn for measurement of cortisol, ACTH and 11-deoxycortisol 
(6 ml bottles containing lithium/heparin) as well as renin and aldosterone 
(potassium EDTA bottles). Blood was immediately spun at -4°C and 3100 rpm 
for 10 minutes (Allegra 21R centrifuge, Beckman Coulter, UK). Plasma was 
then decanted and transferred to storage at -70°C (Forma Scientific freezer. 
Thermo Electron Corporation) for ‘snap’ freezing before transfer after 24 
hours for longer-term storage at -20°C (Gram UK).
Visit 1-Cortisol/ACTH relationship
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Subjects attended at 10pm and between 7-8 am the following morning for 
baseline blood measurements. If normotensive volunteers, then no nighttime 
visit was required.
Visit 2-Effects of dexamethasone suppression 
Four days before visit, subjects were asked to follow a standard salt diet 
(Appendix II) to ensure a sodium intake of approximately 120mmol/day. On 
the day before (midnight to midnight), a 24-hour urine collection was 
performed. 50mls of the final volume was aliquoted for storage at -20°C 
(Gram UK) for analysis of corticosteroid excretion rates whilst the rest was 
sent to the Biochemistry department for urinary sodium quantification.
At midnight the night before the visit, subjects took 125 micrograms of 
dexamethasone and attended the day ward fasted the next morning between 
7-8am for blood collection as detailed above.
Visit 3-Response to ACTH 
Again, subjects were asked to follow a standard salt diet and perform a 
24hour urine collection as detailed above. At midnight the night before the 
visit, subjects took 1 milligram of dexamethasone and attended the day ward 
fasted the next morning between 7-8 am.
Baseline blood samples after 30 minutes supine rest were drawn in the 
manner described above. Subjects were then administered 1 microgram of 
synthetic ACTH (synacthen®. Alliance Pharmaceutical Corp USA) 
intravenously. After a further 30 minutes of supine rest, blood was drawn, 
spun and stored in the manner described above.
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2.3 Analysis of genotype and intermediate corticosteroid phenotype in large 
study populations
2.3.1 The BRIGHT Study
The British Genetics of Hypertension (BRIGHT) Study is a large multicentre 
investigation into the genetic basis of hypertension. Hypertensive subjects 
were recruited from primary care with entry to the study being dependent on a 
pre-treatment blood pressure of >145/95mmHg (mean of 3 readings), which 
lies within the top 5% of the population blood pressure distribution in the UK. 
Subjects with a BIVII> 30 were excluded from the study. Full details of the 
recruitment strategy have been published elsewhere(359). However, the 
primary aim of the study was to perform genetic linkage analysis, and the total 
study population comprised > 2000 affected sibling pairs and trios. 512 
unrelated subjects were selected entirely randomly from the entire BRIGHT 
cohort for further analysis as detailed below. Full demographic information on 
the subjects included is outlined in chapter 4. Ethical approval for the study 
was granted by the local ethics committees of the partner institutes and fully 
informed written consent from all of the participants was obtained.
2.3.2 MONICA IV Cohort
The Multinational Monitoring of Trends and Determinants in Cardiovascular 
Disease (MONICA) project was a World Health Organisation (WHO) 
coordinated, observational, long-term study(360). Its main objective was to 
measure trends in cardiovascular mortality and morbidity and to assess the 
extent to which these trends were related to changes in risk factor levels and 
medical care, measured at the same time in different communities in different 
countries.
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In the fourth MONICA survey, a random sample of the north Glasgow patient 
lists of 30 general practitioners was selected for further analysis(361). Study 
subjects were invited to complete a health questionnaire and attended for a 
structured medical examination to assess overall cardiovascular risk. 
Approval was obtained from the appropriate ethics committee. Of the original 
sample of 597 subjects in whom full urinary corticosteroid data were available, 
158 were excluded from the study on the grounds that they were receiving 
medication likely to alter cardiovascular risk parameters (e.g. cardioactive 
drugs or hormone-replacement therapy) or adrenal function (e.g. inhaled or 
topical steroids). There remained 238 male and 201 female subjects; their 
demographic details are summarised in chapter 4.
2.3.3 Genotyping
DNA was extracted from all participating subjects using standard methods as 
described in section 2.6 and each subject was genotyped for CYP11B2 -  
344C/T and 1C alleles as detailed in section 2.8.
2.3.4 Urinary corticosteroid excretion
The same subjects also underwent analysis of corticosteroid phenotype by 
measurement of urinary corticosteroid metabolites by gas 
chromatography/mass spectroscopy (GGMS; section 2.12). Each individual 
provided a 24-hour urine collection. Final volume was noted and 50 ml of 
urine aliquoted for storage at -20°C before further analysis.
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2.4 The origin of 18-oxocortisol and 18-hvdroxvcortisol in man 
For this clinical study of the biosynthesis of the so-called ‘hybrid’ 
corticosteroids 18-oxocortisol (18-oxoF) and 18-hydroxycortisol (18-OHF), 8  
normal, healthy male volunteers were recruited by local advertisement. All 
were aged <40y, had a BMI<30kg/m^, had no history of hypertension and 
were on no corticosteroid medications.
2.4.1 Study Protocol
The study was subdivided into three 24-hour urine collections (excretion of 
18-oxoF, 18-OHF, free cortisol and free cortisone) each separated by one 
month (summarised in chapter 6  table 6.2a). In stage one, 24-hour urine 
collections were obtained without treatment. In stage two, 24-hour urine 
collections were obtained after treatment with dexamethasone only (Img 
twice daily at 8  am and 8 pm for three days). In stage three, 24-hour urine 
collections were obtained after treatment with dexamethasone (Img twice 
daily for three days) and hydrocortisone (2 0 mg twice daily on the 3’’^  day 
only). In addition, 24-hour urine collections were obtained from 6  patients with 
primary adrenocortical insufficiency. Five had autoimmune adrenal failure 
(Addison’s disease) and one had undergone bilateral adrenalectomy for 
phaeochromocytoma. Five of the subjects were taking hydrocortisone (15- 
30mg/day) as replacement and one was on dexamethasone (0.75mg/day).
2.4.2 Sample storage and analysis
Again, 50ml aliquots of urine were stored at -2Q°C for analysis of steroid 
excretion by GCMS (performed by Dr Loai Shakerdi (362)). Urinary steroid 
excretion rates were measured by gas chromatography-mass spectrometry
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using the methods of Shackleton (363) and Palermo et ai(364) with minor 
modifications. The internal standard was allo-THDOC. A DBS capillary gas 
chromatography column (J&W Scientific, Folsom CA), 30m, (0.25mm id,
0.25pm stationary phase) was used. The temperature programme was: 50“C 
for 3 minutes, 27°C/min up to 220°C, and 1.7°C/min up to 300°C. Separate 
Sep-pak cartridges were used for extraction of conjugates and for subsequent 
extraction of steroids released by hydrolysis. The source of B-glucuronidase 
was the edible snail (Biosepra, Cergy-Saint-Christophe, France). A Varian 
Saturn GCMS was used.
2.5 Endogenous corticosteroid synthesis in patients after bilateral 
adrenalectomy
Ten subjects who had undergone bilateral adrenalectomy and were stable on 
exogenous corticosteroid replacement regimes were recruited from the 
endocrine clinics of the Western Infirmary. The principal exclusion criteria are 
listed in table 2.5a.
2.5.1 Study protocol
Subjects were studied on three occasions under different conditions in 
random order and at least two weeks apart. The study protocol is summarised 
in chapter 7 (table 7.2b). For each study period, subjects were asked to 
discontinue the replacement mineralocorticoid, fludrocortisone three days 
before the study day. On all three occasions, subjects were asked to carry out 
a 24-hour collection of urine commencing at 8am on day three and finishing at 
8am on the study day (day 4). This was for measurement principally of 18-
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Exclusion criteria
Inability to follow study instructions
Subjects within 6 months of bilateral adrenalectomy
Any inter-current illness
Hypertension
Significant renal impairment (creatinine >120 mcg/L)
Table 2.5a. Exclusion criteria applied to studies of corticosteroid 
production patients after bilateral adrenalectomy
0X0F, 18-OFIF, aldosterone and cortisol metabolites. Subjects attended the 
day ward at 9am on the morning of the fourth day fasted and having taken no 
corticosteroid replacement since the previous evening. After 30 minutes of 
supine rest, blood was extracted from an in-dwelling cannula for 
measurement of plasma steroids (Li-heparin tubes 3x 7ml), plasma 
electrolytes (Sep pak clot activator tubes-5ml) and renin/aldosterone (K EDTA 
as described previously). Blood was spun and plasma extracted and stored as 
detailed in section 2.2.3.
MOLECULAR
2.6 DNA extraction and quantification
Genomic DNA was extracted from peripheral blood samples using a variation 
of the method of Miller et al (365). Ten millilitres of EDTA-preserved whole 
blood was placed in a 50 ml Falcon tube (Becton Dickinson) and 40 ml of 
erythrocyte lysis mix (Appendix) added. Tubes were mixed by inverting five 
times before centrifuging (International Equipment Company PR700) at 2800 
rpm for 10 minutes. The resulting pellet was resuspended in 3 ml of nuclei 
lysis mix (Appendix), and 200pi 10% SDS (sodium dodecyl sulphate; Sigma) 
and 100pi proteinase K (lOmg/ml; Sigma) were added. Tubes were incubated 
overnight at 37°C. After incubation, 1ml of 6M (saturated) NaC! was added 
with vigorous shaking. 5ml of phenol:chloroform:isoamyl alcohol (25:24:1, pH 
aqueous phase >7.6) was added and the tubes spun (lEG) for 20 minutes at 
2800rpm. The upper aqueous phase of the supernatant was then transferred 
to a 30ml universal container (Sterilin) and two volumes of absolute alcohol 
added. DNA was then spooled out with a glass rod and resuspended in 400pl
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CIH2O in a 1.5ml microtube (Alpha). DNA was allowed to settle at room 
temperature for 48 hours before storage at 4°C.
The concentration of each DNA sample was determined by measuring the 
optical density of samples at 260nm. One microlitre of DNA solution was 
added to 1ml of dH2 0  in a quartz cuvette and the OD260 measured in a dual 
beam spectrophotometer with a deuterium lamp. An optical density of 1 
corresponds to 50 mg/ml of DNA.
2.7 Polymerase chain reaction of CYP11B2
The CYP11B locus is too long to be amplified in a single or even two PCR 
reactions. Therefore, along with my colleagues Marianne Barr and Donna 
Wilkinson, we amplified and sequenced this locus in segments. I concentrated 
on CYP11B2, subdivided into promoter and exons 1-4, exons 5-9 and 3’UTR.
2.7.1 PCR Protocol
Genomic DNA obtained from a bank of normotensive subjects was used as 
the reaction template. Reactions were carried out within sterile Eppendorf 
tubes and kept on ice at all times.
Synthetic oligonucleotides, which were HPLC-purified were designed from the 
published sequence of CYP11B2 and obtained from a commercial source 
(MWG-Biotech, Ebersberg, Germany). Primers were generally between 20- 
24 base pairs and had approximately 50% GC ratios (Table 2.7a). The 
melting temperature of the primers was around 60°C (3’UTR) or 65°C(exons 
5-9).
Both fragments of CYP11B2 were amplified using an Expand High Fidelity 
PCR system (Roche Diagnostics, Mannheim, Germany). This contained both
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Primer Location
(CYP11B2)
Sequence Melting
temperature
(°C)
B2 3’ UTR 3’ untranslated 5’-ATA TTG AGG CCT 59.4
(sense) region GGC AGG TC-3’ 1
B2 3’UTR 3’ untranslated 5’-GAT GTG GIG  ACT 60.3 ■:(anti region AGG GGA G-3'sense)
T2138 Exon 5(sense) 5’-ATT TGG GTG TCG 66 1
GGG GAG TCT-3’ 1
T8303 Exon 1 (sense) 5’-GAA TTC TGG ATC 64
GTG TG AAATTATC-3’ 41;
M6641 Exon 9 5’-CTG TGG AGG TGG 66
(anti-sense) GAG AGA AGA-3’
Table 2.7a. Oligonucleotide sequences of primers used for PCR of 
CYP11B2 exons 5-9 and 3’ UTR.
Taq DNA polymerase and Tgo polymerase to confer proof-reading abilities 
and so minimised unwanted PCR-generated mutations. This system is 
optimised to efficiently amplify DNA fragments up to 5kb.
A 1|il (approximately SOmng/pl) aliquot of DNA to be amplified was placed in a 
sterile Eppendorf tube. Two separate reaction mixes were prepared as 
follows:
Reaction Mix 1: Final Concentration
dATP (1QmM) O.SpI 200pM
dGTP (10mM) 0.5pl 200pM
dTTP (1QmM) 0.5pl 200pM
dCTP (1GmM) 0.5pl 2QGpM
Sense primer (300nM) 0.75pl 3GGnM
Anti sense primer (30QnM) 0.75pl 3GGnM
Distilled water 8pl
Total 11.5|il
Reaction Mix 2: Final Concentration
Expand high fidelity buffer (15mM MgCI) 2.5pl 1x(1.5mM MgCI)
Expand high fidelity enzyme mix 0.75pl 2.6 U/reaction
Distilled water 9.25pl
Total 12.5pl
A 'blank' reagent control was prepared which contained all the necessary 
components for PCR but replaced template DNA with dHgO. The total reaction 
volume was 25 microlitres. The reaction mixes were subsequently combined 
on ice in single 0.2 ml thin-walled amplification tubes (ABgene, Surrey, UK) 
before being placed in a 96-well Alpha™ sample block powered by the PTC- 
225 DNA Engine Tetrad® Cycler with heated lid (MJ Research, Waltham, MA, 
USA). Amplification cycles and reaction conditions were as follows:
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Thermal cycling protocol 
1.94°C 2 minutes
2. 94°C 15 seconds
3. 60°C 30 seconds
4. 72°C 1 minute
Dénaturation
repeated for 10 cycles
5. 94°C 15 seconds
6. 60°C 30 seconds
6. 72°C 1 minute + 5second cycle
elongation for each 
successive cycle
7. 72°C 7 minutes
8 .4°C Indefinitely
repeated for 15 cycles
2.7.2 Determination of PCR products
Agarose (1g) (Invitrogen, Paisley, UK) was added to 1 x TAE buffer (100ml), 
mixed and heated to boiling point in a 650W microwave oven for 60 seconds. 
After 3 minutes of cooling, 1 microtitre of ethidium bromide (lOmg/ml) was 
added and mixed in. The agarose was then poured into gel moulds with 
Teflon combs and allowed to set for 20 minutes before combs were removed. 
Gels were submerged in 1 x TAE buffer in standard electrophoresis tanks 
(Wide Minis Sub Cell Agarose gel apparatus) (Bio-Rad Laboratories, 
Hercules, CA, USA). 10 microlitres of PCR product was loaded with 
5microlitres of loading dye onto the agarose gel. The DNA molecular weight 
marker Hyperladder I (Bioline, London, UK) was also loaded in a separate
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well. The gel was then resolved at 95volts for 40 minutes. DNA bands were 
visualized under a UV light.
2.7.3 PCR clean-up
Prior to sequencing, PCR products were cleaned to remove excess dNTPs 
and primers. This was done using the enzymes Shrimp Alkaline Phosphatase 
(SAP; Amersham Biosciences, UK) and Exonuclease I (Exol; Amersham 
Biosciences, UK). SAP removes the phosphate groups from the excess 
dNTPs left over from the PCR reaction and Exol digests the single stranded 
PCR primers into dNTPs, the phosphate groups are then removed by the 
SAP. This was performed on ice using the following protocol:
1. 5 |.lI of PCR product transferred to sterile, thin walled 0.2 ml PCR tubes.
2. 1 jj.1 SAP (1 U/pl) and 0.5 pi Exol (20U/pl) then added
3. Run on Tetrad® thermal cycler using following program:
Step 1 - 37°C for 30 minutes 
Step 2 - 80°C for 10 minutes
2.7.4 Automated Cycle Sequencing
Automated sequencing was performed using the ABI Big Dye Terminator v3.1 
Cycle Sequencing Kit (PE Applied Biosystems, Foster City, CA, USA). The 
technique is an adaption of the dideoxy termination method of sequencing. 
Each sequencing reaction could only sequence approximately 500 base pairs 
(bp) and so each exon and 500 bp segment of the 3’UTR was sequenced
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separately using separate oligonucleotide primers (MWG-Biotech) listed in 
table 2.7b.
Sequencing Reaction set-up
Sequencing reactions were set up in 96-well plates containing the following:
Template (25-200ng) 1-3 pi
Sequencing Primer (3.2pmol/pl) 1 pi
Ready Reaction mix 0.5 pi
Sequencing Buffer 3.8 pi
Distilled Water (up to final vol 20pl ) 11-13.7 pi
Reaction Conditions
1. 96°C 45 seconds
2. 50°C 25 seconds
3. 60°C 4 minutes
Repeat x 25
Sequencing reaction clean-up
Keeping the sequencing reactions in the 96-well PCR plates, Sodium 
acetate/Ethanol reaction purification was performed.
A solution of sodium acetate (NaOAc) in 95% ethanol (EtOH) in the ratio 2 pi 
3M NaOAc: 50 pi 95% EtOH was prepared and 50 pi of this solution added to 
each sequencing reaction. The plate was then sealed with an adhesive paper 
lid and inverted a few times to mix. The samples were then incubated at room 
temperature for 15 minutes to precipitate the extension products. The plate 
was spun for 30 minutes at 6000G and the supernatant immediately 
discarded and the plate spun whilst inverted on a paper towel for 30 seconds
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Primer Location
(CYP11B2)
Sequence
B2 3’UTR+500 3’ UTR 5’-AAT ACG ATC CTG CAG GGT AG­
S’
5’-TAG CTG ATG AGG ATC AGAB2 3’ UTR
3UTR+1000 GCG-3’
T2138 Exon 5(sense) 5’-ATT TGG GTG TCG GGG CAG 
TCT-3’
T2142 Exon 6(sense) 5 -GAC CCT GCA GAC ATG GCT TC-
3’
5’-TGG ATG CCC CCA CCT CCA 
GG-3’
Y6259 Exon 7(sense)
F31465 Exon 8(sense) 5 -AGT GTG CAG GCT CCG CCT CT- 
3'
5’-TAC TGA CCA GCG CTG ATG 
GAA AC-3’
S6719 Exon 9(sense)
T2140 Exon G(sense) 5 -AGG GCC ACA GGG AGG CCT 
CA-3’
at 500G to remove all residual traces. 150pl of 70% ethanol was added to 
each well and the plated sealed and inverted again before being spun at 
6000G for 10 minutes. Again the supernatant was removed by spinning the 
inverted plate for 30 seconds.
Formamide purification step
15 pi of formamide was added to each well of 96 well PCR plate. This was 
then denatured at 95°C for 2 minutes and placed on ice for a further 1 minute. 
15pl of each sample was transferred to the corresponding well of the 96 well 
bar-coded sequencing plate, covered and spun at 500G for 10 seconds. 
Plates were then stored at -20°C until sequenced.
2.8 Determination of CYP11B2 -344 C/T genotype
This was performed in two stages. Initially, a PCR was performed using 
primers detailed in table 2.8 (Oswel DNA service, Southampton) and a Taq 
polymerase system (Promega). Subsequently, the amplified region of 228 
base pairs was digested using Flae III mix. The 228 bp amplicon contains 2 
Haelll restriction enzyme sites (GG CC). The presence of a C to T transition 
at position -344 (GG CT) removes one of these sites. After digestion, 
individuals homozygous for the transition (TT) produce two bands of 175 and 
53 bp, individuals homozygous for the wild-type (CC) produce bands of 104, 
71 and 53 bp, and heterozygous individuals produce 4 bands.
Formal protocols for the above procedures are outlined below.
2.8.1 PCR Protocol
The reaction mix was prepared in sterile eppendorf tubes on ice.
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dNTP mix (10mM)
Sense primer (10mM) 
Anti-sense primer (10mM) 
MgCI 
Buffer
Taq polymerase 
nf H2O
0.5|_il 
1 .0),lI 
1 .Oj.1l 
1 . 0^1 
2.5j.il 
0.2^lI 
17.8^1
1pl of each DNA sample was added to 24^1 of reaction mix. Each sample was 
then placed in the Tetrad® thermal cycler.
Thermal Cycling Protocol 
1.94°C 3 minutes
2. 94°C 1 minute
3. 65°C 1 minute
4. 72°C 90 seconds
5. 72°C 7 minutes
6 .4°C indefinitely
Repeat 30 times
Determination of PCR product
10|il of PCR product were run on a 1% agarose gel as described previously.
2.8.2 Haelll Digest reaction 
H aelll 1 .Oj.1l
Buffer C (containing MgCI) 1.5j.il
Distilled H20 2.5j.il
This 5pl reaction mix was added to 15jul of PCR product. Samples were then
incubated at 37°C for 90 minutes.
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Primer
Sense
Anti-sense
Oligonucleotide sequence
5' GTG TCA GGG CAG GGG GTA 3' 
5' AGG CGT GGG GTC TGG ACT 3'
Table 2.8a. Oligonucleotide primers used for -344C/T PCR
Primer Oligonucleotide sequence
Sense
Anti-sense
5’AGG AAC CTC TGC ACG GCC TT3' 
5’CAG AAA ATC CCT CCC CCC TA3’
Table 2.9a. Oligonucleotide primers used for 10 PCR
Determination of genotype
After digestion reaction, the resulting DNA fragments were resolved in a 5% 
agarose gel (5g agarose in 100 mis of TAE buffer) as described previously.
2.9 Determination of Intron Conversion genotype
This was determined by 2 separate PCRs. Reaction 1 identified the normal 
gene (termed ‘wild type;’ WT) and reaction 2 determined the gene containing 
intron 2 conversion allele (termed ‘intron conversion;’ 1C).
The PCR protocol for both reactions differed only in terms of the 
oligonucleotide primers used (Oswel Research Products UK; table 2.9) and is 
outlined below:
Template DNA (lOOng) 1pl
nf HzO 15.3pl
10X buffer 2.5j.il
dATP(0.2mM) 1j.il
dGTP(0.2mM) 1j.il
dCTP(0.2mM) 1j.il
dTTP(0.2mM) 1jil
Reaction 1 or 2 sense primer (1:10; 20pmol) 1 jal
Reaction 1 or 2 anti-sense primer (1:10; 20pmoi) Ijil
Taq polymerase 0.2j.il
Each sample was prepared in sterile 0.5ml eppendorf tubes on ice. Each 
sample was then transferred to the Tetrad® thermal cycler.
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Thermal Cycling Protocol (both reactions)
1. 94°C 2 minutes
2. 94°C 1 minutes
3. 66°C 30 seconds
4. 72°C 30 seconds
5. 72°C 7 minutes
6. 4°C Indefinitely
X30
10 ii\ of PCR product were then resolved on 1% agarose gel as described 
previously and visualised under UV light. Detection of a 418 bp product with 
reaction 1 identified the WT allele and in reaction 2 identified the 1C allele.
2.10 Genotvoing for CYP11B1 5’UTR Polymorphisms
As discussed in chapter 3, my colleague, Marianne Barr, identified 2 novel 
polymorphisms within the promoter region of CYP11B1 during sequencing of 
this region within a normotensive cohort. These polymorphisms were 
subsequently identified within both hypertensive subjects and normotensive 
controls undergoing investigations to examine the effect of variation within 
CYP11B on pituitary-adrenal function (details in section 2.1).
2.10.1 Nested PCR protocol
In order to increase specificity of this technique, a nested PCR was 
performed. The initial reaction amplified a 2kb region specific to CYP11B1 
and the second reaction used this product as a template to specifically amplify 
the region of interest. In both reactions, a heat-activated thermostart Taq
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polymerase (Abgene, UK) was used. The sense and anti-sense primers used 
in both reactions are outlined in table 2.10a.
The detailed protocol is outlined below:
PCR Amplification 1 
Buffer (1 OX)
MgCI
dNTPs
B1 5’UTR (sense)
B1 prom-260 (anti-sense) 
Taq polymerase 
dHzO
2.5pl 
1.5pl
1).lI X 4(200mM each) 
1 jil (400mM)
1 jul(400mM)
0.25jil (1.25U)
8.75fal
Ip l (25-50 ng/jul) of each DNA sample was added to 20^1 of reaction mix. 
Each sample was then placed in the Tetrad® thermal cycler.
Thermal Cycling Protocol
1. 95°C
2. 95°C
3. 60°C 
4 .72°C
5. 72°C
6. 4°C
15 minutes 
30 seconds 
30 seconds 
3 minutes 
7 minutes 
Indefinitely
X 35
The PCR products were then diluted 1:10 in nuclease free H2O and used as a 
template for a second PCR reaction as detailed below.
PCR Amplification 2 
Buffer (10X)
MgCI
2.5j.Ll 
1 .5 jllI
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Reaction Primer Sequence
PO R I 
PCR 2
Sense (B15'UTR) 
Antisense (B1 prom-260) 
Sense (B157-32) 
Antisense (B15'393-369)
5’-TCC TTC GCA TCC CTT GTA AGT T-3'
5 ’-CTT GGA TTA TTC ATC TCC TTG CAA GG-3’ 
5 -GCA TCC CTT GTA AGT TGG ATT CCT AA-3' 
5’-AAG CAT TCC CTT TGA AAA CTG GTA C-3'
Table 2.10a. Oligonucleotide sequences of primers used for nested PCR 
of CYP11B1 promoter SNPs.
Primer Sequence
B1 Prom-1750(as) 5' AAG TCA AAT TGT CTC TGT TTG
Table 2.10b. Oligonucleotide primer used in sequencing of CYP11B1 
promoter SNPs.
dNTPs
B1 5’ 7-32 (sense)
B1 393-369(anti-sense) 
Taq polymerase 
dHzO
1 |_il X 4(200mM each) 
1pi (400mM) 
1pl(400mM)
0.125|il (0.625U)
11.75]al
24 pi of reaction mix was added to the template comprising 1pl of 1:10 dilution 
of PCR product from reaction 1. As before, samples were transferred to the 
Tetrad®thermal cycler and the protocol is detailed below.
Thermal Cycling Protocol
1. 95°C
2. 95°C
3. 60°C 
4 .72°C
5. 72°C
6. 4°C
15 minutes 
30 seconds 
30 seconds 
3 minutes 
7 minutes 
Indefinitely
x35
PCR products were then cleaned using the SAP/Exo 1 system outlined in 
section 2.7.3 prior to the determination of genotypes by sequencing (section
2.7.4. The sequencing primer used is illustrated in table 2.10b.
BIOCHEMICAL
2.11 Measurement of excretion rates of urinary steroids 
24h collections of urine were performed to measure the excretion rates of a 
number of corticosteroid metabolites listed in Table 2.12a. The method of 
Shackleton (Shackleton CHL Profiling steroid hormones and urinary steroids.
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Corticosteroid Urinary metabolite Abbreviation
Glucocorticoids Cortisol Tetra hydrocortisol 
allotetrahydrocortisol
THF
aTHF
Cortisone Tetrahydrocortisone THE
Deoxy cortisol Tetrahydrodeoxycortisol THS
Mineralocorticoids Corticosterone Tetrahydrocorticosterone
allotetrahydrocorticosterone
THB
alH B
Deoxycorticosterone T etra hyd rodeoxycorticosterone THDOC
Aldosterone Tetrahydroaldosterone THAIdo
Androgens Androsterone
Aetiocholanolone
Dehydroepiandrosterone
Table 2.12a. Major corticosteroid hormones and their urinary 
metabolites
Journal of Chromatography 1986; 379: 91-156) was used with minor 
modifications. Briefly, steroid conjugates were extracted (Sep-Pak C-18 
cartridges. Waters Chromatography Division, Millipore Corporation) and 
hydrolyzed with Helix pomatia juice (IBP Biotechnics). The released steroid 
metabolites were then extracted, also on C-18 cartridges, and their 
methyloxime trimethylsilyl ether derivatives were then synthesized. Two gas 
chromatograph -  mass spectrometers (GCMS) were used. A Varian 3400 GC 
coupled to a Finnegan MAT ITS40 ion trap MS was used for the metabolites 
of cortisol, cortisone, DOC and 11-deoxycortisol. A Varian CP3000 GC 
coupled to a Saturn 2000 ion trap MS/MS was used for metabolites of 
corticosterone, aldosterone and some of the measurements of 18-oxocortisol 
and 18-hydroxycortisol. The internal standard was allo-tetrahydroDOC. Both 
GCMS machines were fitted with a fused silica capillary column (30m x 0.25 
mm id, J & W Scientific) coated with a non-polar (0.25 um DB5/MS) stationary 
phase.
The conditions for the GCMS analysis were the same for both instruments. 
Mobile phase gas (helium) flow was Iml/min. The temperature programme 
was as follows: 50° for 3 min, 27°/min to 220°, 1.7°/min to 300°, 3.5 min at 
300°. The transfer line and ion trap temperatures were 300° and 220° 
respectively.
The remainder of the 18-oxo- and 18-hydoxycortisol measurements and all 
measurements of 18-hydroxy-tetrahydro-11 -dehydrocorticosterone (180H- 
THA) were made using a Thermoquest GCQ plus ion trap GCMS. Here the 
temperature programme was as follows: 100° for 3 min, 20°/min to 190°, 
2°/min to 285°, 285° for lOmin. Details of the 180H -THA assay are given by
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Shakerdi et al (J Chromatography B 2002; 784: 367-373). importantly, a non- 
homologous standard, p-cortolone, was used because 18-OH-THA is not 
commercially available. Identification and quantitation were done using 
specific ion monitoring (SIM). The ions used are shown in table 2.12b.
2.12 Measurement of urinary electrolytes
Measurement of urinary sodium and potassium was performed on 24-hour 
urine collections by the department of biochemistry using an ion-selective 
electrode method.
2.13 Measurement of plasma steroid metabolites
Plasma aldosterone and cortisol were measured by radioimmunoassay 
utilising the ‘Coat-A-Count’ system (Euro/DPC Ltd, Caernarfon, Wales). The 
radioisotopes used were ^^ 1^ cortisol and ^^ ®l aldosterone respectively.
Plasma ACTH measurements were performed by Professor Anne White, 
University of Manchester by radioimmunometric assay (IRMA). This technique 
uses iodinated radiolabelled monoclonal antibodies for ACTH 1-17, with 
another solid phase monoclonal specific for ACTH 34-39(366).
Plasma renin concentration (PRC) was measured by Dr Ian Morton with a 
technique based on radioimmunoassay of angiotensin I generated during 
incubation of plasma and excess sheep or ox renin substrate(367).
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COMPOUND ION (MASS)
aTHDOC 476
THE 579
THF 562
aTHF 562
THS 564
THDOC 476
THB 564
aTHB 564
THALDO 606
180HF 385
180X0F 619
Table 2.12b Ions used for selected ion monitoring (SIM) scans
18-OHF: 18-hydroxycortisol; 18-oxoF: 18-oxocortisol
Chapter 3: Genetic Variation and Linkage Disequlilbrium across the 
CYP11B Locus in a Normotensive Cohort
3.1 Introduction:
It has become clear that the most consistent intermediate corticosteroid 
phenotype seen in association with the -344 T and intron conversion (1C) 
alleles of CYP11B2 is increased plasma deoxysteroids (DOC and 11- 
deoxycortisol) basally and in response to ACTH stimulation (350). This 
suggests altered activity of the enzyme 1112,-hydroxylase (encoded by the 
adjacent and highly homologous gene, CYP11B1) in such individuals. We 
have therefore speculated that the -344 T ± 1C alleles of CYP11B2 are in 
linkage with key variant(s) in CYP11B1 causing a reduction in enzyme 
efficiency and the phenotype of increased deoxysteroid levels.
In addition, the -344 T allele of CYP11B2 has been shown to be associated 
with increased plasma aldosterone(342), increased urinary excretion of the 
aldosterone metabolite (tetrahydroaldosterone, THAIdo )(340) as well as 
hypertension with a raised ARR(343). However, these associations are not 
invariable(345;346) and in-vitro studies have shown no discernible effect of 
this allele on gene transcription(207). Therefore, it remains possible that this 
polymorphism is in linkage with others elsewhere within CYP11B2 directly 
resulting in changes in aldosterone production.
Thus, the aim of this study is to explore the pattern of variation across the 
entire CYP11B locus within a normotensive population known to be 
homozygous for the CYP11B2 -344C/T and 1C polymorphisms. In turn, this
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should allow identification of variants within CYP11B1 and CYP11B2 that are 
in linkage with these known polymorphisms as well as construction of 
common haplotypes across this locus.
3.2 Methods:
3.2.1 Samples
Genomic DNA was obtained from a bank of normotensive subjects recruited 
for the Scottish MONICA (Monitoring trends and determinants in 
cardiovascular disease) study (total of 469 subjects). These samples had 
already been genotyped for the -344 and 1C polymorphisms. Subjects were 
subdivided according to haplotype, selecting those homozygous for each 
mutation such that 3 subgroups were identified (Table 3.2a). 10 samples from 
the common haplotype groups (T/conv, C/WT) and all from the less common 
haplotype (T/WT; n=6) underwent further sequencing analysis.
3.2.2 Sequencing
The CYP11B2 locus was amplified in segments by PCR (detailed method 
outlined in section 2.7.1). The presence of any genetic variants was 
determined by direct sequencing of the PCR products as described in section
2.7.4. This was done in collaboration with other members of the group who 
sequenced the CYP11B1 gene of these subjects to determine the pattern of 
linkage across the entire CYP11B locus.
Sequence data from PCR products was compared to the consensus 
sequence published by the NCBl database (D13752).
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Genotype Number of subjects
TT/ convconv 10 (from a possible 78)
CC/WTWT 10 (from a possible 88)
TT/WTWT 6
Table 3.2a Genotype subgroups from MONICA population
convconv-homozygous for intron 2 conversion allele of CYP11B2 
WTWT-homozygous for wild-type allele of intron 2 in CYP11B2 
Only 6 TTAA/TWT samples available and no CC/convconv; this reflects 
population frequency of these genotypes.
3.2.3 Linkage analysis
Pairwise linkage disequilibrium (LD) between all possible pairs of loci was 
calculated using EMLD (expectation maximization linkage 
disequilibrium)(368). (http://request.mdacc.tmc.edu/~qhuanq/Software/pub.htm)
This programme is specifically designed to estimate LD by first estimating pair 
wise haplotype frequencies and is applicable to samples from unrelated 
individuals. Both D’ and r^  values were measured
A Bayesian statistical method implemented in PHASE version2.1 was used to 
construct phased haplotypes from phase-unknown genotype data.(369)
3.3 Results:
3.3.1 Sequencing
Figures 3.3a and 3.3b show the results of a typical PCR amplification of 
segments of CYP11B2 on a few MONICA subjects. Sequencing reactions 
were subsequently carried out on PCR-amplified DNA from each of the 26 
subjects studied (Figure 3.3c).
In total, 83 SNPs were identified across the CYP11B locus in linkage with -  
344 C/T and 1C polymorphisms (Figure 3.3d &e); 64 were in CYP11B2 and 
the majority are previously unreported.
CYP11B2
SNPs identified in CYP11B2 are shown in Figure 3.3e. Previously identified -  
344C/T and 1C polymorphisms are highlighted as are the three SNPs found to 
occur in coding regions. Of these, two (codon 169-C/T, codon 374 -A/C) do
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Figure 3.3a. 1500bp PCR fragment from 3’ UTR of several different 
MONICA samples, resolved on a 1% agarose gel
10000 hp 
4000 hp 
1000 hp 
400 hp
Figure 3.3b 4kb PCR fragment of exons 5-9 of MONICA samples on 1% 
agarose gel
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Figure 3.3c. Electropherogram of sequencing of CYP11B2 3’ UTR and 
illustrating a base change {GIT) at position 891.
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Figure 3.3d. Polymorphisms identified after sequencing of CYP11B1
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Figure 3.3e. Polymorphisms identified after sequencing of CYP11B2
   Previously identified -344 and 1C polymorphisms
— —  Synonymous exonic polymorphisms
   Non-synonymous exonic polymorphism
------------  SNPs within non-coding regions
not result in an amino acid change. The A/G transition at codon 173 is a well- 
described variant causing a lysine-arginine transition(370).
Figure 3.3e illustrates that the remainder of identified SNPs within CYP11B2 
were in untranslated regions. Whilst SNPs within the 5’ untranslated regions 
(5’ UTR) can be assessed using reporter gene constructs, SNPs within 
introns, splice site consensus sequences or 3’ UTR are much more difficult to 
assess in vitro.
CYP11B1
Nineteen SNPs were identified across CYP11B1 and are illustrated in figure 
3.3d. With the exception of 2 synonymous exonic SNPs (A/G-codon 75, C/T- 
codon 82) the remainder of these were in untranslated regions. In particular, 2 
SNPs in the 5’ UTR (-1888 G/T, -1858 A/G) were found to be in tight LD with 
the T/Conv haplotype.
3.3.2 Linkage
In general, linkage was high across the entire region although, as expected, 
decreased with distance. Loci within CYP11B1 were generally in greater LD 
with each other than with loci in CYP11B2 (figure 3.3f).
LD described by the D’ metric was almost uniformly high across the entire 
region (Figures 3.3f1 & 3.3g1) approaching the maximum of 1 across much of 
the region and decreasing to approximately 0.75 between pairs of loci 
spanning the CYP11B1 and CYP11B2 genes.
LD described by the r^  metric was less uniform as might be expected given 
that r^  is more stringent and dependent upon identical allele frequencies. 
However, allele frequencies varied across the locus. There were a few pairs
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of loci spanning the genes which were in strong LD. In general, r^  ranged from 
approximately 0.5 to approximately 1.0 (Figures 3.3f2 & 3.3g2).
3.3.3 Haplotype analysis
The theoretical number of haplotypes across this region assuming free 
recombination was calculated to be 9.671 x 10^  ^ (83 biallelic loci across 
44,631 basepairs).
However, PHASE constructed 136 haplotypes most of which were low 
frequency (Table 3.3a). Four haplotypes had frequencies of >5% and 
accounted for 6 8 % of chromosomes in the data set (Figure 3.3h). Nine 
haplotypes had frequencies of >1% and described 75% of chromosomes in 
the data set (Table 3.3a).
3.4 Discussion:
The primary purpose of this study was to identify candidate SNPs/variants in 
the CYP11B locus in linkage with established variants within CYP11B2 (-344 
T/C and 1C) accounting for the phenotype of hypertension with an elevated 
ARR.
Within CYP11B2 only 3 SNPs were identified within exons. Of these, 2 were 
synonymous whilst the other (A/G at codon 173) resulted in the substitution of 
lysine (K) for arginine (R). The wild-type allele (A) is associated with the T 
allele of -344. This K173R polymorphism has already been described and the 
R variant found to be more common in hypertensive subjects with suppressed 
renin(371). However, it has no effect on enzymatic activity in vitro(371). More 
recent studies assessing levels of mRNA transcripts in adrenal tissue suggest
136
index Haplotype E(freq) > 5 %  >1%
1 11121212122121111211122221211112212211211221211122122211211111122211111122221122121 
5 11121212122121111211122221211112212211211221211122122211211111122211111122222122121
9 11121212122121111211122221211112212211211221211122122211211121122211111122221122121
29 11121112122121111211122221211112212211211221211122122211211111122211111122221122121 
87 21221112212221111122211112122221121122112221211122211111211222221121121221112211212 
89 21221112212221111122211112122221121122112221211122211111211222221121122221112211212
132 22212121211212222122211112122221121122122112122211211222122222211211111122211211212
133 22212121211212222122211112122221121122122112122211211222122222211212111122211211212 
136 22212121211212222122211112122221121122122112122211211222122222211122222211112211212
0.202 X X
0.014 X
0.069 X X
0.112 X X
0.015 X
0.011 X
0.012 X
0.022 X
0.297 X X
Table 3.3a 9 common haplotypes constructed after sequencing of 26 
normotensive subjects from MONICA survey (136 possible haplotypes 
identified altogether)
83 SNPs were identified and are coded 1 or 2 in alphabetical order. In the 
case of insertions, no insertion is 1 insertion is 2. In the case of deletions, no 
deletion is 1 deletion is 2. Of the 136 possible haplotypes identified 4 had 
frequencies of >5% and a further 5 had frequencies of >1 %
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Figure 3.3f: Raw data plots showing pairwise linkage disequilibrium.
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Figure 3.3g: Data plots extrapolating pairwise linkage disequilibrium 
across the region.
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Figure 3.3h. Four commonest haplotypes across 0YP11B locus and 
their respective frequencies.
that the -344T and K173 haplotype is associated with higher gene expression 
than the opposite -344C and R173 haplotype. Thus whilst this work supports 
previous studies linking the -344T allele with increased aldosterone 
production it still does not provide a causative variant within CYP11B2.
A number of SNPs were identified in linkage with the -344C/T and/or 1C 
variants within untranslated regions of CYP11B2 (fig 3.3e). In particular, G/A 
(linked to -344 T allele) at the beginning of intron 2 and G/A (linked to -344 0  
allele) at the beginning of intron 3 are close to known splice sites and may 
well interfere with post transcriptional processing. Similarly, the IC C  insertion 
site found within 3’UTR in association with 10 wild type allele may also have 
post- transcriptional effects. In particular, the relatively long length of 3’-UTRs 
in human genes suggests that the human genome has evolved to make 
increased use of post-transcriptional control mechanisms to regulate gene 
transcription. In different mRNAs, 3’-UTRs have been reported to be involved 
in the regulation of mRNA stability, translation and localisation(372). Whilst 
such variants are difficult to assess in vitro their effects could be investigated 
in genotype-phenotype studies within different populations to look for an 
association with blood pressure and aldosterone status.
Thus, so far, we have failed to find an easily assessable candidate SNP within 
CYP11B2, linked to -344 T and/or intron conversion alleles, to account for the 
phenotype of aldosterone-associated hypertension. However, given that the 
most consistent corticosteroid phenotype in hypertensives homozygous for -  
344T allele is increased DOG/B and S/F ratios (implying impaired activity of 
1 1 1^-hydroxylase) then this seemingly negative finding is, in fact, hardly
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surprising and places appropriate emphasis on the results of sequencing and 
linkage studies involving CYP11B1.
Linkage studies confirmed high ID  across the entire CYP11B locus. The most 
stringent measure of LD (r^) varied from 0.5-1. Thus, this provides strong 
evidence to support the hypothesis that variation within CYP11B2 (-344CyT 
and 1C) is actually linked to causal variant(s) within CYP11B1.
No non-synonymous SNPs in linkage with -344G/T and/or IG alleles were 
identified within GYP11B1 (Fig 3.3d). However, 2 closely related SNPs in the 
5’ promoter region (-1888 G/T, -1858 A/G) were found to be in tight LD with 
the T/conversion haplotype of GYP11B2.
These SNPs have been the subject of in vitro studies using a luciferase- 
reporter gene construct (M Barr, personal communication) and preliminary 
results suggest that the variants (T and G alleles respectively) associate with 
reduced transcriptional activity of GYP11B1. In addition, chapter 5 details the 
association of these alleles and corticosteroid phenotype in hypertensive and 
normotensive populations.
Haplotype analysis confirms high LD across the GYP11B1 locus; 4 haplotypes 
account for 6 8 % of chromosomes. In theory, this should allow selection of 
‘tag’ SNPs to aid high-throughput genotyping to give genetic information in 
large study populations. However, the value of this haplotype data is limited 
by small study numbers and by the fact that this population was pre-selected 
according to genotype at -344G/T and IG. Further studies are in progress to 
confirm these haplotypes in larger, unselected, populations.
Thus, this study does provide a number of candidate SNPs within GYP11B2, 
in linkage with -344 T and/or intron conversion alleles which may account for
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the phenotype of hypertension with aldosterone excess but need further 
evaluation. However, more importantly, this work confirms high LD across the 
CYP11B locus supporting the theory that -344 T and/or 1C are in linkage with 
variant(s) within CYP11B1 accounting for the phenotype of reduced 11R- 
hydroxyiase efficiency found in these individuals. Finally, in addition, this 
study identifies 2 SNPs within the 5’ promoter of CYP11B1 which appear to 
reduce its transcriptional activity; these could represent plausible candidate 
SNPs accounting for this phenotype. Further genotype/phenotype studies are 
reported in chapter 5 to examine the effect of these SNPs on corticosteroid 
phenotype in vivo.
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Chapter 4: Phenotypic Consequences of Variation across the CYP11B2 
Locus in large Normotensive and Hypertensive Cohorts
4.1 Introduction
The “ 344C/T and intron conversion (1C) variants of CYP11B2 associate 
consistently with an increased ratio of 1 1 -deoxycortisol/cortisol implying 
reduced efficiency of 11 (3-hydroxylase (encoded by CYP11B1) in subjects 
with the T and conversion alleles(350). This has led us to speculate that, in 
such individuals, cortisol levels are maintained as a consequence of a slight 
increase in pituitary production of ACTH (or ACTH-related peptide) at the 
expense of a minor increase in its precursor, 11-deoxycortisol. We have also 
proposed that this mild increase in ACTH will have trophic effects on the zona 
glomerulosa, leading to increased aldosterone production in response to its 
more conventional trophins, Ang II and potassium.
If altered 11 (3-hydroxylase efficiency is indeed associated with these 
CYP11B2 polymorphisms, the resulting increase in ACTH drive required to 
maintain cortisol levels should leave recognisable changes in the overall 
pattern of adrenal steroid metabolism. This hypothesis was explored within 
two contrasting populations. One was a large hypertensive cohort derived 
from the BRItish Genetics of HyperTension (BRIGHT)(359) study and the 
other a group of normotensive individuals from the fourth IVIultinational 
Monitoring of Trends and Determinants of Cardiovascular Disease (MONICA) 
survey(360).
These cohorts were analysed to look for differences in 11 (3-hydroxylase 
efficiency according to genotype and blood pressure as well as the influence
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of genotype and other factors on indirect markers of increased ACTH drive to 
the adrenal gland. Relationships between these changes in corticosteroid 
metabolism and known cardiovascular risk factors were also examined.
4.2 Methods
4.2.1 Studv Subiects
Details of recruitment of subjects for the BRIGHT and MONICA populations 
as well as inclusion and exclusion criteria have been outlined in chapter 2 . 
Each subject underwent medical evaluation which included assessment of 
blood pressure and anthropometric indices including weight, height, body 
mass index (BMI; ratio of weight (kg)/height^ (m^)).
4.2.2 Blood Sampling
Blood was drawn using the Vacutainer system (Becton-Dickinson) for 
measurement of lipids and electrolytes by standard biochemical methods. 
DNA was also extracted from plasma and subjects were genotyped for -344 
C/T and 1C polymorphisms as previously described (sections 2.6, 2.8 & 2.9)).
4.2.3 Urinarv Corticosteroid Metabolite Measurements
Urine samples (24 hour) were collected in plain plastic containers without 
preservative. Aliquots of urine were stored at -2 0 "C. Excretion rates of steroid 
metabolites (listed in Table 4.3d as median and inter-quartile ranges) were 
measured by gas chromatography/mass spectroscopy using the method of 
Shackleton(373) with minor modifications (section 2.11). The ratio of 11- 
deoxycortisol/ total cortisol (THS/F) was used as an index of 1113-hydroxylase 
activity
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4.2.4 Statistical analysis
It was calculated that 180 homozygous subjects would be required to achieve 
80% power to detect a difference in THS/F ratio of 0.004 with an a level of 
0.05. THS/F ratios did not follow a normal distribution and so were compared 
by non-parametric methods (Mann-Whitney test). Steroid excretion rates (log 
transformed) were compared by simple correlation and then adjusted for 
confounders (age, sex, BMI, WHR, blood pressure) using stepwise multiple 
regression. All data were corrected for multiple comparisons using the 
Bonferroni method such that a p value of <0.001 was required for statistical 
significance.
Preliminary analysis comparing subjects with good blood pressure (<140/90 
mm/Hg) control versus poorly controlled subjects (>140/90 mm/Hg) showed 
no systematic effect of the major anti-hypertensive drug groups on excretion 
rates of cortisol, aldosterone or androgens (Table 4.2a). Therefore, no 
adjustment for drug effects was required.
4.3 Results
4.3.1 Demographic data
Blood pressure and other relevant demographic data are shown in Tables 
4.3a and 4.3b; the BRIGHT population was significantly hypertensive but not 
significantly overweight. In contrast, the MONICA population was a 
normotensive lean population. There were no differences in characteristics of 
subject groups separated according to -344C/T genotype in either of the 
cohorts.
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Drug Group Total F THS/Total F THAIdo Total Andro
A 0.072 0.402 0.254 0.336
B 0.290 0.402 0.925 0.836
C 0.142 0.490 0.846 0.278
D 0.640 0.285 0.178 0.464
Table 4.2a. Effect of anti-hypertensive drug classes on urinary 
corticosteroid excretion (p values shown)
BRIGHT subjects (512) were sub-divided into well controlled (BP<140/90 
mm/Hg) and poorly controlled (BP> 140/90 mm/Hg) groups and steroid 
excretion compared by Mann Whitney analysis within the major anti­
hypertensive drug categories
A-ACE inhibitors, ARBs; B-beta-blockers; C-calcium channel blockers; D- 
diu reties
ALL SUBJECTS 
n=511
TT SUBJECTS 
n=161
CC SUBJECTS 
n=73
p*
AGE (y) 64  (5 7 -7 0 ) 6 3  (5 8 -7 0 ) 63  (5 6 -6 8 ) 0 .2 9 4
MEAN SBP 180 (1 5 3 -1 9 1 ) 157 (1 5 2 -1 9 0 ) 183 (1 5 3 -1 9 0 ) 0 .7 1 3
(mm/Hg) 
MEAN DBF 103 (9 8 -1 1 0 ) 103  (9 8 -1 1 0 ) 104 (1 0 0 -1 1 0 ) 0 .4 9 0
(mm/Hg) 
BMI (kg/m^) 2 7  (2 5 -3 0 ) 2 7  (2 5 -3 0 ) 2 7  (2 5 -3 0 ) 0.771
WHR 0 .8 8  (0 .8 1 -0 .9 4 ) 0 .8 8  (0 .8 2 -0 .9 3 ) 0 .8 7  (0 .8 1 -0 .9 4 ) 0 .3 1 5
Table 4.3a. Demographic information on BRIGHT study sub-group 
separated by -344C/T genotype (median and IQ range)
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass
index, WHR-waist-hip-ratio
^comparison between TT and CC homozygotes
ALL SUBJECTS 
n=418
TT SUBJECTS 
n=124
CC SUBJECTS 
n=69
p*
AGE (y) 4 9  (4 0 -5 8 ) 4 9  (3 9 -5 9 ) 4 8  (4 2 -5 6 ) 0 .4 8 8
MEAN SBP 127 (1 1 4 -1 4 1 ) 1 2 7 (1 1 4 -1 4 3 ) 129 (1 1 5 -1 4 2 ) 0.51
mm/Hg) 
MEAN DBF 79  (7 0 -8 7 ) 7 9  (6 8 -8 7 ) 79  (7 1 -8 7 ) 0 .6 9 5
mm/Hg)
BMI 26  (2 4 -2 9 ) 2 6  (2 3 -2 9 ) 2 6  (2 4 -2 9 ) 0.481
(kg/m^)
WHR 0 .8 5  (0 .7 8 -0 .9 3 ) 0 .8 5  (0 .7 9 -0 .0 .9 3 ) 0 .8 6  (0 .7 8 -0 .9 3 ) 0 .9 2 8
Table 4.3b. Demographic information on MONICA IV cohort separated by 
-344C/T genotype (median and inter-quartile range)
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass
index, WHR-waist-hip-ratio
^comparison between TT and 0 0  homozygotes
Table 4.3c compares the key demographic variables of the 2 populations. As 
expected, the BRIGHT group has significantly higher blood pressures but is 
also significantly older, with higher BMIAA/HR, than the MONICA cohort.
4.3.2 Genetic analvsis of CYP11B2
The frequencies of the -344C/T and 10 polymorphisms in both groups are 
illustrated in figure 4.3a. (BRIGHT: -344 T 0.6 0  0.4; 10: WT 0.49, Oonv 0.51; 
MONICA: -344 T 0.566, 0  0.432; 10 WT 0.53, Oonv 0.47). These alleles were 
in Hardy-Weinberg equilibrium.
There was no significant difference in genotype frequencies between the two 
groups (-3440/T p=0.284, 10 p=0.683).
4.3.3 Urinarv corticosteroid excretion rates
The major urinary corticosteroid metabolites examined are listed in table 4.3d. 
BRIGHT
There was no significant difference in total cortisol metabolite excretion rate 
(mcg/24 hours) between -344 TT and 0 0  genotypes (p=0.3420).
The THS/ total F ratio (index of 1113-hydroxylase activity) was significantly 
higher in TT homozygotes then in 0 0  homozygotes (p=0.001) in all subjects 
(Table 4.3d, Figure 4.3b) as well as in female subjects (TT 0.01175, 0 0  
0.00794 p=0.03) and male subjects (TT 0.0081, 0 0  0.0058 p=0.035). Figure 
4.3b summarises the ranges of THS/F ratios in the 3 genotype groups. There 
was no statistically significant difference between the TT and OT groups but
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Figure 4.3a. Frequencies of -344C/T and 1C polymorphisms of CYP11B2 
in BRIGHT and MONICA populations
(I)
STEROID METABOLITE 
(mcg/24h)
ALL
SUBJECTS
TT
SUBJECTS
CC
SUBJECTS
p*
ALDOSTERONE 3 3 3 0.95
(THAIdo) (2 -6 ) (1-5) (2-5)
CORTISOL 1443 1448 1637 0.342
METABOLITES
(TOTAL F; 
THF+aTHF+THE)
(786-2500) (731-2444) (898-2611)
ANDROGEN 606 560 682 0.29
METABOLITES
(TOTAL ANDRO; 
DHA+AETIO+ANDRO)
(318-1208) (339-1150) (319-1421)
11B-HYDROXYLASE 0.00856 0 . 0 1 0 2 0.00683 0.001
EFFICIENCY
(THS/TOTAL F)
(0.005-0.01) (0.006-
0.015)
(0.005-0.01)
STEROID METABOLITE 
(mcg/24h)
ALL
SUBJECTS
TT
SUBJECTS
CC
SUBJECTS
p*
ALDOSTERONE
(THAIdo)
1
(0-7)
1
(0-3.5)
1
(0 -2 )
0.069
CORTISOL
METABOLITES
(TOTAL F; 
THF+aTHF+THE)
3652
(2250-5806)
3662
(2411-5786)
3438
(2469-5652)
0.637
ANDROGEN
METABOLITES
(TOTAL ANDRO; 
DHA+AETIO+ANDRO)
976
(559-1471)
1080
(666-1429)
1062
(628-1434)
0.971
11R-HYDROXYLASE
EFFICIENCY
(THS/TOTAL F)
0 . 0 1 1
(0.004-0.02)
0 . 0 1
(0.004-0.02)
0.009
(0.003-0.02)
0.83
Table 4.3d. Urinary corticosteroid excretion (median and inter quartile 
range) according to -344C/T genotype in (I) BRIGHT and (II) MONICA 
cohorts
THF: tetrahydrocortisol, (a)THE (alio) tetrahydrocortisone, DHA: 
dehydroepiandrosterone, Aetio: aetiocholanolone, Andro: androsterone 
THAIdo.tetrahydroaidosterone, THS: tetrahydrodeoxycortrsol 
^comparison between TT and CC homozygotes
0.054
p=0.001
0.04-
p=0.002p=0.847
0.03-
0 .02 -
0 . 01 -
0.00-
cccr
Figure 4.3b. 11B-hydroxylase efficiency (THS/total F ratio) in all BRIGHT 
subjects stratified by -344C/T genotype
THS/F ratio for ail 3 genotype groups compared by non-parametric testing 
(Mann-Whitney).
VARIABLE BRIGHT MONICA P
AGE 64 (57-70) 49 (40-58) <0.0001
SBP 180 (153-191) 127 (114-141) <0.0001
DBF 103 (98-110) 79 (70-87) <0.0001
BMI 27 (25-30) 26 (24-29) <0.0001
WHR 0.88 (0.81-0.94) 0.85 (0.78-0.93) <0.001
Table 4.3c. Comparison of demographic information summarising entire 
BRIGHT and MONICA study populations
the THS/F ratio remained significantly higher in the heterozygous group than 
the CC subjects.
The IC/WT allele had no significant effect on THS/F ratio (p=0.137) or total 
cortisol metabolite excretion rate (p=0.892).
MONICA
There was no significant difference in the excretion rates of any corticosteroid 
variable according to -344 genotype (Table 4.3d).
4.3.4 Corticosteroid excretion and demographic parameters
The relationships between urinary corticosteroid excretion rates and major 
demographic variables within each population, assessed by Pearson 
correlation co-efficients, as well as in subject groups separated by -344 C/T 
genotype, are shown in table 4.3e. Expected significant relationships were 
found (between systolic and diastolic blood pressures, systolic blood pressure 
and age and BMI and WHR) but there were no significant relationship 
patterns between these morphometric variables and any of the corticosteroid 
variables. In particular, the significant correlation between WHR and cortisol 
was lost when adjusted for sex, age and blood pressure.
4.3.5 Corticosteroid relationships 
BRIGHT
As expected, given their co-dependence on ACTH drive, there was a strong 
correlation between excretion rates of total cortisol and total androgens 
(p<0.00005) irrespective of sex or genotype.
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(a)
(i) SBP DBF WHR BMI AGE CHOL THALDO CORTISOL ANDRO
SBP —  0.518 -0.025
DBF —  0.032
WHR 
BMI 
AGE 
CHOL 
(M)
SBP —  0.501 0.1
DBF —  0.116
WHR 
BMI 
AGE 
CHOL
(Mi)
SBP —  0.614 -0.138
DBF —  -0.056
WHR 
BMI 
AGE 
CHOL
0.017 0.408 0.15 -0.006 -0.1 -0.149
0.005 0.097 0.077 0.07 -0.012 -0.011
0.296 0.008 -0.107 0.209 0.234 0.276
-0.021 -0.011 0.08 0.157 0.035
--- 0.08 -0.069 -0.03 -0.297
— -0.06 -0.116 -0.151
0.137 0.331 0.188 0.092 -0.047 -0.082
0.087 0.068 0.107 0.069 0.147 0.142
0.309 0.14 -0.233 0.235 0.164 0.162
— 0.146 -0.036 0.146 0.074 -0.06
--------- 0.132 0.085 0.083 -0.187
— 0.051 -0.17 -0.128
0.061 0.408 0.102 0.05 -0.234 -0.004
-0.105 0.063 0.057 0.272 -0.163 -0.102
0.328 -0.099 -0.1 0.245 0.35 0.435
------ -0.072 -0.002 -0.104 0.251 0.06
--- 0.102 0.095 -0.002 -0.308
-0.104 -0.03 -0.205
AGE 1CHOL THALDO 1CORTISOL ANDRO
0.184 0.356 -0.019 0.027 0.129 -0.049
0.203 0.219 -0.009 0.067 0.164 0.072
0.274 0.289 -0.06 0.045 0.285 0.177
"""" 0.135 0.105 0.058 0.222 0.065
0.034 -0.072 0.04 -0.326
--- 0.168 0.061 -0.015
0.24 0.553 0.398 -0.149 0.084 -0.189
0.221 0.367 0.229 -0.022 0.153 -0.091
0.464 0.329 0.194 -0.031 0.422 0.175
--- 0.137 0.165 0.03 0.384 0.139
— 0.467 -0.235 0.101 -0.395
— 0.15 0.102 -0.23
0.129 0.458 0.373 0.101 0.122 0.11
0.235 0.2 0.138 0.07 0.218 0.344
0.293 0.348 0.064 0.242 0.359 0.27
--- 0.182 0.157 0.252 0.169 0.013
0.261 -0.033 -0.089 -0.334
--- 0.147 0.018 0.013
(b)
(i) SBP DBF WHR BMI
SBP —  0.697 0.251
DBF —  0.324
WHR —
BMI 
AGE 
CHOL
(îi)
SBP —  0.691 0.146
DBF —  0.284
WHR 
BMI 
AGE 
CHOL 
(in)
SBP —  0.627 0.452
DBF —  0.437
WHR —
BMI 
AGE 
CHOL
Table 4.3e Correlation analysis between cardiovascular parameters and excretion 
of major corticosteroid sub-groups in (a) BRIGHT and (b) MONICA populations
Pearson correlation co-efficients shown for: (i) all subjects, (ii) TT homozygotes and (iii) 
CC homozygotes.
Correlation relationships significant after Bonferroni correction are shown in bold 
(p<0.005)
* remains significant after adjustment for confounding factors
There was also a highly significant correlation between THAIdo excretion and 
total cortisol (p<0.00005) as well as between the excretion rates of THAIdo 
and total androgens (p<0.00005) in the TT group but not in the CC group 
(p=0.043, 0.085 respectively) (Figure 4.3c). There was no correlation between 
urinary Na:K ratio and THAIdo excretion (p=0.445) irrespective of genotype. 
The correlation between THAIdo and androgens and between THAIdo and 
total F was significant in subjects possessing the 1C variant as well as those 
with the wild type intron (p<0.0005 in all cases).
All these correlations remained significant when data were adjusted for age, 
sex, BP and BMI.
MONICA
Pearson correlation co-efficients demonstrating the relationship between 
excretion of corticosteroid metabolites are outlined in table 4.3f. Again, there 
is a robust relationship between cortisol and androgen excretion throughout 
the genotype groups (p<0 .0 0 1 ), which is maintained when adjusted for sex, 
blood pressure and body mass.
In contrast to the BRIGHT cohort, no significant relationship between 
aldosterone excretion and cortisol or aldosterone and androgen was found in 
any genotype group.
4.4 Discussion
This study is the first attempt to explore the underlying genetic basis and 
overall consequences of an apparent alteration In adrenal 1 Ki-hydroxylation 
efficiency in hypertensive patients. Reduction in 1113,-hydroxylation efficiency
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r=0.253
p=0.043
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Figure 4.3c. Correlation between aldosterone excretion (THAIdo) and 
total cortisol metabolites (Total F) as well as THAIdo and total androgen 
metabolites (Total Andro) in BRIGHT subjects stratified by -344C/T  
genotype.
TT CC WTWT ConvConv
Total F/Total Andro 0.287* 0.634* 0.384* 0.364*
Total F/THAIdo 0.141 0.247 0.313 0.308
THAIdo/Total Andro 0.349 0.183 0.186 0.418*
Table 4.3f. Correlation data demonstrating relationships between 
corticosteroid excretion rates in MONICA subjects separated by -344C/T 
and 1C genotypes (Pearson correlation co-efficients shown)
* denotes statistical significance , p<0 .0 0 1 .
in hypertensive individuals is not a novel concept. In 1985, de Simone and 
colleagues found a higher ratio of DOC/corticosterone and 11- 
deoxycortisol/cortisol in hypertensive subjects compared to normotensive 
controls after ACTH stimulation(353). Subsequently, colleagues made a 
similar observation in hypertensive subjects in whom the plasma ratio of 1 1 - 
deoxycortisol/cortisol was elevated(145). More recently, in a study of 
normotensive subjects, Ganapathipillai and colleagues demonstrated an 
association between the -344 T allele and altered 11(2>-hydroxylation 
efficiency(374). The current data are consistent with this, and with earlier 
observations of a similar biochemical phenotype associated with the same 
genetic variant in young and middle aged subjects(375).
It is of interest that in analysis of the MONICA cohort (subjects with normal 
blood pressure) there was no alteration in 1 1 B-hydroxylation efficiency (no 
elevation of THS/Total F ratio) according to genotype. This finding, as well as 
the studies mentioned above, could suggest that such an effect is confined to 
hypertensive individuals. However, our group has previously demonstrated 
impaired llli-hydroxylase efficiency within normotensive subjects 
homozygous for the -344T allele (increased plasma 11-deoxycortisol/cortisol 
ratios) but only after stimulation with intravenous ACTH; baseline ratios were 
normal(350). Given the retrospective nature of this study, we were obviously 
unable to look at the effect of ACTH stimulation on either cohort.
These data confirm the phenotype of altered 1113,-hydroxylation efficiency 
within a sub-group from a large, severely hypertensive cohort separated 
according to genotype at -344 of CYP11B2. Those subjects homozygous for 
the T allele showed lower 11(2»-hydroxylation efficiency (increased urinary
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TH s/total F ratio) than those homozygous for the C allele. The intron 
conversion polymorphism did not appear to contribute to this variation, as 
there was no significant difference in TH 8 /total F ratios in either genotype 
group (WT and 1C).
Importantly, there was no difference in urinary excretion of total cortisol 
metabolites between the two genotype groups. These findings support the 
hypothesis that, in TT subjects, normal cortisol production is maintained by a 
subtle increase in ACTH drive to the adrenal cortex, which increases the 
availability of its deoxyprecursor.
Further, albeit indirect, evidence in support of this hypothesis can be found 
from the significant correlations seen in the BRIGHT cohort between the 
excretion rates of the three major corticosteroid sub-groups. Predictably, 
excretion of cortisol and androgen, both entirely ACTH-dependent, correlate 
strongly in all groups and in both study populations. However, aldosterone 
production is principally controlled by Ang 11(227) and potassium(376) and 
ACTH is generally considered to have a minor influence(182). Nonetheless, 
within the BRIGHT subjects, the data clearly demonstrate a significant 
correlation between excretion rates of aldosterone with total cortisol 
metabolites and total androgen metabolites in the TT genotype group, where 
an increased ACTH drive is postulated. Thus, it is speculated that, in 
hypertensive subjects homozygous for the-344 T allele, there is an important 
common regulatory influence on adrenal corticosteroid production that could 
well be ACTH.
There was no such relationship seen within the normotensive MONICA 
population with no correlation between aldosterone and cortisol or androgens
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in either -344C/T genotype group. Whilst this cohort is not a comparable 
control group this finding may suggest that this effect is limited only to 
subjects with the T allele and hypertension.
Retrospective analysis has a number of disadvantages. Ideally, when 
assessing mineralocorticoid activity, sodium intake should be controlled, and 
subjects should not be taking drugs known to affect the renin-angiotensin- 
aldosterone axis. However, whilst many patients were on drugs which would 
increase (diuretics) or decrease (beta-blockers, ACE inhibitors) aldosterone 
levels, we could demonstrate no systematic effect of any class of anti­
hypertensive agent on corticosteroid excretion (table 4.2a). Moreover, the 
steroid metabolite pattern described here, indicating an alteration in 11B- 
hydroxylase efficiency, is entirely consistent with previous studies using 
cohorts of hypertensive patients treated similarly(353) as well those on 
untreated subjects(350).
The MONICA cohort differed significantly from the BRIGHT population in age 
and BMI as well as blood pressure (Table 4.3c). Obviously, this population 
cannot be treated as a direct control group for BRIGHT; indeed, as a family 
based study, BRIGHT has no comparable control group. Thus, there can be 
no direct comparison between the two groups.
In conclusion, analysis of urinary steroid excretion patterns together with 
steroid genotype in large populations confirms genotype-dependent alteration 
in the efficiency of 11R>-hydroxylase in hypertensive subjects. The lack of 
difference in cortisol excretion between the two genotype groups, as well as 
genotype-dependent correlations between aldosterone, androgens and
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cortisol also provides evidence in favour of increased ACTH drive in subjects 
with hypertension and favourable CYP11B2 genotype.
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Chapter 5: Consequences of Variation in the CYP11B2 and CYP11B1 
Genes on Hvpothalamic-Pituitarv-Adrenal Axis Activity and Aldosterone
5.1 Introduction
In chapter 3, a high degree of linkage disequilibrium (LD) across the CYP11B 
locus was demonstrated, supporting the hypothesis that the SF-1 -344C/T 
and/or 10 variants are part of a haplotype block with functional variants 
elsewhere in CYP11B2 or in CYP11B1. Indeed, as a result of this work, two 
candidate SNPs in the promoter of CYP11B1 (-1888 G/T, -1858 A/G) have 
been identified which appear to reduce transcriptional efficacy of its enzyme 
product (11li-hydroxylase)(377). In addition, chapter 4 examines the 
consequences of the -3 44 C/T and 10 polymorphisms on the intermediate 
corticosteroid phenotype within a large hypertensive cohort and confirms that 
the -344T allele is associated with reduced 11f3>-hydroxylase efficiency as well 
as providing indirect evidence in favour of increased AOTH drive in 
hypertensive TT individuals.
However, until now, the effect of variation across the 0YP11B locus on 
hypothalamic-pituitary-adrenal (MPA) axis activity in subjects has not been 
studied. It has been speculated (section 1.11) that reduced efficiency of 118,- 
hydroxylation would result in a slight reduction in cortisol levels in response to 
ACTH. In turn, normal feedback regulation should result in a resetting of the 
ACTH cortisol relationship to maintain cortisol production at the expense of a 
slight increase in its precursor, 11-deoxycortisol. Consequently, there will a 
subtle increase in ACTH drive to the adrenal cortex (Figure 1.11a) resulting in 
hyperplasia of the zona glomerulosa and increased responsiveness to the
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principal trophins of aldosterone production, angiotensin II and/or potassium. 
Ultimately, this could result in the final phenotype of interest, hypertension 
with an elevated ARR.
If this theory is correct, then there should be demonstrable differences in HPA 
axis activity in subjects stratified by genotype. In particular, as a result of 
resetting of the HPA axis, subjects might be less sensitive to suppression 
using exogenous glucocorticoid and more sensitive to adrenal stimulation 
using ACTH.
In the following study, activity of the HPA axis and the corticosteroid 
phenotype was examined in hypertensive patients and normotensive control 
subjects stratified according to genetic variation in CYP11B2 polymorphisms 
(-344C/T and 1C) and CYP11B1 (-1888 G/T and -1858 A/G).
5.2 Methods:
5.2.1 Patient recruitment:
Recruitment of subjects with hypertension and control subjects, the study 
protocol and genotyping for the -344C/T polymorphism are described in detail 
in section 2.2. Briefly, hypertensive patients were recruited from hypertension 
clinics in the Western Infirmary Glasgow. Patients had blood pressure 
measurements consistent with BHS criteria for the diagnosis of hypertension 
and were either untreated or on calcium channel blockers (which should have 
no significant effect the on renin-angiotensin-aldosterone system)(314). 
Control subjects were normotensive and on no medication. Exclusion and 
inclusion criteria are outlined in table 2.2a.
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5.2.2 Genotyping:
The major genotypic requirement for inclusion in the study was homozygosity 
at the CYP11B2 -344 locus (TT or CC). Subjects were subsequently 
genotyped for the 1C polymorphism, as well as the recently identified SNPs in 
the 5’ promoter of CYP11B1 (-1888 G/T, -1858 A/G). DNA extraction and 
genotyping techniques are described in chapter 2 (sections 2.6/2.8/2.10).
5.2.3 Study protocol
Subjects who satisfied the inclusion criteria and who were homozygous for the 
polymorphism at position -344 of CYP11B2 were asked to attend for three 
separate study phases (Endocrine Investigation Unit, Western Infirmary).
A summary of the protocol is detailed below and is described in greater detail 
in section 2.2.3.
Phase 1“ Baseline and diurnal changes in corticosteroid patterns
Subjects attended at 10pm and between 7-8 am the following morning for 
baseline blood measurements. For normotensive volunteers, no night time 
visit was required. On each occasion, subjects were rested supine with a 
cannula in position for 30 minutes before blood sampling.
Phase 2-Sensitivity to dexamethasone
Four days before visit, subjects were asked to follow a standard salt diet 
(Appendix II) to ensure a sodium intake of approximately 120mmol/day. On 
the day before (midnight to midnight), a 24-hour urine collection was 
performed for urinary sodium measurement as well as measurement of 
corticosteroid excretion rates. At midnight the night before, subjects took 
125 micrograms of dexamethasone and attended the day ward fasted the 
next morning between 7-8am for blood collection as detailed in section 2.2.
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Phase 3- Response to ACTH
Again, subjects were asked to follow a standard salt diet and perform a 
24hour urine collection as detailed above. At midnight the night before the 
visit, subjects took 1 milligram of dexamethasone and attended the day ward 
fasted the next morning between 7-8 am.
Baseline blood samples after 30 minutes supine rest were drawn in the 
manner described above. Subjects were then given 1 microgram of 
synthetic ACTH (synacthen®. Alliance Pharmaceutical Corp USA) 
intravenously as a bolus. After a further 30 minutes of supine rest, blood 
was drawn, spun and stored in the manner described in section 2.2.
5.2.4 Biochemical measurements:
Urinary sodium and potassium were measured on 24-hour urine collections by 
the Department of Biochemistry using an ion-selective electrode method. 
Plasma aldosterone and cortisol were measured by radioimmunoassay 
utilising the ‘Coat-A-Gount’ system (Euro/DPC Ltd, Caernarfon, Wales). The 
radioisotopes used were ^^ 1^ cortisol and ^^ ®l aldosterone respectively.
Plasma ACTH measurements were performed by Professor Anne White, 
University of Manchester by radioimmunometric assay (IRMA). This technique 
uses iodinated radiolabelled monoclonal antibodies for ACTH 1-17, with 
another solid phase monoclonal specific for ACTH 34-39(366). The lower limit 
of detection for this assay was 2.5ng/L and the coefficient of variation (CV) 
ranged from 0-20%.
Plasma renin concentration (PRC) was measured by radioimmunoassay 
based on generation of angiotensin I (section 2.17)(367). A cut off of 40
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pmol/L/microunit/mi of Aldosterone/PRC ratio was used to describe an 
elevated ratio, as previously defined(378).
5.2.5 Data Analysis
As not all biochemical data were normally distributed, the data were log 
transformed (logio) to allow analysis by parametric methods (Minitab, version 
14). All data were corrected for multiple comparisons using the Bonferroni 
method such that a p value of <0.02 was required for statistical significance.
5.3 Results
5.3.1 Plasma aldosterone and PRC
Two hypertensive subjects (both TT) had an elevated baseline 
aldosterone/PRC ratio (57 & 65 pmol/L/microunit/ml), so that the prevalence 
of aldosterone-associated hypertension in this young, mildly hypertensive 
cohort was 5%.
There were no genotype-dependent differences in aldosterone/PRC ratios 
under the various study conditions (Figure 5.3a)
5.3.2 CYP11B2 Results 
Genotyping
One hundred and twenty one patients were suitable for initial genotyping at 
the -344 locus of CYP11B2. Of these, 56 were heterozygous and so 
immediately excluded. Of the remainder, 42 were TT homozygotes and 23 
were CC homozygotes (Figure 5.3b i). However, a number of individuals
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Fîgure 5.3a Aldosterone/Renin ratios (as Plasma Renin Concentration) in 
al! study groups stratified by -344C/T genotype.
Ail data are logged
(i)
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Figure 5.3b Results of genotyping at (i) -344 C/T and (ii) 1C 
polymorphism of CYP11B2 in hypertensive subjects and normotensive 
controls.
(ii)
12
10
Hypertensives
10
'Controls
WT/Conv WT/WT Conv/Conv WT/Conv WT/WT Conv/Conv
*Fewer controls were genotyped for the 10 polymorphism as there were 
technical difficulties with the assay. Moreover, only those who were 
homozygous or the -344C/T polymorphism were genotyped for 10.
dropped out before the study began and so in total, 27 TT and 12 CC subjects 
were studied in further detail. It had previously been estimated that 
approximately 15 patients per group would be required to give 85% power to 
detect a change in aldosterone concentration of 5ng/dl. Subjects included in 
the study underwent subsequent genotyping for the intron conversion (1C) 
polymorphism and these results are outlined in Figure 5.3b ii.
Forty normotensive volunteers were also recruited. Twenty-three were 
heterozygous and 17 homozygous (10 TT, 7CC) for the -344C/T 
polymorphism. Again, these subjects underwent genotyping for the 10 
polymorphism.
Demographic details
Blood pressure and other relevant demographic data for patients and controls 
are shown in Tables 5.3a & b. There was no significant difference between 
the two genotype groups in either patients or controls. Mean urinary sodium 
excretion was 117 mmol/24h (aim was 120 mmol/24h) with no genotype- 
dependent differences.
Effect of genotype on patterns of corticosteroid variation 
The effects of diurnal variation, dexamethasone suppression and stimulation 
with synthetic ACTH (synacthen) on aldosterone, cortisol and ACTH are 
illustrated in Figure 5.3c.
As expected, cortisol and ACTH showed diurnal variation (values higher in 
morning, p<0.001 in both cases), partially suppressed with 125 micrograms of 
dexamethasone (p=0.02 cortisol, p=0.04 ACTH) and suppressed to a greater
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(i) (ü)
CC
n=12
TT
n=27 P
Age 4 3 .6 4 1 .7 0 .6 6
(years) (3 .7 4 ) (2 .3 )
BMI 28 29 0 .4 3 6
(kg/m^) (1 .2 7 ) (0 .8 7 )
SEP 146 147 0 .8 4 5
(mm/Hg) (3 .2 9 ) (1 .7 4 )
DBF 90 90 0 .9 3 2
(mm/Hg) (1 .77 ) (1 .4 1 )
Urinary 112 .2 106 .8 0 .8 1 7
sodium
excretion
(nmol/24h)
(21 ) (8 .2 )
CC
n=7
TT
n=9 P
Age 33 34 0 .6 7 3
(years) (2 .0 1 ) (2 .3 5 )
BMI 27 2 5 0 .2 8 7
(kg/m^) (1 .4 8 ) (1 .1 8 )
SEP 122 121 0 .9 3 2
(mm/Hg) (4 .2 7 ) (1 .9 2 )
DBF 76 74 0 .7 9 0
(mm/Hg) (1 .7 7 ) (1 .4 1 )
Urinary 140 .2 113.4 0 .4 2 2
sodium
excretion
(nmol/24h)
(23 ) (23 )
Table 5.3a Demographic information on (I) hypertensive subjects and (ii) 
normotensive controls separated according to-344C/T genotype
All figures are means (±SEM)
Hypertension Controls Pn=39 n=16
Age 42 34 0.001
(years) (1 .9 4 ) (1 .5 5 )
BMI 29 26 0 .0 1 5
(kg/m^) (0 .72 ) (0 .9 4 )
SEP 147 121 <0.001
(mm/Hg) (1 .55 ) (2 .0 7 )
DBF 90 75 <0.001
(mm/Hg) (1 .1 1 ) (2 .0 7 )
Urinary 10 8 .2 125.1 0 .3 5 9
sodium (8) (16 )
excretion
(nmol/24h)
Table 5.3b. Demographic information on all study subjects separated by 
blood pressure status
Figures are means (± SEM)
Plasma
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-Cortisol
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Figure 5.3c. Effect of diurnal variation, suppression with dexamethasone 
(125 meg and Im g) and stimulation with Imcg of ACTH on plasma 
steroid levels in all study patients
All plasma steroid values have undergone logarithimic transformation. 
Aldosterone ng/dL, Cortisol mcg/dL, ACTH ng/L.
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Figure 5.3d. Effect of diurnal variation, suppression with 
dexamethasone and stimulation with Imcg of ACTH on mean plasma 
steroid levels according to -344 C/T genotype in all patients
All plasma steroid values have undergone logarithimic transformation. 
Aldosterone ng/dL, Cortisol mcg/dL
extent with 1mg of dexamethasone (p<0.001 in both cases). Cortisol rose 
significantly in response to 1 microgram of intravenous ACTH (p<0.001). 
None of these results were influenced by genotype or blood pressure status.
In contrast, aldosterone failed to suppress with either dose of dexamethasone 
(p=0.4) but rose significantly after ACTH (p<0.001). Again, this pattern was 
seen when looking at the subjects as a whole group or separated according to 
genotype and no difference in demographic features between genotype 
groups was noted. However, a diurnal variation in plasma aldosterone was 
only seen in the subjects homozygous for the -344 T allele (p< 0.02).
Effect of genotype on mean corticosteroid levels
Mean levels of plasma corticosteroids under different study conditions were 
compared according to -344C/T genotype as a whole cohort, in hypertensives 
and in controls. There was no difference in cortisol or aldosterone levels in 
any cohort at baseline, after dexamethasone or ACTH (Figure 5,3d).
Plasma ACTH levels after dexamethasone suppression (1mg) tended to be 
higher in TT versus CC subjects although this did not reach statistical 
significance. However, the cortisol/ACTH ratio was significantly lower in TT 
versus CC subjects (after 1 mg dexamethasone) irrespective of blood 
pressure status implying a genotype-dependent alteration in their relationship 
(Figure 5.3e). Plasma ACTH after 1 mg of dexamethasone was also higher in 
subjects homozygous for the intron conversion allele when compared to wild 
type homozygotes (p=0.05). The ratio of cortisol/ACTH was also lower in this 
sub-group but this did not reach statistical significance (p=0.13).
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Logio
ratio p<0.02
p<0.06
Figure 5.3e. Cortisol/ACTH ratios after 1mg dexamethasone in different 
patient groups separated by CYP11B2 -344C/T genotype
(data shown as means + 95% 01)
Finally, the above observations were seen when subjects were compared 
according to CYP11B2 haplotype. Plasma ACT FI was significantly higher in 
T/Conv subjects (compared to CAA/T; p=0.05); the cortisol/ACTH ratio was 
lower in subjects regardless of blood pressure status but failed to reach 
statistical significance (Figure 5.3f).
Correlation relationships
Pearson correlation coefficients between baseline (8am) cortisol levels and 
aldosterone levels in all subjects stratified by genotype are illustrated in Figure 
5.3g. There was a significant correlation between cortisol and aldosterone in 
TT (r=0.508, p<0.004) but not CC subjects. This correlation remained 
significant when data were adjusted for age, BP and BMI.
There was no significant correlation between baseline (8am) aldosterone and 
ACTH in either genotype group (TT r=0.091, p=0.638, CC r=0.490, p=0.09).
Effect of qenotvpe on corticosteroid response
When the mean absolute difference In plasma corticosteroid levels (according 
to time of day/dexamethasone suppression/ACTH stimulation) was compared 
between genotype groups, no significant differences were found (Table 5.3c)
5.3.3 CYP11B1 Results 
Demographic data
Of the 39 hypertensive patients homozygous for the SF-1 -344 polymorphism 
of CYP11B2 included in the study, 20 were homozygous for the -1888 (G/T) 
and -1858 (A/G) polymorphisms in the promoter of CYP11B1 (9 GGAA, 11
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ratio
p<0.41p<0.07 p<0.15
- 0 . 6 -
-0.9-
-1.24
Figure 5.3f, Cortisol/ACTH ratios after 1mg dexamethasone in different 
patient groups separated by CYP11B2 haplotype (means + 95% 01)
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p<0.004
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12  0 .5 -  <oD)
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Figure 5.3g. Correlation relationships in all subjects between early 
morning plasma cortisol and aldosterone levels according to CYP11B2 
344C/T genotype
Mean absolute
change
TT
Mean absolute
change
CC
P
Aldosterone Diurnal 0,703 0.658 0.628
ng/dl Dex 125mcg 0.589 0.723 0.443
Dex 1 mg 0.357 0.662 0.134
ACTH 1.068 1.131 0.506
Cortisol Diurnal 0.915 0.843 0.489
mcg/dl Dex 125mcg 0.457 0.525 0.638
Dex 1 mg 1.046 1.026 0.818
ACTH 1.217 1.15 0.219
ACTH Diurnal 0.971 1.099 0.405
ng/l Dex 125mcg 0.530 0.734 0.345
Dex 1 mg 0.979 1.15 0.05
Table 5.3c Mean absolute change (all subjects) in plasma corticosteroid 
level in response to diurnal variation, suppression with dexamethasone 
(125mcg and 1mg) and stimulation with Imcg of ACTH.
Alt data are logged
TTGG). 18 normotensive controls homozygous for these polymorphisms were 
also studied. (11 GGAA, 7 TTGG). Wild type alleles are GGAA whilst TTGG 
genotype represents the novel polymorphism.
There was no significant difference in age, BMI or blood pressure between the 
genotypes when looking at the entire cohort (Table 5.3d) or as hypertensive 
and normotensive sub-groups.
Plasma corticosteroid relationships
There was no significant effect of B1 genotype on mean absolute differences 
of plasma corticosteroid levels according to diurnal 
variation/dexamethasone/ACTH.
However, when mean levels of corticosteroids were compared according to 
genotype, plasma ACTH was higher in TTGG group after Img of 
dexamethasone (p<0.05). This also resulted in a lower F/ACTH ratio in this 
genotype group although this did not quite reach statistical significance (p 
0.07) (Figure 5.3h).
Aldosterone and cortisol correlated closely in TTGG subjects (r=0.563, 
p=0.02) but not in GGAA (r=-0.284, p=0.3) whilst there was no correlation 
between aldosterone and ACTH in either genotype group (GGAA p=0.08, 
TTGG p=0.4)(Figure 5.3i).
5.4 Discussion
The -344T and 1C alleles of CYP11B2 have previously been shown to 
associate with apparent reduced IIRhydroxylase efficiency (increased 
deoxycortisol/cortisol ratio) in both normotensives(350) and in a large
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GGAA
n=21
TTGG
n=17 P
Age 38 39.5 0.687
(years)
BMI 27 27 0.972
(kg/m^)
SBP 131 139 0.144
(mm/Hg)
DBP 81 82 0.141
(mm/Hg)
Table 5.3d. Demographic information on all study subjects separated by 
SNP identified in promoter of CYP11B1
1.00 H
0 .75 -
Logio plasma 
corticosteroid 
level
0 .50 -
0 .25 -
0.00
-0.25
-0.50 H
p<0.05
p<0.07
-I----------------------------------------------------------------1------------------------------ 1--------------------------------------------------------------T-
ACTH Img dex GGAA ACTH Img dex TTGG F/ACTH Img dex GGAA F/ACTH Img dex TTGG
Figure 5.3h. Effect of CYP11B1 genotype on mean plasma corticosteroid 
levels (log transformed).
TTGG
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Figure 5.3i. Correlation relationships in all subjects between early 
morning plasma cortisol and aldosterone levels according to CYP11B1 
genotype
hypertensive cohort (chapter 4). The current data indicate that these variants 
may be associated with altered hypothalamic-pituitary-adrenal axis activity 
and aldosterone regulation in subjects with hypertension and normotensive 
controls.
As a consequence of a tightly regulated negative feedback system, any 
reduction, however slight, in cortisol levels should result in an increase in 
adrenal stimulation by its major trophin, ACTH. In turn, this subtle increase in 
ACTH secretion should make it more resistant to suppression by exogenous 
glucocorticoid.
In support of this hypothesis, early morning plasma ACTH levels after 1mg of 
dexamethasone were consistently higher in individuals homozygous for the -  
344T or conversion alleles and subjects with the T/conv haplotype. This effect 
was independent of blood pressure. Moreover, there was no genotype- 
dependent difference in plasma cortisol levels after dexamethasone 
suppression, so that a significant decrease in cortisol/ACTH ratios in TT, 
conv/conv and T/conv subjects was seen (figures 5.3e & 5.3f). Thus, this 
provides evidence that the -344T ± conversion alleles are associated with an 
alteration in the cortisol/ACTH relationship and the feedback regulation of 
ACTH.
No apparent difference was noted in aldosterone or aldosterone/PRC ratio 
between genotype groups. However, in studying untreated hypertensives 
recruitment was usually limited to young patients with relatively mild 
hypertension. Table 5.4a highlights the significant differences in age and 
severity of blood pressure between this cohort and the severely hypertensive 
subjects studied in the BRIGHT study. Increasing age is an important risk
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BRIGHT
n=611
UNTREATED
n=55 P
Age 63 42 <0.001
(years) (9) (12)
BMI 28 29 0.08
(kg/m^) (3.8) (4.5)
SBP 173 147 <0.001
(mm/Hg) (24) (10)
DBP 104 90 <0.001
(mm/Hg) (9) (7)
Table 5.4a Comparison of hypertensive cohorts studied here and in the 
BRIGHT study.
Values are means ±SEM
factor for hypertension and these individuals are more likely to exhibit 'low- 
renin’ hypertension with low plasma renin activity (PRA), which does not 
respond normally to sodium restriction(83;336). Such subjects also respond 
optimally to diuretic treatment consistent with the previous findings that elderly 
hypertensive patients (>55 years) tend to have higher body sodium content 
than younger (<35 years) subjects with hypertension(379). Thus, a lack of 
difference in aldosterone status could be explained by the relatively young 
age of my cohort. Moreover, the hypothesis under investigation is that chronic 
subtle changes in adrenal corticosteroid production are amplified with time 
and other environmental factors. Thus, studies that compare groups of 
patients of different ages and that follow up patients over time are clearly 
indicated.
Despite the absence of a clear difference in aldosterone levels, these data do 
provide some indirect evidence of a genotype-dependent effect on the 
regulation of aldosterone. Specifically, diurnal variation in basal aldosterone 
levels was only seen in TT subjects. This is usually typical of cortisol 
production and is classically associated with the regulation of aldosterone 
production in the majority of patients with Conn’s syndrome and GRA, when 
aldosterone production is predominantly responsive to ACTH(212;380). 
Furthermore, plasma cortisol and aldosterone levels correlate strongly in TT 
subjects implying a common regulatory factor such as ACTH. This finding is 
similar to data from analysis from the BRIGHT study (chapter 4). In this 
severely hypertensive cohort urinary excretion of THAIdo correlated closely 
with total cortisol excretion in subjects homozygous for the -344 T allele. 
Although ACTH has been reported to cause only short-term stimulation of
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aldosterone production(354), these results provide indirect evidence that it 
plays a more chronic role in the regulation of aldosterone production in TT 
individuals.
The concept that variation in a gene (CYP11B2) encoding one enzyme 
(aldosterone synthase) can affect the efficacy of another (11p-hydroxylase) 
initially seems paradoxical. However, section 1.6.5 illustrates that these genes 
are highly homologous and lie close together on chromosome 8. Thus, a key 
hypothesis under investigation is that the -344C/T and intron conversion 
alleles of CYP11B2 are in LD with functional variants in CYP11B1. Two 
candidate SNPs in the 5' promoter of CYP11B1(~1888 G/T and -1858 A/G) 
have been identified by my colleague (377). These are in linkage with the 
T/conv haplotype of CYP11B2 and associate with reduced 11 (3-hydroxylase 
efficiency (increased THS/Total F ratio) in the BRIGHT cohort. Moreover, in 
vitro studies using promoter constructs altered by site-directed mutagenesis to 
contain the novel alleles and transfected into murine adrenal cells have shown 
a significant reduction in the number of mRNA transcripts in response to 
ACTH or forskolin when compared to constructs containing the wild type 
alleles. Thus, these SNPs are plausible candidates to explain the well 
established but poorly understood observation of impaired 11 (3-hydroxylase 
activity in normotensives (350) and hypertensives (353) (chapter 4) seen in 
association with -344 T ± intron conversion alleles.
The effects of these novel SNPs on HPA axis activity and aldosterone 
production were studied in this population of hypertensive subjects and 
normotensive controls. Similar changes to those seen in -344TT subjects in 
the cortisol/ACTH relationship were observed in TTGG individuals.
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specifically, plasma ACTH was less suppressible by 1mg of ACTH (Figure 
5.3h) leading to a decrease in the cortisol/ACTH ratio in TTGG compared to 
subjects with the wild type alleles. Additionally, plasma aldosterone and 
cortisol correlated strongly in TTGG and not GGAA individuals (figure 5.3i), 
again suggesting genotype-dependent co-regulation of these steroids. 
Testing for the phenotype associated with these novel CYP11B1 SNPs was 
neither the primary aim nor the major inclusion criterion of this study, and 
these data are limited by small patient numbers. Nonetheless the results do 
suggest an effect of -1888T and -1858G on HPA axis activity and 
aldosterone regulation.
There was no significant difference in the suppressibiiity of cortisol or 
aldosterone by dexamethasone or its responsiveness to stimulation with 
ACTH according to CYP11B2 or CYP11B1 genotype. This may simply be a 
reflection of limited patient numbers in each genotype/blood pressure group 
giving insufficient power to detect such subtle changes in corticosteroid 
responsiveness. Moreover, our hypothesis not only speculates that very 
subtle changes in HPA axis activity occur in response to variation in CYP11B 
locus but that these changes are amplified over time with increased exposure 
to environmental factors such as salt intake and other permissive factors to 
result in the final phenotype-hypertension with relative aldosterone excess. 
Thus, in selecting untreated hypertensives, we have been limited to a 
relatively young patient group where this phenotype has not been completely 
established.
In summary, this study has shown that variation in CYP11B2 is associated 
with alteration in the cortisol/ACTH relationship and provides evidence that
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ACTH contributes to the regulation of aldosterone production in subjects with 
-344T and intron conversion alleles. In addition, a similar phenotype is found 
in subjects with SNPs in the promoter of CYP11B1 tightly linked to T/Conv 
haplotype of CYP11B2. It is variation in this gene that may lead to altered 
11E"hydroxylation efficiency and ultimately a subtle change in the 
cortisol/ACTH relationship demonstrated in this study. Further work, to define 
more closely the corticosteroid phenotype seen in association with CYP11B1 
promoter variants and to examine genotype-phenotype relationships in an 
older, more severely hypertensive population is warranted.
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Chapter 6: The Origin of 18-Oxocortisol and 18-Hvdroxvcortisol in 
Normal Human Subjects
6.1 Introduction
The adrenal cortex is subdivided into 3 distinct anatomical zones; zona 
glomerulosa, zona fasciculata and zona reticularis (described in detail in 
section 1.4.2). These zones are also functionally discrete due to selective 
expression of key enzymes in the synthesis of the principal human 
corticosteroids. Hence, the zona glomerulosa expresses aldosterone 
synthase and so is the site of aldosterone production whilst 11U-hydroxylase 
is located within the zona fasciculata making this the principal location of 
cortisol production. Alteration in corticosteroid production by the adrenal gland 
is a key intermediate phenotype in a significant number of hypertensive 
individuals identified by a raised ARR. Thus, it is relevant to consider in more 
detail the precise mechanism of synthesis of adrenal corticosteroids 
classically found in subtypes of PA.
The major corticosteroid products of the adrenal cortex are aldosterone, 
cortisol and adrenal androgens. However, the adrenal gland synthesises a 
number of lesser-known steroid compounds. In 1982, Chu & Uiick isolated a 
novel compound from the urine of patients with PA, which they identified as 
the 20,18-hemiketal form of l ip ,  17a, 18,21 -tetrahydroxy-4-pregnene-3, 20- 
dione (18-hydroxycortisol, = 17a-hydroxyaldosterone)(381). In 1983, they 
isolated another C-18-oxygenated steroid after incubating cortisol with bullfrog
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interrenal gland; this was identified as 11 p, 17a, 21-trihydroxy-3, 20-diketo-4- 
pregnene-18-al (18-oxo-cortisol)(382).
These compounds have been subsequently termed ‘hybrid’ corticosteroids 
with both zona glomerulosa (i.e. 18-oxygenation) and zona fasciculata (i.e. 
cortisol-like, hydroxylation at C-17) characteristics (211;212;383) (Figure 
6.1a). Their biological significance is unclear; 18-hydroxycortisol has no 
mineralocorticoid activity and negligible glucocorticoid activity(384), whereas 
18-oxocortisol is a full mineralocorticoid agonist (with 1% of the biological 
activity of aldosterone)(385) with mild glucocorticoid properties.(386) 
18-Oxocortisol and 18-hydroxycortisol were previously only thought to be 
found in hypertensive disorders with aldosterone excess, specifically Conn’s 
syndrome and GRA where they still play a diagnostic role(387;388). Flowever, 
both compounds have now been identified in normal subjects (363;389). In 
the normal human adrenal cortex, 18-hydroxycortisol may be produced in the 
zona fasciculata from cortisol by the action of 11p-hydroxylase (390). 
Apparent control of its levels by ACTFl is further evidence of this (391). In vitro 
studies using hamster lung cells stably transfected with CYP11B1 or 
CYP11B2 suggest that 18-hydroxycortisol can be produced by the action of 
either enzyme on cortisol(392). However, 18-oxocortisol synthesis requires 
the additional ‘18-oxidation’ step, the capacity for which is restricted to 
aldosterone synthase in the normal zona glomerulosa, and so cannot be 
produced by 11 E-hydroxylase. These studies confirm that 18-oxocortisol can 
only be produced by the action of aldosterone synthase on cortisol (Figure 
6.1b).
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Figure 6.1a Chemical structures of 18-oxocortisol and 18- 
hydroxycortisol
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Figure 6.1b Schemata depicting production of 18-oxo and 18- 
hydroxycortisol within the human adrenal cortex.
However, cortisol is produced within the zonae fasciculata and reticularis and 
should not, under normal circumstances, gain access to the zona glomerulosa 
since blood flow through the adrenal cortex is centripetal towards the medulla. 
In PA due to GRA or Conn’s adenoma, normal adrenal architecture is 
disrupted and so locally produced cortisol is exposed to zona glomerulosa 
aldosterone synthase. However, the origin of this corticosteroid in normal 
subjects remains obscure. One possibility is that it is produced by the action 
of aldosterone synthase on peripheral, recirculating, cortisol.
Thus, the aim of this study was to determine, more precisely, the origin of 18- 
hydroxycortisol and especially 18-oxocortisol in normal subjects; in particular, 
to explore the hypothesis that these steroids can be synthesised from 
circulating, rather than locally produced, cortisol.
6.2 Methods:
6.2.1 Study subiects:
Full details of recruitment of subjects and study protocol are found in section 
2.4.1. Briefly, eight healthy men were recruited by local advertisement. There 
were three study phases each separated by one month (Table 6.2a) and a 24- 
hour urine collection was performed on day three.
In addition, 24-hour urine samples were obtained from six hypoadrenal 
subjects stable on glucocorticoid replacement therapy.
6.2.2 Steroid analysis:
Urinary steroid excretion rates were measured by gas chromatography-mass 
spectrometry using the methods of Shackleton(373) and Palermo et al(364) 
with minor modifications as described in chapter 2(section 2.4.2).
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Phase
1
2
3
Protocol_______________________________________________
No corticosteroid treatment
Dexamethasone only (1 mg twice daily for 3 days)
Dexamethasone (as above) plus hydrocortisone (20 mg twice daily 
on day 3)
Table 6.2a Study protocol for 8 healthy male volunteers.
24-hour urine collections were performed in all stages; in phases 2 and 3 this 
was done on day 3.
6.2.3 Statistical analysis:
Urinary steroid excretion rates were compared by one-way analysis of 
variance (ANOVA).
6.3 Results:
6.3.1 Normal volunteers
Average 24-hour urinary excretion rates of free cortisol, free cortisone, 18- 
hydroxycortisol and 18-oxocortisol are shown in Figure 6.3a. Comparisons 
between urinary excretion rates of these steroids are also presented in Table 
6.3a. Urinary excretion rates of cortisol, cortisone, and 18-oxocortisol were 
significantly decreased in volunteers who were receiving dexamethasone 
compared with no treatment. They were significantly increased when the 
volunteers were taking hydrocortisone and dexamethasone together 
compared with dexamethasone alone. Using the sum of cortisol and cortisone 
excretion rates as an index of cortisol ‘status’, 18-oxocortisol excretion rate 
correlated closely with this (r=0.914, p<0.01) (Figure 6.3b) while that of 18- 
hydroxycortisol did not (r=0.216; p=0.312).
6.3.2 Hvooadrenal subiects
Cortisol and cortisone were found in high concentration in the urine of the 5 
patients taking hydrocortisone replacement therapy (Figure 6.3c). Low 
concentrations of 18-hydroxycortisol, at the limit of detection, were also found
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Figure 6.3a. Urinary corticosteroid excretion rates (mean +SEM) under 
differing conditions in 8 normal subjects
Steroid No Dexamethasone Dexamethasone P
(mcg/24h) Treatment + Cortisol
Cortisol 11.2±2.5 52.6 ± 8.2 1.3 ±0.7 <0.0001
Cortisone 44.7± 10.8 87.3 ±20.2 3.4 ±0.7 0.001
18-OH-F 19.4 ±8.5 10.9 ±3.14 5.3 ±2.7 0.205
18-Oxo-F 4.04 ± 0.8 11.6 ± 1.4 1.8 ±0.4 <0.0001
Table 6.3a. Urinary steroid metabolite excretion rates 8 normal male 
subjects were studied untreated, under dexamethasone suppression and on 
dexamethasone plus cortisol. The results were compared by one-way 
analysis of variance (ANOVA, unstacked)
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Figure 6.3b. Correlation between 'cortisol status’ (sum of F +E) with 18- 
oxocortisol excretion in 8 healthy volunteers
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Figure 6.3c. Urinary corticosteroid patterns in 6 patients with 
hypoadrenalism on corticosteroid replacement therapy
in the urine of three patients who were taking hydrocortisone. 18-Oxocortisol 
was also easily detectable in all patients who were taking exogenous cortisol. 
As expected, no cortisol metabolites were detected in the patient receiving 
dexamethasone.
6.4 Discussion:
These data illustrate for the first time that the hybrid corticosteroids, 18- 
hydroxycortisol and 18-oxocortisol can be synthesised from recirculating, 
peripheral sources of cortisol. In normal subjects, suppressing the adrenal 
source of cortisol by dexamethasone reduced 18-hydroxycortisol and 18-oxo­
cortisol excretion rates. Subsequent administration of hydrocortisone to 
subjects simultaneously with dexamethasone increased excretion rates of 
both compounds. In this hydrocortisone + dexamethasone phase, 18-oxo­
cortisol excretion rate exceeded control (untreated) levels but that of 18- 
hydroxycortisol did not achieve control levels. The cortisol status achieved, of 
which the sum of cortisol and cortisone excretion rates Is a convenient index, 
was higher during cortisol + dexamethasone than during the control 
(untreated) period. This suggests that, in this extreme situation, the zona 
glomerulosa used extra-adrenal cortisol to make 18-oxo-cortisol and 18- 
hydroxycortisol. 1 ip-Hydroxylase production of 18-hydroxycortisol is probably 
less important here because extra-adrenal cortisol is less accessible to the 
zona fasciculata than to the zona glomerulosa. Moreover, previous in vitro 
work has demonstrated that 11 {3-hydroxylase is less efficient than aldosterone 
synthase at 18-hydroxylation(393).
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in patients with primary adrenal insufficiency, traces of 18-oxocortisol and 18- 
hydroxycortisol were found in the urine in those on hydrocortisone treatment 
but none was detectable in the patient on dexamethasone treatment. Since 
endogenous adrenal cortisol production is absent, circulating cortisol from 
replacement therapy must have been the substrate for the production of these 
steroids. In the one adrenalectomised patient, it is likely that they were 
synthesised from cortisol at extra-adrenal sites; in the other four patients, a 
proportion might also have arisen from perfusion by plasma of residual 
functional zona glomerulosa tissue.
In human subjects, the only source of 18-oxo-cortisol is likely to be 
aldosterone synthase using peripheral cortisol as a substrate. Its excretion 
rate was significantly increased by exogenous cortisol treatment, suggesting 
that cortisol reperfusing the zona glomerulosa is a significant source of this 
steroid. However, aldosterone synthase and 11p-hydroxylase are expressed 
in organs other than the adrenal glands(394-396) albeit at much lower rates; 
extra-adrenal production cannot be ruled out. The close correlation between 
urinary cortisol metabolites and 18-oxocortisol levels in the volunteer study 
supports the conclusion that conversion of circulating cortisol is a major 
source of this steroid. Other studies also support the dependence of 18-oxo- 
and 18-hydroxy-cortisol on cortisol availability. The plasma levels of both 
compounds correlate with that of cortisol and not aldosterone (389) and, 
although the renin-angiotensin system may have some influence(397), the 
major control factor is ACTH(397;398). Dexamethasone suppressed the 
levels of both compounds in the current study and in others (399).
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In normal subjects, cortisol for 18-hydroxycortisol or 18-oxocortisol synthesis 
may derive either by reperfusion from the circulation or from local tissue 
production. Cortisol is produced in the zona fasciculata but aldosterone 
synthase is essential at least to 18-oxocortisol synthesis. Direct penetration of 
zona fasciculata-synthesised cortisol to the glomerulosa is unlikely because 
the blood supply of the adrenal gland is centripetal. There are, however, 
plausible alternative explanations. A transitional anatomical zone was 
identified between the fasciculata and glomerulosa in rats (400;401) but not 
so far humans. In the human adrenal gland, zona glomerulosa tissue may 
penetrate the zona fasciculata along the surfaces of small blood vessels, 
providing a potentially extensive interface sufficient for cortisol to enter 
glomerulosa cells. Finally, aldosterone might be converted to 18-oxo-cortisol 
by 17a-hydroxylase in the zona fasciculata. Early experiments(399;402) 
showed that 18-hydroxycortisol and 18-oxo-cortisol are produced in beef 
adrenal outer slices. The authors suggested that aldosterone synthase and 
17a-hydroxylase coexist in these outer slices, allowing synthesis of these two 
steroids, and inferred that 17a-hydroxylase could convert aldosterone into 18- 
oxo-cortisol and 18-hydroxycorticosterone into 18-hydroxycortisol. 
Interpretation is difficult because in vitro incubation of mixed cell slices 
destroys the strict compartmentalisation of enzymes and substrates 
maintained in vivo. There is as yet no similar evidence in human tissue.
In summary, these studies demonstrate that cortisol can be converted to 18- 
hydroxycortisol in both the zona fasciculata and zona glomerulosa by 11p- 
hydroxylase and aldosterone synthase respectively. Since cortisol synthesis is 
restricted to the zona fasciculata in vivo, it is likely that most 18-
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hydroxycortisol in normal subjects is produced by 1ip-hydroxylase. The lack 
of correlation between urinary excretion rate of 18-hydroxycortisol and 
‘cortisol status’ in normal volunteers supports this. In contrast, 18-oxo-cortisol 
is a unique product of aldosterone synthase. The source of cortisol in normal 
subjects may be circulating cortisol, zona fasciculata cortisol diffusing across 
the interphase between glomerulosa and fasciculata or a combination of both.
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Chapter 7: Endogenous Corticosteroid Production in Subiects after 
Bilateral Adrenalectomy- Evidence of Extra-adrenal Aldosterone 
Synthase Activity?
7.1 Introduction:
Chapter 6 demonstrated that the hybrid corticosteroids, 18-oxo and 18- 
hydroxycortisol could be synthesized by the human adrenal cortex using 
recirculating (exogenous) cortisol as a substrate. This study, in normal 
volunteers, also concluded that 18-hydroxycortisol is normally produced by 
the action of 11fi-hydroxylase on locally produced cortisol (i.e. within the zona 
glomerulosa), whilst 18-oxocortisol is the exclusive product from the action of 
aldosterone synthase on cortisol (Figure 7.1a).
Given the dependence, in particular, of the production of 18-oxocortisol on 
aldosterone synthase, it was surprising that both steroids could be found in 
easily detectable amounts in patients with hypoadrenalism and probably 
absent adrenal function due to autoimmune adrenal cortex destruction 
(Addison’s Disease) (Figure 6.3c). Moreover, 18-oxocortisol was readily 
detectable in one patient with bilateral adrenalectomy (and hence absent 
adrenal cortex tissue). Thus, these data have raised the possibility that extra­
adrenal aldosterone synthase could contribute to the synthesis of 18-oxo and 
18-hydroxycortisol as well as aldosterone. A number of studies by our group 
and others have already demonstrated expression of aldosterone synthase in 
extra-adrenal sites such as brain(258;403), blood vessels(404) and, more 
controversially, the heart(259;260). However, the exact functional significance 
and regulation of this remains unclear.
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Figure 7.1a Schematic representation of functional and anatomical 
subdivisions of the adrenal cortex.
18-Oxocortisol is produced by the action of aldosterone synthase on 
recirculating cortisol whilst 18-hydroxycortisol is mainly produced by action of 
11 R-hydroxylase on locally available cortisol in the zona fasciculata.
In this study, the hypothesis under investigation is that significant capacity to 
produce aldosterone and other adrenal steroids in a paracrine manner may 
exist. Using 18-oxocortisol as a marker of aldosterone synthase activity, the 
production of this and other adrenal steroids was studied in subjects with 
absent adrenal function after bilateral adrenalectomy.
7.2 Methods:
7.2.1 Studv subiects:
10 patients (3 male) were recruited from the endocrine clinics of the Western 
Infirmary, Glasgow. All had undergone bilateral adrenalectomy at least one 
year previously and were stable on glucocorticoid (hydrocortisone; 10- 
30mg/day) and mineralocorticoid (fludrocortisone; 50-100 micrograms/day) 
replacement. Patient details are listed in table 7.2a. Local ethical committee 
approval for the study was obtained from the North Glasgow Hospitals 
University NHS Trust and all patients gave informed, written consent.
7.2.2 Studv protocol:
This is outlined in chapter 2 (section 2.5.1) and summarized in table 7.2b.
7.2.3 Corticosteroid analvsis:
24-Hour urine samples were collected into a plain container and then aliquots 
stored at -20°C. Urinary steroid excretion rates were measured by gas 
chromatography-mass spectrometry using the methods of Shackleton and 
Palermo et al with minor modifications(364) outlined in chapter 2 (section 
2 .11).
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PATIENT SEX AGE
(years)
BP
(mm/Hg)
TIME SINCE 
SURGERY
REASON FOR 
SURGERY
1 F 40 95/57 11 years Cushings disease
2 F 43 130/82 14 years Cushings disease
3 M 47 118/66 21 years Cushings disease
4 F 64 119/80 12 years Cushings disease
5 F 63 141/96 3 years Phaeochromocytoma
6 F 64 138/76 10 years Cushings disease
7 M 52 123/68 22 years Cushings disease
8 F 65 116/67 3 years Adrenal hyperplasia
9 M 58 117/86 1 year Cushings disease
10 F 57 138/76 2 years Phaeochromocytoma
Table 7.2a Details of study patients 
Phase Protocol
Hydrocortisone 30mg daily (20mg mane, 10mg nocte) 
Dexamethasone only (1 mg twice daily for 3 days) 
Dexamethasone (as above) plus hydrocortisone (30mg in divided 
doses on day 3)
Table 7.2b. Study protocol for 10 adrenalectomised patients
Each phase lasted 3 days
24-hour urine collections were performed in all phases, beginning on day 3
Total cortisol was defined as the sum of tetrahydrocortisoi (THF), 
allotetrahydrocortisol (aTHF) and tetrahydrocortisone (THE).
Urinary corticosteroid excretion rates were analysed by one-way analysis of 
variance (ANOVA).
7.3 Results:
Cortisol:
Total cortisol excretion rates during the three study phases are illustrated in 
figure 7.3a. As expected, cortisol excretion fell to almost undetectable levels 
when on dexamethasone replacement (phase 2) but was restored when 
hydrocortisone was given in conjunction with dexamethasone (phase 3).
Aldosterone:
The principal urinary metabolite of aldosterone is tetrahydroaldosterone 
(THAIdo). Figure 7.3b demonstrates that THAIdo was easily detectable in all 
adrenalectomised patients. There was no significant difference in its urinary 
excretion rates during each of the study phases.
18-Hvdroxvcortisol/18-Oxocortisol:
18-Hydroxycortisol and 18-oxocortisol excretion rates were easily detectable 
in phase 1 and suppressed significantly in phase 2 illustrating their 
dependence upon cortisol as a substrate (Figure 7.3c & d). Excretion rates 
were restored in phase 3 (dexamethasone + hydrocortisone) suggesting that 
production of these hybrid corticosteroids was not acutely ACTH-dependent.
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Figure 7.3(a-d) Urinary excretion rates of corticosteroids in 10 
adrenalectomised subjects during all 3 study phases.
Day 1- hydrocortisone alone 
Day 2-dexamethasone alone 
Day 3-dexamethasone + hydrocortisone 
In a, b and c, dashed line represents median normal values (from urine of 
100 healthy volunteers).
(c) Excretion of 18-hydroxycortisol
6001
p<0.0001500-
400-
n
300-
200-
100-
PHASE
(d) Excretion of 18-oxocortisol
II
3.54
3.0-
2.5-
2.0 -
1.5-
1.0-
0.5-
0.0-
p<0.0001
2
PHASE
7.4 Discussion:
These novel data demonstrate that corticosteroids usually produced by the 
adrenal cortex can be detected in subjects with apparently no adrenal tissue. 
In particular, the major urinary metabolite of aldosterone (THAIdo) is clearly 
present, albeit at low levels, and its production is not ACTH-dependent. 
18-Oxocortisol, the exclusive product of aldosterone synthase, is also easily 
detectable. Its production in the subjects in this study was dependent on 
availability of exogenous cortisol as a substrate and appeared to be 
independent of acute ACTH effects. The presence of aldosterone and 18- 
oxocortisol in adrenalectomised subjects is consistent either with significant 
extra-adrenal aldosterone synthase resulting in production of adrenal steroids, 
which may act locally in a paracrine manner, or significant re-growth of 
adrenocortical tissue.
Extra-adrenal conversion of cortisol to 18-oxocortisol implies that circulating 
cortisol is available to access aldosterone synthase within the systemic 
circulation. The concept that extensive modification of steroids can occur in 
this way is well established from the studies of cortisol to cortisone 
interconversion in a wide range of tissues (405). The notion that enzymes 
usually found within the adrenal gland might have a significant systemic 
distribution is also established. Expression of a number of 
corticosteroidogenic enzymes has been previously demonstrated in several 
extra-adrenal tissues, including central nervous system (CNS), vascular and 
renal tissue. CYP11B1 (11R-hydroxylase) and CYP11B2 (aldosterone 
synthase) transcripts have been isolated from human pulmonary artery(406), 
aorta(407), human vascular endothelial cells (HUVEC)(408) as well as rat
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mesenteric artery(409). Vascular CYP11B transcript levels also appear to be 
regulated in a similar manner to the adrenal cortex; in HUVEC, angiotensin II 
and potassium increased CYP11B2 but not CYP11B1 mRNA levels whilst 
ACTH raised CYP11B1 but not CYP11B2 mRNA(408). In human brain, 
CYP11B1 and CYP11B2 transcripts are widely distributed along with other 
key steroidogenic enzymes, suggesting an autocrine or paracrine model of 
corticosteroid action in the CNS(257).
Cardiac expression of CYP11B transcripts is more controversial. The most 
recent data from my group used a highly sensitive quantitative RT-PCR 
method to measure CYP11B1 and CYP11B2 mRNA levels in cardiac tissue of 
several rat models of cardiovascular pathology (congestive heart failure, 
genetic hypertension and cardiac hypertrophy). Cardiac CYP11B1 and 
CYP11B2 mRNA transcript levels from all groups were never greater than 10  ^
copies per microgram of total RNA and therefore too low to be detected 
reproducibly(262). In human cardiac tissue, CYP11B transcripts have been 
reported in fetal organs(407) and in the failing heart(410) but not in normal 
adult human heart. Moreover, quantitative analysis of the transcript levels in 
heart samples estimated them, where present, to be 100-10000-fold lower 
than those in the adrenal gland(407).
Whilst extra-adrenal sites remain the most likely source of aldosterone 
synthase in these subjects, It is also possible that small amounts of functional 
adrenal tissue remain or re-grow after surgery. There is evidence of adrenal 
re-growth in salt fed adrenalectomised rats that can develop ‘adrenal 
regeneration hypertension’ with evidence of mineralocorticoid excess(411). 
However, in this poorly understood model, bilateral adrenalectomy was
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incomplete with enucleation of the left adrenal gland (leaving an intact capsule 
and zona glomerulosa)(412). The presence of adrenal tissue in humans after 
bilateral adrenalectomy has not been studied in detail and would require 
precise functional imaging. Brauckhoff and colleagues described a case 
series of 10 subjects who underwent subtotal bilateral adrenalectomy, leaving 
15-30% of the cortex intact. In each case, there was evidence of good 
functional recovery with no requirement for long-term steroid 
replacement(413). Thus it remains possible, though difficult to prove, that very 
small residual amounts of adrenal cortical tissue in our subjects could have 
been a source of low levels of hybrid corticosteroid production utilising high 
levels of recirculating exogenous cortisol as a substrate, although this implies 
that such tissue has a blood supply sufficient to deliver enough cortisol to cells 
expressing aldosterone synthase. Finally, ectopic adrenal tissue is present in 
up to 50% of neonates(414); however, such ‘adrenal rests' are rare in 
adulthood with a prevalence of around 1%(415), and it is unlikely that this was 
a significant steroid source in the 10 subjects studied.
18-Hydroxycortisol was easily detectable in adrenalectomised subjects with 
median excretion rates far exceeding rates in normal volunteers (Figure 6.3c). 
This corticosteroid is produced by the action of 11fi-hydroxylase or 
aldosterone synthase on cortisol, although our previous work has 
demonstrated that aldosterone synthase is more efficient at 18-hydroxylation 
of cortisol than 11S-hydroxylase(393). This fact, along with the ACTH- 
independence of 18-hydroxycortisol production (on phase 3), would suggest 
that aldosterone synthase is the likely principal source of 18-hydroxycortisol 
under these circumstances.
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The explanation for much higher excretion rates of 18-hydroxycortisol in 
adrenalectomised versus normal subjects (chapter 6, figure 6.3a) remains 
unclear. One possibility is that extra-adrenal aldosterone synthase ±118.- 
hydroxyiase enzymes are exposed to significantly higher levels of circulating 
cortisol than in normal subjects. It is now well accepted that many individuals 
on glucocorticoid replacement therapy are over-treated(416) although there is 
no consensus on an optimal dosing schedule. Another, less likely, possibility 
is that adrenalectomised subjects undergo post-operative induction of these 
extra-adrenal enzymes, although the mechanisms underlying this are 
obscure. The final possibility is variability in mass spectrometry data between 
the studies. Whilst this method of urinary corticosteroid quantification is well 
validated and robust, measurement of the hybrid corticosteroids 18- 
oxocortisol and 18-hydroxycortisol is less routine and it would be useful to 
confirm urinary levels with plasma quantification (RIA assay kits for these 
steroids are available commercially). Whatever the mechanism, it is unlikely 
that these apparent high levels of 18-hydroxycortisol are of biological 
significance since in vitro and in vivo bioassays have confirmed that this 
steroid has virtually no mineralocorticoid or glucocorticoid activity(384). The 
importance of its detection, as well as the detection of 18-oxocortisol (a full 
agonist at the mineralocorticoid receptor but with weak mineralocorticoid 
effects), in adrenalectomised subjects is that it demonstrates the capability of 
aldosterone synthase ± 118,-hydroxylase (in extra-adrenal or residual tissue) 
to synthesise these corticosteroids from recirculating cortisol.
Finally, these data suggest that it may be plausible to suggest that 
aldosterone is produced in sites other than the adrenal cortex. This may have
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important biological repercussions. As detailed in chapter one (section 1.8) 
aldosterone is an important cardiovascular hormone and recent studies have 
illustrated its role in cardiac fibrosis(240) and left ventricular hypertrophy as 
well as in impaired vascular reactivity(256). Moreover, many of these actions 
have been shown to be independent of its known effects on blood 
pressure(241). The risk of cardiovascular and cerebrovascular morbid events 
in subjects with hypertension and aldosterone excess is substantially higher 
than in patients with essential hypertension with similar blood pressure 
levels(417). In a clinical setting, the benefits of aldosterone blockade in 
cardiovascular disease have been adequately demonstrated in recent large, 
randomised clinical trials(272;274). Thus, evidence of significant extra-adrenal 
aldosterone production is likely to be of relevance to cardiovascular 
pathophysiology and provides further support for the use of aldosterone 
antagonists in this situation.
In summary, these results demonstrate for the first time, significant production 
of adrenal corticosteroids in adrenalectomised subjects. Whilst adrenal re­
growth or residual adrenal tissue cannot be completely excluded as possible 
sources, the findings of this study provide compelling evidence for significant 
extra-adrenal aldosterone synthase ± 1 lli-hydroxylase activities.
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Chapter 8: Conclusions
2003 marked the 50^ anniversary of the discovery of aldosterone by Simpson 
and Tait (147). This has coincided with increasing recognition of aldosterone 
as an important hormone in hypertension and cardiovascular disease. The 
evidence from almost every continent suggests that PA affects 5-13% of 
patients with hypertension. In addition, and as a result of increased use of the 
ARR as a screening tool, the prevalence of hypertension with relative 
aldosterone excess is much higher than previously thought. Whilst the debate 
continues as to how many of these individuals have classical PA, these facts 
highlight corticosteroid production by the adrenal gland as a key intermediate 
phenotype in a significant number of hypertensive individuals and study of its 
underlying molecular and biochemical basis forms much of the focus of this 
thesis.
Until now, the search for a genetic basis for aldosterone-associated 
hypertension has focussed on variants within the gene CYP11B2 (-344C/T, 1C 
polymorphisms) which encodes aldosterone synthase. In particular, earlier 
studies have generated the hypothesis that variants within CYP11B2 (-344 
C/T, 10 polymorphisms) are in linkage with functional variants within 
CYP11B1, causing altered activity of its enzyme product, 118,-hydroxylase. 
This phenotype, and its association with -344T and 10 alleles, was initially 
identified in normotensive subjects. However, in chapter 4, it is confirmed, for 
the first time, in a large, severely hypertensive cohort taken from the MRO 
BRIGHT study.
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The entire CYP11B locus was sequenced in a cohort of normotensive 
subjects (chapter 3). This confirmed tight LD across this locus (r  ^ 0.5-1) 
providing support for the original hypothesis. Moreover, a number of novel 
SNPs in linkage with -344C/T and 1C polymorphisms were identified in both 
CYP11B1 and CYP11B2. However, as most are in non-coding regions 
detailed in vitro study of their functional effects is beyond the scope of this 
thesis. Nonetheless, 2 SNPs in the 5’ promoter of CYP11B1 have emerged 
as plausible candidates to account for altered activity of this enzyme and their 
in vitro effects are described briefly elsewhere(418).
In addition, several novel polymorphisms in the 5’ UTR of CYP11B2 (the gene 
encoding aldosterone synthase) were identified whose functional significance 
is unclear at this time. It may well be that these new variants also contribute to 
altered aldosterone regulation, possibly by changing the expression of 
CYP11B2 in response to angiotensin II or potassium. Thus, development of 
hypertension associated with inappropriate aldosterone production (ie, 
hypertension with a raised ARR) may be a consequence of a digenic effect 
mediated by variation within both CYP11B1 and CYP11B2 (analogous to the 
Dahl hypertensive rat, where variations across the same genes result in 
hypertension with altered aldosterone production and increased salt 
sensitivity). This is a concept that deserves further investigation.
As a result of altered efficiency of 118,-hydroxylase, cortisol production may 
be maintained by a subtle and chronic increase in ACTH drive to the adrenal 
gland. In turn, this may also lead to increased production of aldosterone; 
perhaps by hyperplasia of the zona glomerulosa and an increase in its 
responsiveness to trophins such as potassium and Ang II. In chapter 4, this
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concept was explored further in a large, severely hypertensive cohort. In this 
population, cortisol production was unaffected by CYP11B2 genotype but 
there was a significant elevation of the ratio of deoxycortisol to cortisol in 
subjects homozygous for the -344T allele, suggesting reduced efficiency of 
1 Ki-hydroxylase. In addition, excretion of aldosterone was found to correlate 
strongly with that of ACTH-dependent steroids (total cortisol and adrenal 
androgens) in TT subjects. This suggests that in such subjects, there is an 
important common regulatory influence on adrenal corticosteroid production. 
This is likely to be ACTH.
Until now, there has been no report of the association between variation in the 
aldosterone synthase gene and activity of the HPA axis. If the above 
hypothesis was true, then hypertensive subjects with the -344TT genotype 
should demonstrate subtle changes in the ACTH/cortisol relationship as well 
as in aldosterone production. In chapter 5, this was investigated in 
hypertensive volunteers homozygous for the -344C/T polymorphism. In this 
study, TT homozygotes demonstrated diminished suppressibility of ACTH with 
dexamethasone, resulting in a decreased cortisol/ACTH ratio. These findings 
are in keeping with a mild increase in ACTH secretion in order to maintain 
cortisol production. Additionally, aldosterone exhibited diurnal variation and 
correlated closely with cortisol levels only in TT homozygotes. This supports 
further the proposal that, in TT individuals, ACTH contributes to the regulation 
of aldosterone production.
Clearly, the hypothesis requires that variants in CYP11B1 linked to the -  
344T+ 1C alleles of CYP11B2 lead to altered HPA axis activity as well ACTH 
contributing to aldosterone production. Accordingly, the relationships of novel
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SNPs identified in the promoter of CYP11B1 to HPA activity were examined 
within the same population. The novel alleles (-1888T and -1858G) 
associated with similar changes in cortisol/ACTH relationship and in 
aldosterone regulation as the -344T± 1C alleles of CYP11B2. This is in 
agreement with tight LD between these SNPs and CYP11B2 -344T/IC 
identified in chapter 3. Therefore, these alleles provide a plausible explanation 
for the altered efficiency of 118,-hydroxylation described in several 
populations.
Finally, adrenal corticosteroids are of undoubted importance in hypertension 
and a better understanding of corticosteroid physiology and production is 
necessary. 18-OxocortisoI and 18-hydroxycortisol are corticosteroids whose 
levels are elevated in Conn’s syndrome and GRA but are also found in normal 
subjects. Evidence is presented in chapter 6 that 18-oxocortisol is produced 
in normal subjects by the action of ZG aldosterone synthase on recirculating 
cortisol whilst 18-hydroxycortisol is produced by the action of ZF 118,- 
hydroxylase on locally produced cortisol. Subsequently, 18-oxocortisol was 
used as a marker of aldosterone synthase activity and was detectable in 
adrenalectomised individuals (chapter 7). 18-Hydroxycortisol was also found 
in easily detectable amounts and its production was independent of ACTH 
suppression by dexamethasone again supporting the concept of extra-adrenal 
aldosterone synthase activity. Given the importance of aldosterone in 
hypertension and cardiovascular disease, evidence of significant extra­
adrenal aldosterone production is of interest in cardiovascular 
pathophysiology and may further support the use of aldosterone antagonists 
in this situation.
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In conclusion, I have shown that there is strong LD across the CYP11B locus. 
In particular, variants in the 5’ UTR of CYP11B2 (-344T) are in tight LD with a 
number of polymorphisms across this and the adjacent CYP11B1 locus. 
These polymorphisms (of which -1888T and -1858G are likely candidates) 
result in altered expression of the enzyme product of CYP11B1, 118- 
hydroxylase. In turn, this leads to changes in HPA axis activity consistent with 
a subtle increase in ACTH-mediated adrenal stimulation to maintain cortisol 
production. Finally, the data are consistent with a contribution of ACTH to the 
production of aldosterone (in -344T & CYP11B1 -1888T/-1858G), leading to 
the eventual phenotype of hypertension with an elevated ARR.
Conventionally, ACTH is regarded as having only a transient stimulatory effect 
on aldosterone production and prolonged administration of ACTH is reported 
to lead to a fall in aldosterone production after a few days. However, these 
experiments used supra-physiological amounts of ACTH in normotensive 
subjects (of presumably mixed genotype), often in a sodium replete state. It is 
possible that the suppressive effects of sodium on renin production override 
stimulation by ACTH to result in reduced aldosterone production in these 
cases. However, the effect of very subtle increases in ACTH sustained over 
time in individuals with hypertension has not been studied directly. It is entirely 
plausible that in this circumstance there is insufficient sodium retention to 
entirely suppress renin and so the stimulatory effect of ACTH is maintained. 
Accordingly, in in vitro experiments, and in humans where renin is inhibited by 
beta blockade, ACTH stimulation of aldosterone production is maintained, 
presumably because there is no secondary effect of sodium retention.
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In developing this hypothesis, it is acknowledged that the development of 
hypertension associated with relative aldosterone excess (elevated ARR) is a 
chronic process and that the pathophysiological basis is present throughout 
life and will involve additional genes and environmental influences not studied 
here. However, in patients with other genetic and environmental factors that 
favour development of hypertension, the above proposal offers an 
amplification mechanism that will gradually lead to increasing 
mineralocorticoid effects on the vasculature with time. Given that aldosterone 
excess has adverse consequences on endothelial, renal, cardiac, and central 
nervous system tissues, early identification of subjects at risk of development 
of aldosterone-modulated blood pressure should be of increasing importance 
in reducing the worldwide cardiovascular burden.
Future work:
The studies reported in this thesis do highlight a number of areas that require 
further investigation:
1. Characterisation of novel polymorphisms in CYP11B2 (chapter 3)
2. Investigation of the functional significance of these polymorphisms 
especially in the 5’ UTR.
3. Investigation of the alteration in adrenal corticosteroid production and 
regulation over time in hypertensive subjects by longitudinal studies.
4. Further investigation of the association with CYP11B genotype or 
haplotype with corticosteroid phenotype
(In particular, to assess the effect of low dose ACTH infusion under 
careful conditions of salt intake (low salt and high salt states) on 
aldosterone production).
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Appendices:
Appendix I Nucleotide sequences of human CYP11B1 and CYP11B2
Appendix II Dietary information given to all study subjects (chapter 5)
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Appendix I: Nucleotide sequences of human CYP11B1 and
CYP11B2
Nucleotide Sequence
The nucleotide sequences for human CYP11B1 and CYP11B2 were obtained 
from the Entrez Nucleotide database. The accession numbers for these 
sequences are as follows:
CYP11B1 CYP11B2
5' flanking region and exon 1 D10169 D10170
Exon 1 and 2 M32863 D13752
Intron 2 X85218 D13752
Exons 3 to 8 M32878 D13752
Exon 9 and 3'UTR M32879 M32881
Exons are shown in bold and the untranslated regions and intron in lower 
case. The oligonucleotides used for PCR and sequencing, listed in chapter 2, 
are indicated by their name above the relevant highlighted sequence. Where 
oligonucleotide sequences overlap the second sequence is underlined as is 
the primer name. Sense and antisense oligonucleotides are indicated by > 
and < respectively.
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B 15'UTR> (B15’7-32 >)1 tccttcqcat cccttgtaag ttggattcct aagtatttta ttctctttga
51 agcaattgtg aatgggagtt cactcatgat ttggcctctc tgtttgtctg
101 ttaagggtgt ataagaatgc ttgtgatttt tgtacattga ttttgtatcc
151 tagagcttgc tgaagttgct tatcagctta aggagatttt gggctgagac
<B 15’258-238201 aatggggttt tctagatata caatcatgtc cgtctgccaa acagagacaa
251 tt-tgacttcc tcttttccta attgaatacc ctttatttcc ttctcctgcc
301 taattgccct ggccagaact tccaacacta tgttgaatag gagtggtgag
<B15'393-369 F81092 >351 agagggcatt cctgtcttgt accagctttG acagggaatg cttccagttt
401 ttgaccattc agtatgatat tggctgtggg tttgccatag atagctctta
451 ttattttgag atacgtccca tcaataccta atttattgag agtttttagc
501 gtgaaggttg ttgaattttg tcaaaggcct tttctgcatc tattgagata
551 atcatgtggt ttttgtcttt ggttctgttt atatgctgga ttacatttat
F81093 >601 tgatttgcat atattgaacc agccttgcat cccagggatg aagcccaett
651 gateatggtg gataagcttt ttgatgtgct gctggattcg gtttgccagt
701 attttattga ggatttttgc atcaatgttc atcaaggata ttggtctaaa
751 attctctttt ttggttgtgt ctctgcccgg ctttggtatc aggatgatgc
801 tggcctcata aaatgagtta gggaggattc cctctctttc tattgattgg
F81094 >851 aatagtttca gaaggaatgg taccagttcc tccttgtacg tctggtataa
901 ttcggctgtg aatccatctg gtcatggact ctttttggtt ggtaatctat
951 tgattattgc cacaatttca gatcctgtta ttggtctatt cagagattca
1001 acttcttact ggtttagtct tgggagagtg tatgtgtcga ggaatttatc
1051 catttcttct agattttcta gtttatttgc gtagaggtgt ttgtagtatt
F81095 >1101 ctctgatggt agtttgtatt tctgtgggat cggtggtgat atccccttta
1151 tcatttttta ttgcatctat ttgattcttc tctctttttt tctttattag
1201 tcttgctagc ggtctatcaa ttttgttgat cctttcaaaa aaccagctcc
1251 tggattcatt aattttttga agggtttttt gtgtctctat ttccttcagt
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1301 tctgcactga ttttagttat ttcttgGctt ctgGtagttt tgaatgtgtt
1351 tgctcttgct tttctagttc ttttaattgt gatgttaggg tgteagtttt
1401 ggatctttcc tgctttGtGt tgtgggeatt tagtgetata aatttccctc
1451 tacacactgc tttgaatgtg ttccagagat tctggtatgc tgtgtctttg
1501 ttctcgttgg tttcaagaaG atGtttattt GtgccttGat tttgttacgt
1551 acccagtagt cattcaggag caggttgctG 
F81097 >
agtttccatg taattgageg
1601 gttttgagtg agtttcttaa tcGtgagttc tagtttgatt.gcactaaaat
1651 ttttaaaaag taaaaaaaat acatgtggtt taataeaatt catgecaaet 
< Blprom-260(as)
1701 cattccctcg ttttttgcta taaacGttgc aaggagatga- ataatccaag
1751 gctcttggat aagataaggg GCCGatccat cttgctcctc tcagGGGtgg
1801 aggaggaggg 
F31463 >
agagtcGttt tCGGGtgtCt acgcteatgc aGccGcaatg
1851 agtccctgcc tccagccGtg acctGtgGCG teggtGtGtG aggeagatCG
1901 agggccagtt GtGGCatgac gtgatGGGtG GGgaaggeaa ggcacGaggc
1951 aagataaaag 
< B9865
gattgeaget gaacagggtg gagggagcat tggaATGGCA E x l
2001 CTCAGGGCAA AGGCAGAGGT GTGCATGGCA GTGCCGTGGC TGTCCCTGCA
2051 AAGGGCACAG GCACTGGGCA CGAGAGCCGC CCGGGTCCCC AGGACAGTGC
2101 TGCCCTTTGA AGCCATGCCC CGGCGTCCAG GCAACAGGTG GCTGAGGCTG
2151 CTGCAGATCT GGAGGGAGCA GGGTTATGAG GACCTGCACC TGGAAGTACA
2201 CCAGACCTTC CAGGAACTGG GGCCCATTTT CAGgtaaagc cctccctggc
2251 Gctcgctgga acacccagtg Gcctgccctt gctgcccagg accctgccgg
2301 gcactcagca ctgccattcc cagcaggtcc cggcactctg GatGGtttgg
2351 aagagggaag ategageaeg tgetgtGtgt gegetgcagg gcagggcatg
2401 tgcagagcaa atgggagctc ggctgcagag agggcaggac tcagaggeae
2451 tgaagttaag aggttGcggg cagtcagcaa gagggcgttt agctgtgaag
2501 GcgGtaatGG 
Y6265 >
aggagagggg agggtggaca ggagaeaett tggattggga
2551 Gtgcagggtg gggccagcag ggactagacc ccgtccagca gggcGtGCtg
2601 cttggGGGGa eagGTACGAT TTGGGAGGAG CAGGCATGGT GTGTGTGATG E x 2
2651 CTGCCGGAGG ACGTGGAGAA GCTGCAACAG GTGGACAGCC TGCATCCCCA
2701 CAGGATGAGC CTGGAGCCCT GGGTGGCCTA CAGACAACAT CGTGGGCACA
< Y6266
189
2 751 AATGTGGCGT GTTCTTGCTg taagcggcga gctgagagct gggagcaggg
2801 tggcagcctg gtgtaggggg gaggcgagag aggcaggacc caaaagcaca
2851 tctgccctgg gcccctgtgg tgggcagtga gggtgagcac ccgacccaga
2 901 ggacggccat tccgtggggt cgtgtctgcc ctgtggttgg ggaagcaggg
2 951 cgtggtggag aaatgggcac gggcacctct gcagagaaga tgcagagcaa
3001 tgagcccttc tgtgtagtga gaacccgctc tgcaccaacc ttggcggatg
3051 ctttctcttg cggtctgggg actgtcttcc ataggtcaga aaactgaggc
3101 ctgagaaggt actccactgg cccaggtcac aggctgagta ctgagcctgt
3151 ggttcgccgg ggccgcagcc tccctcaggg cgctcagggt ccctgcagtc
3201 ctggcaaacc ttcctgatgg ggacagtccg gggcaggagg caggtgggga
B1 Int2(3280) >
3251 tgcaggtggc tggtggctcc attgttctca gaagca'aggc acgaggtggg
3301 gcggttgatg gcactgggga ggatgtttcc tggccctgcg agatgggcgg
3351 ccgttggtca ggtgggcagg gagaggctga tgcttggagt cagtcacctg
34 01 caggaatgtt gtcattagga cgggggaagg actggacgag gatgtcacag
3451 tggcgacagc ccccactcca tggcaggagg agaacgcttt tgggaatagt
3501 ggggtttagg taaaagggca cccaagggtg ggggccttca ctgaggctgg
 BUnt2(358^3551 cctacagacg gacatctggg agggagtcag gacccaggaa ggcaagtcca
3601 gaaggctggg tgcacataac ggaaggaagg ggagcgcacc tgtatgtgtg
3651 tgtgtcttgc atctgtgcac atctgtgtgt ttctctgtac ctgcatttgc
3701 acgtgttgtg tgtgcancgt gtgtgcacgt gtctgtgtgc atgtatgtgt
3751 ggtgtgtgtg cacgagtgtc tctgtgtgtg catgtgcagg tgctggcatg
3801 ggtgtagtgt ctgtgcactt gtgtacatgt gtctcttcac acatggtgtt
3851 gaggtcttgc atgggcgcat gtgagcatgt gcatcttctg cctgccatca 
B1 Int2(3890) >
3901 ctgtcaacag ctcacagcca gctggacata aataaagctt tgagttttgc
3951 aggaatgtgg ctgacagggg aaattcctcc ccaccattcc ctggggcatc
4001 catggagccc ccacgcactc tggctgtagg tgaggatggc atgaagcaca
4051 aagcttggtt tctgtcctgc agaagatgca gacacttcag tcctgctgcc
4101 ccagaggcac tgtgcccagg gcagggaagg gcggggagga gagggcagcc
4151 aggggctctc ccctcaggac actgtgtggg tgaggtgggc aaagcttgac
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4201 aacaggggtc agttcctttc ttgcagaaaa tccctccccc ctactacagg
4251 gagggcccgc atgggtgagg tggtgccaga cttggggcgc caggtcccgg
4301 gaatgacctc agttaccctg tcagcacctg tgggcagaag ctaccatctc
4351 atccctgctt agacctgagt ggcctttgtc cagcacctgg aggcsstctg
4401 agaaaaggct gcagctcgaa cacaaacagg 
Y6263 >
cagcttctac cagggccccc
4451 agtcagctcc ctgcaggccg attccccttg ggacaaggag gatgggatac
4501 gggtcagggc ctgtgtcttg ctggggcggc ctcacaagct ctgccctggc
< N4020
4551 ctctgtagGA ATGGGCCTGA ATGGCGCTTC AACGGATTGC GGGTGAATGG E x 3
4601 A6AAGTGGTG TGGGGGAAGG GTGTGGAGAG GTTGGTGGGG ATGGTGGATG
4651 GAGTGGGGAG GGAGTTGTGG GAGGGGGTGA AGAAGAAGGT GGTGGAGAAG
4701 GGGGGGGGGA GGGTGAGGGT GGAGGTGCAG GGGAGGATGT TGGAGTAGAG
4751 GATAGAAGgt gtgggccaca tgggttgatc cagcctcaga gaccctggag
4801 tggccaggga cggggatggg ggactgaagg gagtgtgggg aggcagccag
B4250 >
4851 gaggcccggt tcccttgtgc tcagcagtgc atcctccccg cagGGAGGAA
4901 GTTGGGTGTT TTTGGAGAGG GGGTGGGGGT GGTTGGGGAG AGGGGGAGTT
4951 GTGGGAGGGT GAAGTTGGTG GATGCGGTGG AGGTGATGTT GAAATGGAGG
5001 GTGGAGCTGA TGTTGATGGG GAGGAGGGTG TGTGGGTGGA GGAGGGGGAA
5051 GGTGTGGAAG GAGGAGTTTG AGGGGTGGGA GTGCATGTTG GAGTAGGgtg
5101 aggccaggga 
< B4251
cccgggcagt gctatgggga aggacacGat GgggGGGGGa
5151 atttctccct ctccaccacc cagtggggaa tggaggccac agggaggggt
5201 cggggattcc tcaccgtcct gccagggaga ttggtgtgag gctggggctg
5251 ggctgggctg atccggagaa tttgggatga 
M6642 >
gagcagggag acttggtgct
5301 gggctagctg gcaggaggag gacactgaag gatgtttccc agcaccaaag
5351 tctgagggct gcctcccgct GCGcggatag GGGAGAAGTG TATGGAGAAA E x 5
5401 ATGTATGAGG AAGTGGGGTT GAGGGGCGGT GAAGAGTAGA GGAGGATGGT
5451 GGGGGAGGTG GTGTTGAATG GGGAAGTGTG GGGAGATGGG ATGAAGGGGA
5501 AGTGTATGGA AGTGAGTGGA GGGAGGGTGG AGAGGgtcag gccggcaaGG
5551 agccccaccc agagagggtg 
< M6643
atgccaagcG
191
tgcGtGCGag gcactgcctg
5601 ccaatgUcac acggcgccca cgtgtcccat gcccaggcta tgggccccac 
5651 atttcttact tgggattgtg atgtgataaa cacgtttgca ggttgccatg
5701 gttggaatgg ggggttcctt tGCttGtgtg gaggactcag ggaaaGgggg
5751 tttggatggg cattaggatt tgaagtGttg ggctGtgtGg tgGtcagggt
5801 atgcatgtct gcaccGctca cagggaggtt gtcctgggag
F42117>
gggtgtcccg
5851 ggggctgagt cGtGctgtgc aaggtGtgac cctgGagctg tgtctGGtgc
5901 agACGGTGTT TCCCTTGCTG ATGACGCTCT TTGAGCTGGC TCGGAAGCCC E x 6
5951 AACGTGCAGC AGGCCCTGCG CCAGGAGAGC CTGGCCGCCG GAGGGAGGAT
6001 CAGTGAACAT CCCCAGAAGG CAACCACCGA GCTGCCCTTG
....<F42299
GTGGGTGGGG
6051 CCCTCAAGGA GACCTTGCGg tgggtgctgg ctgaggcctc CGtgtggccc
6101 gggccctgct ggagagtcag GGCGGactgg gtggttgGag acagaatctg
6151 ggctataaac aGctacccag cagcGatGGt gaGtgGtGtc tGgGgtGaag
6201 gacagggagc tGttGttCCt ctggaatCGc tcttcaacgc cGtggggatt
6251 aacgtggggg catgtccttc tgGgctcggg gGtgcttaag ttaggggagg
6301 tttggccggg Gtcagcaggt gcaaggaagc acttGCtaGa GGtgggcttG
6351 ccatggatct gggaGGtctg cggggtcttc ggtaggaagg gtgcagagag 
Y6259 >
6401 cacaggaacc Gcatcccagc tgagaGGGtt tGtatggatg■GGCCCaCCtC
6451 cagGCTCTAC CCTGTGGGTC TGTTTCTGGA GCGAGTGGCG AGGTGAGAGT E x 7
6501 TGGTGCTTCA GAACTACCAC 
< Y6260
ATCCCAGCTG GGgtgagtga g G C C G a G a G G
6551 ctcgagctga gaacctccct ccGcagtcat tccGtgatcc GcgctGtgct
6601 ccgtccgcag ACATTGGTGC GCGTGTTCCT CTACTCTCTG GGTGGGAAGG E x  8
6651 CCGCCTTGTT CCCGAGGCCT GAGCGCTATA ACCCCCAGCG GTGGGTAGAG
6701 ATCAGGGGCT CCGGCAGGAA CTTCTACCAC GTGCCCTTTG GGTTTGGGAT
6751 GCGCCAGTGC CTTGGGCGGC GCCTGGCAGA GGCAGAGATG GTGGTGGTGG
6801 TGCACCATgt gagcaggccG gggctgggga ggggcctggg cggggtctgg
6 851 gcagcatggg cggggcttga gcaatgtggg actggcctcg gcagagtggg
6901 agtggcctgc atgtttcctg gactgggcag agcgggtact gggagaacct
6951 gggccaggtt gaggctgtgt aggtcctggg caggagttgg tatggtgagg
7001 agcgtaccat ctgggtgagg ttgctgctaa accgggtcag gtgggaactg
192
7051 ggggaagtcg ggtggagcct gtacaggata gtggggGttg ggcaatacct
7101 gggctggatg aattctgggc GtgggGtgta aggtggggct 
M6635 >
ggtGaggaat .;
7151 gaaacaggtt ggaggccagg ctgctgttcc Gccttcagca taatGtGtgG ,7
7201 aactttgagg gtctgagaag gctgcaccac gtgcatgggG tgGggaGGaa
7251 gccagatgga aacccggctt GtgtcGtagG TGGTGAAAGA GGTGGAGGTG E x 9
7301 GAGACACTAA GGGAAGAGGA GATAAAGATG GTGTAGAGGT 
< BlExoii9(as)
TGATATTGAG
7351 GCCGAGCATG TGGGGGGTGG TGAGCTTGAG AGGGATGAAG TAÂtGacgtG ;
7401 tctgcaccca gggtcccagc ctggGaGGag GGtGGGtttC tgcctgacGG
7451 caggccaccc ctcttctctc GGaGatgcac agcttcctga gtcacccctc
7501 tgtctaacca gccccagcac aaatggaact cccgagggcc tctaggacca
7551 gggtttgcca ggctaagcag caatgGcagg gcaGagGtgg ggaagatctt
7601 gctgaccttg tccccagccc cacctggccc tttctccagG aagcactgtG
7651 ctctggcagt ttgcccccat ccGtcGGagt gctggctGca ggGtGGtGgt
7701 gtggccatgc aagggtgctg tggttttgtc ccttgccttG Gtgcctctag
7751 tctcacatgt ccctgttcct GttCCCGtgG GagggGGCGt gcgcagactg
7801 tcagagtcat taagcgggat CGcagcatGt agagtccagt caagttGGGt
7851 cctgcagcct gccccctagg 
< B13'UTR+500
cagctGgagc atgGGGtgag c tc tc tg a a a
7901 gttgtcgccc tggaataggg tcctgcaggg tagaataaaa aggGGGGtgt
7951 ggtcacttgt cctgacatcc GGattttGaa gtgatacaac tgagtctGga
8001 gggacgtgtg ttcGccagct gatGgtgtGa gGctcatgcc cctggcctGa
8051 tctttcatgg accaggcctt gttccaggag tgggcgttgg gtcGtctgct
8101 tcctgtgctg tGCGGtgggg aaggtccGaa ggatgGtgtc aggagatgga
8151 agagtcatgt ggggtgggaa cctggggtgt ggttccagaa atgtttttgg
8201
8251
caacaggaga
actattctct
gaGaggattg
gaca
ggccaaGaag gactGagaGg agttttattg
CYP11B2
T8303D >
193
1 Gaattctgca tcctgtgaaa ttatccttca aaagtgaaca taaatatttt
51 ctcaggtaaa taaaaattga ggggattcgc tgccaataga aGtgaGttgc
101 cagaaatgtt ttttaaaagt tctgcagaga gaaagaaaat gatacaggtc
151 agcaaccctg agctacataa agaaaggaag agcatttcag aaggaatGag
201 t aaag agaaa atgaagtctt ttattttttc ttaatcttaa ttgatctaag
251 agtttgctaa aacaaaacaa caacaataaa aataggccgg gGgGggtgaG
301 tcaccacacc tgtaatccca gcactttggg aggccgaggt gggGagatca
351 Gctgaggtca ggagttcgag actagcctgg ccaacacggt gaaaccGcgt
401 ctctactaaa aatacaaaaa ttagctgggc gtggtggtgg caGatgGctg
451 taatcccagc tacttgggag gctgaggcgg gagaattgct tgaacGGggg
501 agacagaggt cgcagtgagc cgagatcaca Gcattgcact ctagcctggg
551 cgacagagtg agactctgtc tcaaaaataa ataaataaat aaataaataa 1
601 ataataaaaa taaataaata aaagccagaa agtgtatttg atgatcatag ;8,
651 ttatgtatat gtgaaatgaa ggacagcaat gatgcaaggg atgggtgagt
701 ggaattaaaa atatcttatt atttatttat tttgagatgg agtGttgctt
751 tgctgcccag gttggagtgc agtgggatga tctGaaGtca ctgcaacctc i:
801 cgcctccttg attcaagcat tcatcttgac tGagcctgct gagaagccga 'Î:
851 gattacaggc atgcgccacc acacctggct aattttgtat ttttagtaga i:
901 gacagggttt tgccatgttg gccaggctgg tctGgaactc GtgacctGag
A
951 gtgatccacc tgcatcagcc tcccaaagtg GtgggatgaG agacatgagc
1001 cactatgccc agcctaagaa tatctgatga ttataaagtg cttgcattac
1051 ctctgaagct gtatagtgtt atatgaaggt ggagttggag agatgagttt ;
1101 taagcgtata ttgcaaactc tagggcaacc actaaagaag tgagaGGGag ;
1151 cctctagaaa aaaaaaaaaa aaaggaaatt agGtatcaag Gcacgaaaag j
1201 aaatggagga accttaaacg catattacta aGtgagataG gtcactttga i
1251 aaaggctaca aacggtgtca ttccaactat acaacatttt ggaaaaggcc 1
1301 aaagcatggt gatgataaaa aagatcggag atgtGaggga ctggggcagg
1351 agggatgagc aggcagagca caggttttct tttcctcttt ttaagacagt i'
1401 gaaaatactc ctaggatcct gcaaggaggg ataGaaatta Gatacatttg
194
1451 tcaaaaccca cagcatgttg accaccagga ggagacccca tgtgactcca
1501 ggaccctggt tgataacaac gtatcgagat tcctcacatg gaaccagtgc
1551 gctcctgtgg tggagggtgt acctgtgtca gggcaggggg tacgtggaca
1601 ttttctgcag tttttgatca attttgcaat gaactaaatc tgtggtataa
1651 aaataaagtc tattaaaaga atccaaggct ccctctcatc tcacgataag
1701 ataaagtccc catccatttt actcctctca gcGctggaga aaggagaggc
1751 caggtcccac GaGGttccac cagcatggac CGCcagtcca gaccccacgc
1801 cttttctcag catcctcaga ccagcaggac ttgcagcaat ggggaattag
1851 gcacctgact tctGGttGat Gtacctttgg ctgggggcct Gcagccttga
1901 Gcttcgctct gagagtctca ggcaggtcca gagccagttc tcGcatgacg
1951 tgatatgttt ccagagcagg ttcctgggtg agataaaagg atttgggctg
2001 aacagggtgg agggagGatt ggaATGGCAC TGAGGGGAAA GGGAGAGGTG E x l
2051 TGCGTGGCAG CGCCCTGGCT GTCCGTGCAA AGGGGAGGGG GAGTGGGGAG
2101 TAGAGCCGCT CGGGCCCCTA GGAGGGTGGT GGGGTTTGAA GGGATGGGGG
2151 AGCATCCAGG CAACAGGTGG CTGAGGCTGG TGGAGATGTG GAGGGAGGAG
2201 GGTTATGAGC ACCTGCACCT GGAGATGCAC GAGAGGTTGG AGGAGGTGGG
2251 GCCCATTTTC AGgtaaagGG GtcGGtggcc Gtcgctggga acacccagat
2301 CGGtgGCCCt gGtgGGGagg accctgccag gcactcagca ctgccattcc
2351 cagcaggtGG cggcactctg catcctttgg aggatgggga aggagtgcag
2401 cacatgGtgg tctgtggtgc tgccagggca ggggatagtg cagagaaaac
2451 GCcagctcaG tgcagagagg gcaggactca gaagcactaa agttgaaagg
2501 ttCGagggag ccagcaggag ggctttagct gtgaagccgc taatccagga
2551 gGagggaggg tggacaggag acactttgga ttgggactgc agggtggggc
2601 caGgagggac atgacGGcgt ccagcagggc ctcctgcttg gccccacagG
2551 TACAACTTGG GAGGACCACG GATGGTGTGT GTGATGGTGG GGGAGGATGT E x 2
2701 GGAGAAGCTG CAACAGGTGG AGAGGGTGGA TGGGTGGAGG ATGATGGTGG
2751 AGCCCTGGGT GGCCTACAGA GAAGATGGTG GGGAGAAATG TGGGGTGTTG
2801 TTGTTgtaag cggcgagttg ggagctgaga gctgggagca gggtgggcag 
2 851 cctgggtgta ggggggaggc gagagaggta ggacccaaaa gcacatctgc
195
2901 cctgggcccc tgtggtgggc agtgagggtg agcacccggc ccagaggacg
2951 gccatcctgt ggggtcgcgt ctgcactgtg ggttggggaa gcagggcggt
3001 ggtggagaaa tgggcacggg cacctctgca gagaagacgc agagcaatga
3051 gcccttctgt gtagtgagaa cccgctctgc accaacctcg gcggctgctt
3101 tctcttgcgg tctggggact gtccttccca taggtcagaa aactgaggcc
3151 ctgagaaggg gacttccact ggcccaggtc acaggctgag tgctgagcct
3201 ggtgttcgcc ggggccgcag cctccctcag ggcgctcagg gtccctgcag
3251 tcctggcaaa ccttcctgat ggggacagtc cggggcagga ggcaggtggg
3301 gacgcaggtg gctggtggtt ccgttgttct cagaagcaag gcacaaggtg
3351 gggcggttga tggcactggg gaggatgttt cctggcccgt ggagagggtg
3401 gcgcctggtc aggtgggcag ggagaggctg atgcttggag tcggtcacct
3451 gcagggatgt tgtcattagg acgggggaag gactggatga ggatgtcaca
3501 gtggtgacag cccccactcc atggtaggaa gggaacgcta ttgggaatag
3551 tggggtttag gtaaaagggc acccgtgggt cggggccttc actgaggctg
3601 gcctatagat gacatctggg agagagtcag gacccaggaa ggcaggtcca
3651 ggaggctggg tgcgcataat ggaaggaagg ggagcgctcc tgtctgtgtg
3701 tgtgtcttgc atctgtgcac atgctgtgtg tttctctgta cctgcattgc
3751 acatgtgtag tgtgtgcacg tgtcgtgtgt gaatgtatgt gtggtgtgtg
3801 tgcacaagtg tctgtgtgtg tgcatgtgca ggtgccggca tgggtgtagt
3851 gtttgtgcac acatgcacat gcgtctcttc acacatggtg ttgaggtctt
3901 gcatgggcgc acgtgtgcat gtgcatcttc tgcctgtcat cactgtcaac
3951 agctcacagc agccagctgg acataaataa aggagttttg caggaatgtg
4001 gctgacaggg gaaattcctc cccaccattc cctgggggca tccatggagc
4051 ccccacgcac tctggctgtg ggtaggatgg catgaagcac aaagcttggt
4101 ttctgtcctg cagaagatat agatgcttca cagagacagc agagcagatg
4151 ccccagaggc actgtgccca gggcggggaa gggtggggag gagagggcag
4201 ccaggggctc tcccctcagg acactgtgtg ggtgaggtgg gcaaagcttg
4251 acaacagggg tcacctcctt tcttggagaa aagccctacc ctgttactac
4301 agggagggcc cgcatgggtg aggtggtgcc agacttgggt cgccaggtcc
196
4351 cgggaatgac ctcagttacc ctgtcagcac ctgtgggcag aagctaccat
4401 ctcatccctg cttagacctg agtggccttt gcccagcacc tggaggccgc
4451 tctgagaaaa ggctgcagct cgaacacaaa caggcagctt ctaccagggc
4501 ccccagtcag Gtccctgcag gccgattccc cttggggaca aggaggatgg
4551 gatacgggtc agggcctgtg tcttgctggg gcggcctcac aagctctgcc
4601 ctggcctctg t agGAATGGG GGTGAATG6G GGTTGAAGGG ATTGGGGGTG E x 3
46 51 AACCCAGATG TGCTGTCGCC CAAGGCCGTG CAGAGGTTCC TCCCGATGGT
47 01 GGATGCAGTG GCCAGGGACT TCTCCCAGGC CCTGAAGAAG AAGGTGCTGC
47 51 AGAACGCCCG GGGGAGCCTG ACCCTGGACG TCCAGCCCAG CATCTTCGAC
4 801 TAGAGGATAG AAGgtgtggg ccatgcggga aggtccagcc ccagagaccc
4 851 tggagtggcc agggatgggg atggaggact gaagggagtg tggggaggca
4901 gccaggaggc ctggggctgc cttgtgctca gcagtgcatc ctccccgcag 
4951 GGAGGAAGTT AGGTGTTTTT GGAGAGGGGG TGGGGGTGGT TGGGGAGAGG E x 4
5001 GGGAGTTGTG GGAGGGTGAA GTTGGTGGAT GGGGTGGAGG TGATGTTGAA
5051 ATGGAGGGTG GAGGTCATGT TGATGGGGAG GAGGGTGTGT GGGTGGATGA
5101 GGGGGAAGGT GTGGAAGGAG GAGTTTGAGG GGTGGGAGTG GATGTTGGAG
5151 TACGgtgagg ccagggaccc 
< F33915
gggcagtgct atggggaagg gacaccatgg
5201 gggcccaatt tctccttctc caccacccag tggggaatgg aggccacagg
5251 gaggggtcgg ggattcctca ccttcctgcc ggggagattg gtgcgaggct
5301 ggggctgggc tgggctgatc 
T2138 >
cggagaattt gggatgagag cagggag'att
5351 tgggtgtcgg ggcagtctgg gcaggaggag gacactgaag gatgcttccc
5401 agcaccaaga tctgagggct gtcccctgct ccctggacag GTGAGAAGTG E x 5
5451 TATGGAGAAA ATGTAGGAGG AAGTGGGGTT GAAGGGGGGT GAAGAGTAGA
5501 GAGGGATGGT GGGGGAGGTG GTGTTGAAGG GGGAAGTGTG AGTAGAAGGG
5551 ATGAAGGGGA AGTGTATGGA AGTGAGTGGA GGGAGGGTGG AGAGGgtcag
5601 gccagcaacc agccccaccc agagagggtg atgccaagcc tgcctcccag
5651 gcactgcctg ccaatgccac acggcaccca cgttccccat ccccaggcta
5701 caggccccac atttctgttg ccctcagcct tccccctcct ttgttaaggg
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5751 atgagatttg caggggaggg gaaatgtgag ctccccctca catgagactg
5801 agtttgcagt tacctgtgtg gggatccatg ctccaggctg gaagaaagtt
5851 ggatgaggcc ctggacacac agcagctctg tccccactgg aaagctctgg
5901 gtgtacaagg agaaggaggg ttgagaggca gctggaggac tccactgggc
5951 acccttccca gtgtgcccgg tcaccttggg ccagaaatgt agatgcatgg
6001 gagggcaggg ttgtggggaa gacagcagca caggctccag ccagtgcaga
6051 ggggcctgtg ggtgcacagt ggggagaact caatggaagc agagggagct
6101 ggggctccag aactccctgg atgatgctga ggtgtggccc cctgccctaa
6151 tggtggctgt gagaacccgc cctgaagagg ctgcagggga cctgggcctt
6201 ggtggagatg ggggtcacct ttccctgaag aagtcaggga atctggccca
6251 agtggtcatc aaggtttcag atccggggtc ccagggctct gtttttgctc
6301 agggcatgga tgtctccacc cctcagaggg aggttgtcct gggaggggtg
6351 tcccgggggc tgagtcctcc tgtgcaaggt ctgaccctgc agacatggct
6401 tctgtagACA GCGTTTCCCT TGCTGATGAC GCTCTTTGAG CTGGGTCGGA E x 6
6451 ACCCCGACGT GCAGCAGATC CTGCGCCAGG AGAGCCTGGC GGGGGGAGGC
6501 AGCATCAGTG AACATCCCCA GAAGGCAACC ACCGAGCTGC GGTTGGTGGG
6551 GGCGGCCCTC AAGGAGACCT TGAGgtgggt gctggctgag gcctccctgt
6601 ggccctggcc ccctgctgga gagcagcccc cactgggtgg tggcagacag
6651 aatctggggc tgataaacag cgtcacccag cagcccattc ccctgcacct
6701 gctcttcctc cccctcaagg acagggagct cttcttcctc tggaatccct
6751 cttcaacgcc ctggggatta acgtggggca tgtccttctg cgctcggggc
6801 tgcttaagtt aggggaggtt tggctgggct cagcaggtgc aaggaagcac
6851 ttcctacgac ctgggcttcc catggatctg ggacctctgc ggggtcttcg
6901 gtaggaaggg tgctgagagc acagggagcc ccatccagct gaggaccctt
6951 tctgtggatg cccccacctc cagGCTCTAC CCTGTGGGTC tgt tt t t g g a E x 7
7001 GCGAGTGGTG AGCTCAGACT TGGTGCTTCA GAACTACCAC ATGGGAGGTG
7051 GGgtgagtga gccccacacG cctcgagctg agaacctccc tccccagtca
7101 ttccctgatc cctgctctgc accgtccgca gACATTGGTA GAGGTTTTGG E x 8
198
7151 TCTACTCGCT GGGTCGCAAT GCCGCCTTGT TCGGGAGGGG TGAGGGGTAT
7201 AATCCCCAGC GCTGGCTAGA CATCAGGGGC TGCGGGAGGA AGTTGGAGGA
7251 CGTGCCCTTT GGCTTTGGCA TGCGCCAGTG GGTGGGGGGG GGGGTGGGAG
7301 AGGCAGAGAT GCTGCTGCTG GTGCACCACG TAAGGAGGGG TGGGGGGGGG
7351 GGCGGGACCT GGGCAGCAGA GGGGGGAGGT GGAGAGTGGG G6GGGGGGTT
7401 GCATGGTGTg attgacacct gggaacagtg gatggggcct tggttggttg
7451 aggtcggcgt gaccagggag gatctgtgct gagcaagaca gggtaggatc
7501 tgggtgaggt tgcttctaaa cattgaaatg gggactaggg gagtggggtg
7551 gagcctgtac agaataatgg ggcttgggca agacctgggc aggattcagt
7601 ctgggcctgg tccgcaaggt ggggctggtc agaaatggga taggttgggg
7651 cccaggctgc tgctccccct tcagcataat tgttgcacct gggacgatgg
7701 gaggaagctg ccccaggtcc atgggctact gaccaggcca gatggaaacc
7751 cagcctctgt cctagGTGCT GAAGGAGTTG GTGGTGGAGA GAGTAAGTGA Ex9 
B2 3'UTR >
7801 AGAGGACATA AAGATGGTCT AGAGGTTGAT ATTGAGGGGT GGCAGGTGGG
7851 CCCTCCTCAC TTTCAGAGCG ATTAAGTAGt cttgcatctg cacccagggt
7901 CGcagcctgg ccaccagctt 
< M6641
ccctctgcct gaccccaggc cacctgtctt
7951 ctctcccacg tgcacagctt cctgagtcac cGctctgtcc agccagctcc
8001 tgcacaaatg gaactcccca gggcctccag gactggggct tgccaggctt
8051 gtcaaatagc aaggccaggg cacagctgga gacgatcttg ctggcagggc
8101 ctggccttgt ccccagcccc acctggcccc ttctccagca agcagtgccc
8151 tctggacagc ttgactctac tcctcccagc gctggctcca ggctcctcat
8201 gaggccatgc aagggtgctg tgattttgtc ccttgccttc ctgcctagtc
8251 tcacatgtcc ctgtccctct cgccctggcc agggcctctg tgcagacagt
8301 gtcagagtca ttaagcggga tcccagcatc tcagagtcca gtcaagttcc
8351 ctcctgcagc ctgaccccag gcagctcgag catgccctga gctctctgaa
8401 agttgtcacc cagaaatacg atcctgcagg gtagactaaa aaggcccctg
8451 tggtcactta tactgacaca ttttaagtga tacaactgag tctcgagggg
8501 cgtgtgttcc ccagctgatc atgtcagcct catgccccag gcctcgtctt
8551 tcatggacca ggtcttgttc aagcagcgag tgttgggtcc tctgcttcct
199
8601 gagctgtccc ctggaaaagg tcccgaggat gctgtcagga gatggaagag
8651 tcatgtgggg tgggaacctg gggtgtggtt ccagaaatgt ttttggcaac
8701 aggagagaca ggattgggcG aacaaggact cagatgagtt tattgactca 
< B2 3'UTR
8751
9251
ttcctctgga
agtcagcaca
agatacgcag
tc
........ . . . .ctcS.ect
Appendix 11: Dietary information given to all study patients (chapter 5)
Food Group Salty Foods to Avoid Suitable Alternatives
Breakfast
Cereals
All others W eetabix, Shredded Wheat
Bread, Cakes 
and Biscuits
All others Bread (W holemeal/white max 4 
slices/day), sweet cakes or 
sweet biscuits only.
Starchy
Carbohydrates
All others Potatoes, rice, pasta.
Eggs Scotch Eggs Boiled, poached, scrambled or 
fried
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Milk Salted Las si A pint semi-skimmed milk 
daily
Cheese Cottage/cream cheese, 
maximum o f 50g daily
Meats and 
Poultry
Bacon, ham, gammon. All smoked 
meats. Salami, sausages, beefburgers. 
Tinned meats, e.g. corned beef, luncheon 
meat. M eat pies and manufactured meat 
dishes. Dehydrated packed meals. Meat 
paste and pate.
All fresh and frozen meats e.g. 
beef, lamb, pork, turkey, 
chicken etc.
Fish All smoked, cured, salted, tinned or 
pickled fish. Fish paste and pate, 
taramasalata. Shellfish e.g. prawns, 
shrimps. Manufactured fish dishes.
All fresh or frozen fish. Fish in 
batter or breadcrumbs.
Soups Packet and tinned. Home made soup with no added 
salt or stock
Drinks Fruit Juice, reduced sugar fruit 
squash, diet fizzy drinks, 
mineral water, tea, coffee, tonic 
water.
Fruit Olives, salted nuts. Fresh, frozen or tinned in 
natural juice. Unsalted nuts.
Vegetables Tinned unless labelled “no added salt”. 
Baked beans.
Fresh, frozen or tinned in 
natural juice.
Spreads All others. Polyunsaturated margarine.
Miscellaneous M eat or yeast extract e.g. Bovril, 
M armite, Oxo. Gravy granules, stock 
cubes, garlic salt. Pickles, chutneys, 
tomato ketchup, W orcester sauce, tomato 
juice, chilli sauce.
Use black pepper, herbs and 
spices to flavour food. Use 
unsalted snacks or fresh or 
dried fruit as snacks
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